AU2010201384A1 - 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments - Google Patents
8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments Download PDFInfo
- Publication number
- AU2010201384A1 AU2010201384A1 AU2010201384A AU2010201384A AU2010201384A1 AU 2010201384 A1 AU2010201384 A1 AU 2010201384A1 AU 2010201384 A AU2010201384 A AU 2010201384A AU 2010201384 A AU2010201384 A AU 2010201384A AU 2010201384 A1 AU2010201384 A1 AU 2010201384A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- xanthine
- piperidin
- amino
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Description
Australian Patents Act 1990 - Regiulation 3.2A ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title "8-[3-amino-piperidin-I-yl]-xanthines, the production thereof and the use of the same as medicaments" The following statement is a full description of this invention, including the best method of performing it known to me/us:- C:\WRPorblDCCRBR2X426091 .DOC 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions This application is a divisional application of Australian Application No. 2003253418 the specification and drawings of which as originally filed are incorporated herein in their entirety by reference. The present invention relates to new substituted xanthines of general formula 0 3
NH
2 R0 N the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type 11 diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (1) or a physiologically acceptable salt thereof as well as processes for the preparation thereof. In the above formula I
R
1 denotes a methyl group, -2 a methyl group which is substituted by a dimethylaminocarbonyl, pyrrolidin-1 ylcarbonyl, piperidin-1-ylcarbonyl, tert.-butylcarbonyl or a cyclohexylcarbonyl group, a methyl group which is substituted by a naphthyl, methylnaphthyl, methoxynaphthyl, nitronaphthyl or dimethylaminonaphthyl group, a methyl group which is substituted by a 2-phenylethenyl or a biphenylyl group, a methyl group which is substituted by a phenyloxadiazolyl, 5-methyl-3-phenyl isoxazolyl, phenylpyridinyl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, methylisoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2 dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro 3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl 4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a 2-methoxyethyl, 2-phenyloxyethyl or 2-cyanoethyl group, a phenylcarbonylmethyl or a 1-(phenylcarbonyl)-ethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino) carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, CANRPonbIX'ORBR\29426(9 LDOC -3 a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylaminocarbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4 ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 (methoxycarbonyl)-ethyloxy or a 1 -(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups or a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CH 2
-CH
2 -O or a -N(CH 3 )-CO-O group,
R
2 denotes a hydrogen atom, a methyl, isopropyl, 2-propen-1-yl, 2-propyn-1-yl or phenyl group or a cyanomethyl or methoxycarbonylmethyl group and
R
3 denotes a 2-cyanobenzyl or 2,6-dicyanobenzyl group, CANRPortblOCC\RR\2g42609 I.DOC -4 a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen-1-yl group a 2-buten-1-yl, 3-methyl-2-buten-1-yl or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group. The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions, and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved in vivo. Such groups are described for example in WO 98/46576 and by N.M. Nielsen et al. in International Journal of Pharmaceutics 39 75-85 (1987). Compounds which contain a group that can be cleaved in vivo are prodrugs of the corresponding compounds wherein this group that can be cleaved in vivo has been cleaved. By a group which can be converted in vivo into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C 1 .e-alkanol, a phenyl-C 1
.
3 -alkanol, a
C
3 .9-cycloalkanol, while a Cs-8-cycloalkanol may additionally be substituted by one or two C 1
-
3 -alkyl groups, a C 5
-
8 -cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C 1
.
3 -alkyl, phenyl-C 1
.
3 -alkyl, phenyl-C 1
.
3 -alkyloxycarbonyl or
C
2 -6-alkanoyl group and the cycloalkanol moiety may additionally be substituted by C:\NRPotblDCC\RBR\242609 L DOC -5 one or two C 1
-
3 -alkyl groups, a C 4
.
7 -cycloalkenol, a C 3
.
5 -alkenol, a phenyl
C
3 .- alkenol, a C3.
5 -alkynol or phenyl-C 3
-
5 -alkynol with the proviso that no bonds to the oxygen atom start from a carbon atom which carries a double or triple bond, a
C
3 -- cycloalkyl-C 1
-
3 -alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two
C
1
.
3 -alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula Rp-CO-O-(RqCRr)-OH, wherein Rp denotes a C 1
-
8 -alkyl, C 5
.
7 -cycloalkyl, C 1
.
8 -alkyloxy, C 5
.
7 -cycloalkyloxy, phenyl or phenyl- C 1
-
3 -alkyl group, Rq denotes a hydrogen atom, a C 1
-
3 -alkyl, C 5
.
7 -cycloalkyl or phenyl group and Rr denotes a hydrogen atom or a C 1
.
3 -alkyl group, by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl,
C
1 4-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino,
C
1 .--alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C 1 .e-alkylsulphonylaminocarbony group and by a group which can be cleaved in vivo from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C 1
-
3 -alkyl or C 1
-
3 -alkoxy groups, while the substituents may be identical or different, a pyridinoyl group or a C1.
16 -alkanoyl group such as the formyl, acetyl, C VNR~wbhDfCORRQS42609_1 DC -6 propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C1.
16 -alkoxycarbonyl or C 1
.
1 -alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C 1 .e-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3 amino-propionyl group wherein the amino group may be mono- or disubstituted by
C
1 .e-alkyl or C 3 7 -cycloalkyl groups and the substituents may be identical or different, a C 1
-
3 -alkylsulphonyl-C 2 4-alkoxycarbonyl, C 1
.
3 -alkoxy-C 2 4-alkoxy C24-alkoxycarbonyl, Rp-CO-O-(RqCRr)-0-CO, C1.e-alkyl-CO-NH-(RCRt)-O-CO- or Cwalkyl-CO-0-(RsCRt)-(RsCRt)-0-CO- group, wherein Rp to Rr are as hereinbefore defined, R, and Rt, which may be identical or different, denote hydrogen atoms or C1-3-alkyl groups. A first object of the invention relates to compounds of general formula (1) wherein
R
1 denotes a methyl group which is substituted by a dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, tert.-butylcarbonyl or a cyclohexylcarbonyl group, a methyl group which is substituted by a naphthyl, methylnaphthyl, methoxynaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, -7 a methyl group which is substituted by a 2-phenylethenyl or a biphenylyl group, a methyl group which is substituted by a phenyl-oxadiazolyl, 5-methyl-3-phenyl isoxazolyl, phenyl-pyridinyl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, methylisoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2 dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro 3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl 4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a 2-methoxyethyl, 2-phenyloxyethyl or 2-cyanoethyl group, a phenylcarbonylmethyl or a 1-(phenylcarbonyl)-ethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino) carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylaminocarbonylmethoxy, C~~~~ ~ ~ ~ 8~nIDCRR24(N - O -8 dimethylaminocarbonylmethoxy, pyrrolidin-1 -ylcarbonylmethoxy or morpholin-4 ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 (methoxycarbonyl)-ethyloxy or a 1 -(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups or a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CH 2
-CH
2 -O or a -N(CH 3 )-CO-O group,
R
2 denotes a methyl, isopropyl or phenyl group and
R
3 denotes a 2-methyl-2-propen-1 -yl, 2-chloro-2-propen-1 -yl or 3-bromo-2-propen 1-yl group a 2-buten-1-yl or 2,3-dimethyl-2-buten-1-y group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group, C : PortbICC\RBR\28426W9 I.DOC -9 as well as the compounds 1 -(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl)-xanthine, 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -(1 -methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl) xanthine, 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl) xanthine, 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, C,\NRPonib\DCCRDBR\2 842609 1 DC - 10 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl) xanthine, 1 -methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 yl)-xanthine, 1 -methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin- 1 -yl)-xanthine, 1-methyl-3-(2- propyn-1-yI)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1-{2-[3-(2-oxo-imidazolidin-1 -yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -methyl-3-(2-propen-1 -yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine, 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 yl)-xanthine, 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, CAkNRPonbI\DCC\RBR\2942609-1 DOC 1 -[(cinnolin-4-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino-piperidin-1 yI)-xanthine, 1 -[(1 -methyl-2-oxo-1 ,2-d ihyd ro-quinolin-4-yI)methyl]-3-methyl-7-(3-methyl-2-buten 1 -yI)-8-(3-amino-piperid in-i -yI)-xanthine, I -[(4-oxo-3,4-dihydro-phthalazin- 1 -yI)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, 1 -[(quinazolin-4-yI)methylj-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -[(5-methyl-3-phenyl-isoxazol-4-yI)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)- 8 (3-amino-piperidin-1 -yI)-xanthine, 1 -[(isoquinolin-3-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperidin-1 -yi)-xanthine, 1 -[(3-phenyl- 1 ,2 ,4]oxad iazol-5-yI)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3 amino-piperidin-1 -yI)-xanthine, 1 -[(4-phenyl-pyrid in-2-yI)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -[(5-phenyl-pyridin-2-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yi)-8-(3-amino piperid in-I -yI)-xanthine, 1 -[(3-methyl-4-oxo-3 ,4-d ihyd ro-phthalazin-1 -yI) methyl]- 3-m ethyl-7-(3-meth yI-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, C.N1RFonbKfCCRBR\284 264 P)-I DC - 12 1 -[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI) 8-(3-amino-piperid in-i -yI)-xanthine, 1 -[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyll-3-methyl-7-(3-methyl-2-buten- 1 -yI) 8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2- (3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3 amino-piperidin-1 -yi)-xanthine, 1 -[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI) 8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten 1 -yI)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -{2-[3-(dimethylam inocarbonyl)-phenyl]-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[3-(morpholin-4-yI-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 -yi)-8-(3 amino-piperidin-1 -yI)-xanthine, I -[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, C.\,NRP-.bIKDCCIRflRX2842609-1 DOC - 13 1 -{2-[2-(d imethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[2-(morpholin-4-yI-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(2 ,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3 amino-piperidin-1 -yI)-xanthine, 1 -((E)-3-phenyl-aIlyI)-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino-piperidin-1 -yI) xanthine, 1 -[(benzo~b]thiophen-3-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperid in-I -yI)-xanthine, 1 -[(1 H-indol-3-yI)methyll-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3-amino-piperidin 1 -yI)-xanthine, 1 -[(biphenyl-4-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino-piperidin 1 -yI)-xanthine, 1 -(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -(3, 3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten- I -yi)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -({5-((methoxycarbonyl)methylamino]-isoquinolin- 1 -yllmethyl)-3-methyl-7-(3 methyl-2-buten-1 -yI)-8-(3-amino-piperidin- 1 -yI)-xanthine, C-\NRPlbInDCCRBR2X426(9 I DOC - 14 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(piperidin-1 -yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[(2-methyl-1 -oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-buten-1 -yl) 8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)- 8 -(3 amino-piperidin-1 -yl)-xanthine, 1-[2-(pyrrolidin-1 -yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3 amino-piperidin-1 -yl)-xanthine, 1 -methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -[(isoquinolin-1 -yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1 -yl) 8-(3-amino-piperidin-1-yl)-xanthine, C VNRPoMN\DC0RSRUW6(N - DOC - 15 I -(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yI)-8-(3-amino-piperid in-i -yI)-xanthine, 1 -[2-(2-{[(ethoxycarbonylamino)carbony]amino}-pheny)-2-oxo-ethy]-3-methy-7 (3-methyl-2-buten-1 -yI)-8-(3-amino-piperid in-i -yi)-xanthine, 1 -[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-((S) 3-amino-piperidin-1 -yI)-xanthine, 1 -(2-{2-[(methylaminocarbonyl)methoxyJ-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yI)-8-((S)-3-amino-piperid in-i -yI)-xanthine, 1 -methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin- 1 -yI)-xanthine, 1 -(2-{2-[(isopropylcarbonyl)amino]-phenyl)-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-i -yI)-8-(3-amino-piperid in-i -yI)-xanthine, 1 -(2-{2-[(methoxycarbonyl)am ino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten- 1 -yI)-8-(3-amino-piperid in-i -yI)-xanthine, 1 -[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-y)-2-oxo-ethyll-3-methyl-7-(3 methyl-2-buten-i -yI)-8-(3-amino-piperidin-i -yI)-xanthine, 1 -[2-(2-n itro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8 (3-amino-piperidin-i -yI)-xanthine, 1 -[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI) 8-(3-amino-piperidin-i -yi)-xanthine, C:INRPonbl\DCCRBR\2842(AN_ LDOC - 16 1-[2-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[(3-methyl-isoquinolin-1 -yl)methyl]-3-methyl-7-(3-methyl-1 -buten-1 -yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, 1-[(3-methyl-isoquinolin-1 -yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1-yl)-xanthine and 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1 -yl)-xanthine, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof. A first preferred sub-group of the first object of the invention comprises compounds of general formula I wherein
R
1 denotes a 4-methoxy-1-naphthylmethyl group, a 2-quinolinylmethyl, 4-quinolinylmethyl or a 6-quinolinylmethyl group, a 1-isoquinolinylmethyl, 3-methyl-1-isoquinolinylmethyl, 4-methyl-1-isoquinolinyl methyl or a 3-isoquinolinylmethyl group or a 2-quinazolinylmethyl, 4-methyl-2-quinazolinylmethyl or a 4-quinazolinylmethyl group, C.N'4P-lO C'IBR8460-IDO-C -17
R
2 denotes a methyl group and
R
3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A second preferred sub-group of the first object of the invention comprises compounds of general formula 1, wherein
R
1 denotes a [2-(methylcarbonylamino)-phenyl]-carbonylmethy group, a [2-(ethylcarbonylamino)-phenyl]-carbonylmethyl group or a [2-(isopropylcarbonylamino)-phenyl]-carbonylmethyl group,
R
2 denotes a methyl group and
R
3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A third preferred sub-group of the first object of the invention comprises compounds of general formula I according to claim 1, wherein R' denotes a [2-(aminocarbonylmethoxy)-phenyl]-carbonylmethyl group, [2-(methylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group, C:\NRPortblCC\RBR\2842609 LDOC - 18 a [2-(ethylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group or a [2-(isopropylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group,
R
2 denotes a methyl group and
R
3 denotes a 2-buten-1-yl group, a 2-butyn-1-yl group or a 1-cyclopenten-1-ylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A second object of the invention relates to compounds of general formula I, wherein
R
1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, a methyl group which is substituted by a phenanthrenyl group, a methyl group which is substituted by a 2-phenylethenyl, 2-[(trifluoromethyl) phenyl]-ethenyl, 2-(nitrophenyl)ethenyl, 2-(pentafluorophenyl)ethenyl or a biphenylyl group, a methyl group which is substituted by a phenyloxadiazolyl, phenylpyridinyl, indolyl, methylindolyl, dimethyl-6,7-dihydro-5H-[2]pyrindinyl, benzimidazolyl, methylbenzimidazolyl, (cyanoethyl)-benzimidazolyl, (methylaminocarbonylmethyl)- C RPohn\DlCCRBR\242609- DOC - 19 benzimidazolyl, benzylbenzimidazolyl, benzofuranyl, acetylbenzofuranyl, cyanobenzofuranyl, benzoxazolyl, nitrobenzoxazolyl, benzothiophenyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methyl isoquinolinyl, (difluoromethyl)-isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethyl isoquinolinyl, (1-cyano-l-methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxy isoquinolinyl, methoxy-chloro-isoquinolinyl, methoxy-bromo-isoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, dimethyl-5,6,7,8 tetrahydroisoquinolinyl, 1,2,3,4-tetrahydrophenanthridinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino)-quinazolinyl, pyrrolidin-1 ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1-ylquinazolinyl, morpholin-4 ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, phenyloxyquinazolinyl, imidazo[1,2-a]pyridinyl, methylimidazo[1,2-a]pyridinyl, phenylimidazo[1,2 alpyridinyl, benzylimidazo[1,2-a]pyridinyl, pyrazolo[1,5-alpyridinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, methylphthalazinyl, naphthyridinyl, 2,3-dihydro-benzo[1,4]dioxinyl, 1,2-dihydro-2 oxo-quinolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2-dihydro-2-methyl-1-oxo isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro-3-methyl-4-oxo-phthal azinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl-4-oxo-quinazoliny or a 2-oxo-2H-chromenyl group, a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, (ethyloxycarbonylmethyl)amino, (methylaminocarbonyl)methylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, phenylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino)-carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, C:\N b\DCC\RBR\2 2609 ].DOC - 20 a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy, carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylamino carbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4-ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 (ethyloxycarbonyl)-1 -methyl-ethyloxy, 1 -(methoxycarbonyl)-ethyloxy or a 1 (aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and a nitro group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and an amino group, C XNftortbIMCCkRBRU426AN_ I WOC -21 a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CF 2 -0, -O-CH 2
-CH
2 -0, -NH-CO NH, -N(CH 3 )-CO-NH, -N(CH 3
)-CO-N(CH
3 ), -NH-CO-0- or a -N(CH 3 )-CO-0 group, a (2-phenylethyl)carbonylmethyl group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group,
R
2 denotes a methyl, isopropyl, cyclopropyl, phenyl or fluorophenyl group and
R
3 denotes a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen 1-yl group a 1-buten-1-yl, 3-methyl-1-buten-1-yl, 2-buten-1-yl, 2-methyl-2-buten-1-yl or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof.
C:NRPortb\DCC\RBR\28426M9 LDOC - 22 A preferred sub-group of the second object of the invention comprises compounds of general formula I wherein R' and R 2 are as hereinbefore defined and
R
3 denotes a 1-buten-1-yl, 2-buten-1-yI or 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A particularly preferred sub-group of the second object of the invention comprises compounds of general formula I wherein R' denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1 methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxyisoquinolinyl, 1,2,3,4 tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino) quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1 ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, [1,5]naphthyridinyl, [1,6]naphthyridinyl, [1,8]naphthyridinyl or a 1,2-dihydro-1-methyl-2-oxo-quinolinyl group, C NRPnbWCC\RBR\2842609 1.DOC -23 a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CF 2 -0, -O-CH 2
-CH
2 -0, N(CH 3
)-CO-N(CH
3 ) or a -N(CH 3 )-CO-0 group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group,
R
2 denotes a methyl, isopropyl, cyclopropyl, phenyl or 4-fluorophenyl group and
R
3 denotes a 1-buten-1-yl, 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A second preferred sub-group of the second object of the invention comprises compounds of general formula 1, wherein R 1 and R 2 are defined as immediately above and R 3 denotes a 1-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
C:\NRPonb\DCC\RR\28426"9 L DOC - 24 A third preferred sub-group of the second object of the invention comprises compounds of general formula I wherein R 1 and R 2 are defined as immediately above and R 3 denotes a 2-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A fourth preferred sub-group of the second object of the invention comprises compounds of general formula I wherein R 1 and R 2 are defined as immediately above and R 3 denotes a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A third object of the invention relates to compounds of general formula I wherein
R
1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl- group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, or a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1 methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxyisoquinolinyl, 1,2,3,4 tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino) quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1 ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, [1,5]naphthyridinyl, [1,6]naphthyridinyl, [1,8]naphthyridinyl or a 1,2-dihydro-1-methyl-2-oxo-quinoliny group, C \NRPortb[DCC\RBR\25426tNI DOC -25
R
2 denotes a methyl, isopropyl, cyclopropyl or phenyl group and
R
3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A first preferred sub-group of the third object of the invention comprises compounds of general formula I wherein
R
1 denotes a (3-methyl-isoquinolin-1-yl)methyl group,
R
2 denotes a methyl group and
R
3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A second preferred sub-group of the third object of the invention comprises compounds of general formula I wherein R 1 and R 2 are as hereinbefore defined and R 3 denotes a 2-chlorobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A third preferred sub-group of the third object of the invention comprises compounds of general formula I wherein R 1 and R 2 are as hereinbefore defined and R 3 denotes a 2-bromobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
C\N'RPonbIVDCM~BR\2X4.264)vI DOC - 26 A fourth preferred sub-group of the third object of the invention comprises compounds of general formula I wherein R 1 and R 2 are as hereinbefore defined and R 3 denotes a 2-ethynylbenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. A fifth preferred sub-group of the third object of the invention comprises compounds of general formula I wherein R 1 and R 2 are as hereinbefore defined and R 3 denotes a 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. Most particularly preferred are the following compounds of general formula 1: (1) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1 yl)-xanthine, (2) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, (3) 1 -(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yI)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, (4) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten- 1 -yl)-8-((R)-3-amino-piperid in 1-yl)-xanthine, (5) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino piperidin-1 -yl)-xanthine, (6) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine, C'RPonb\DCCBRIR426O)_I1 DOC -27 (7) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino piperidin-1 -yl)-xanthine, (8) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yi)-xanthine, (9) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-(3-(R)-amino-piperidin-1 -yl)-xanthine, (10) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine, (11) 1-[(4-methoxy-naphthalen-1 -yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (12) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1-yl)-xanthine, (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino piperidin-1 -yl)-xanthine, (14) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-((S)-3-amino-piperidin- 1 -yl)-xanthine, (15) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, (16) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine, C XNRPonbmCCRBR\2g.&2(AP, DOC -28 (17) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-((R)-3-amino-piperidin-1 -yi)-xanthine, (18) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, (19) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine, (20) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine, (21) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-((R)-3-amino piperidin-1-yl)-xanthine, (22) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1-yl)-xanthine , (23) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1-yl)-xanthine , (24) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1-yl)-xanthine, (25) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1 -yl)-xanthine, (26) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine, C:VRP~tbWC,RR\2(6N- DOC - 29 (27) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (28) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (29) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3 amino-piperidin-1-yl)-xanthine and (30) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine as well as the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. According to the invention the compounds of general formula I are obtained by methods known per se, for example by the following methods: a) reacting a compound of general formula 0 R3 R N N wherein
R
1 to R 3 are as hereinbefore defined and C RPonbIlDCC\RBR\2M426tN I DOC - 30 Z' denotes a leaving group such as a halogen atom, a substituted hydroxy, mercapto, sulphinyl, sulphonyl or sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyl or methanesulphonyloxy group, with 3-aminopiperidine, the enantiomers thereof or the salts thereof. The reaction is expediently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, dimethylformamide, dimethylsulphoxide, ethyleneglycol monomethylether, ethyleneglycol diethylether or sulpholane, optionally in the presence of an inorganic or tertiary organic base, e.g. sodium carbonate, potassium carbonate or potassium hydroxide, a tertiary organic base, e.g. triethylamine, or in the presence of N-ethyl-diisopropylamine (Hunig base), while these organic bases may simultaneously also serve as solvent, and optionally in the presence of a reaction accelerator such as an alkali metal halide or a palladium-based catalyst at temperatures between -20 and 180*C, but preferably at temperatures between -10 and 120*C. The reaction may, however, also be carried out without a solvent or in an excess of the 3-aminopiperidine. b) deprotecting a compound of general formula 0 R3 \ N O Nl O N wherein R 1 , R 2 and R 3 are as hereinbefore defined. The tert.-butyloxycarbonyl group is preferably cleaved by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with C:\RPortbl\DCC\RBR\284269 I DOC -31 bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethyl ether at temperatures between 0 and 80 0 C. c) In order to prepare a compound of general formula I wherein R 1 according to the definition provided hereinbefore contains a carboxy group: deprotecting a compound of general formula O R3 NH2 N N (IV), O N N wherein R 2 and R 3 are as hereinbefore defined and R contains a carboxy group protected by a C 1 _-alkyl group. The protecting group is cleaved by hydrolysis, for example, using an acid such as hydrochloric acid or sulphuric acid or an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent such as metha nol, ethanol, isopropanol, tetrahydrofuran or dioxane in the presence of water. In the reactions described hereinbefore, any reactive groups present such as carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction. For example, a protecting group for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and C \NRPotbr\DCC\RBR\242609 I DOC - 32 protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group. Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0 C, preferably at temperatures between 10 and 100C. However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100*C, but preferably at temperatures between 20 and 60*C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisol. A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxan, methanol or diethylether. A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 1200C, or by treating with sodium hydroxide CA1NRPonbhDCCRBR\242609 I DC - 33 solution, optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50*C. A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50*C. Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers. Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above. The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst -34 the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl. Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid. Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, etha nolamine, diethanolamine and triethanolamine. The compounds of general formulae Il to IV used as starting materials are either known from the literature or may be obtained by methods known from the literature (cf. Examples I to LXXI). As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV. The biological properties of the new compounds were investigated as follows: C:\NPorbl\DCC\RBR\2846091 DOC - 35 The ability of the substances and their corresponding salts to inhibit the DPP-IV activity can be demonstrated in a test set-up in which an extract of human colon carcinoma cell line Caco-2 is used as the DPP-IV source. The differentiation of the cells in order to induce the DPP-IV expression was carried out as described by Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco 2" , which appeared in Proc. Nati. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was obtained from cells solubilised in a buffer (10mM Tris HCI, 0.15 M NaCl, 0.04 t.i.u. aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g of for 30 minutes at 4*C (to remove cell debris). The DPP-IV assay was carried out as follows: 50 pl substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final concentration 100 pM, were placed in black microtitre plates. 20 pl of assay buffer (final concentrations 50 mM Tris HCI pH 7.8, 50 mM NaCl, 1 % DMSO) was pipetted in. The reaction was started by adding 30 pl of solubilised Caco-2 protein (final concentration 0.14 pg of protein per well). The test substances to be investigated were typically added prediluted in 20 pl, and the volume of assay buffer was then reduced accordingly. The reaction was carried out at ambient temperature, incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420 Multilabel Counter, the excitation wavelength being 405 nm and the emission wavelength being 535 nm. Blank readings (corresponding to 0 % activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100 % activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as IC 50 values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained: Compound DPP-IV inhibition (Example no.) IC 50 [nM] 2(3) 2160 C.ANRPo,.bI\DCMBR24Z&O -I.DOC -36 2(9) 264 2(12) 16 2(17) 32 2(20) 12 2(25) 4 2(27) 9 2(35) 5 2(37) 5 2(43) 6 2(51) 6 2(52) 9 2(59) 250 2(66) 22 2(80) 1 2(86) 2 2(96) 2 2(99) 1 2(100) 3 2(108) 3 2(129) 3 2(130) 3 2(131) 3 2(132) 1 2(135) 3 2(137) 13 2(138) 8 2(139) 4 2(142) 1 2(145) 4 2(148) 1 C:\NRPoftb CC\RBR\242609_I DOC -37 2(150) 1 2(151) 3 2(152) 4 2(185) 3 2(217) 4 2(247) 2 2(251) 12 2(256) 8 2(260) 13 2(264) 6 2(277) 6 2(280) 5 2(285) 3 2(287) 11 2(288) 14 The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 2(80) were administered to rats by oral route no changes in the animals' behaviour could be detected. In view of their ability to inhibit DPP-IV activity, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type 1 and type 2 diabetes mellitus, diabetic complications (such as e.g. retinopathy, nephropathy or neuropathies), metabolic acidosis or ketosis, reactive hypoglycaemia, insulin resistance, metabolic syndrome, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. In addition these substances are capable of preventing B-cell C:NRPo1bPlDCC\RRR\2Z4269) 1.DOC - 38 degeneration such as e.g. apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV inhibition, it is likely that the compounds according to the invention are suitable for achieving, inter alia, a sedative or anxiety-relieving effect and also for favourably affecting catabolic states after operations or hormonal stress responses or reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. Furthermore, the compounds according to the invention may be used to treat inflammatory diseases of the respiratory tract. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases such as e.g. irritable bowel syndrome (IBS), Crohn's disease or ulcerative colitis and also pancreatitis. It is also likely that they can be used for all kinds of damage to or impairment of the gastrointestinal tract such as colitis and enteritis, for example. It is also expected that DPP-IV inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the infertility is connected with insulin resistance or polycystic ovary syndrome. On the other hand these substances are suitable for affecting sperm motility and can thus be used as male contraceptives. The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature, and may also be used to advantage in any indications in which growth hormone may be used. The compounds according to the invention are also suitable, on the basis of their inhibitory effect on DPP-IV, for treating various autoimmune diseases such as e.g. rheumatoid arthritis, multiple sclerosis, thyroiditis and Basedow's disease, etc. They may also be used to treat viral diseases and also, for example, in HIV infections, for stimulating blood production, in benign prostatic hyperplasia, gingivitis, as well as for the treatment C NRPo 4UCCR8R%2842&)9_1D0C - 39 of neuronal defects and neurodegenerative diseases such as Alzheimer's disease, for example. The compounds described may also be used for the treatment of tumours, particularly for modifying tumour invasion and also metastasisation; examples here are their use in treating T-cell lymphomas, acute lymphoblastic leukaemia, cell-based pancreatic carcinomas, basal cell carcinomas or breast cancers. Other indications are stroke, ischaemia of various origins, Parkinson's disease and migraine. In addition, further indications include follicular and epidermal hyperkeratoses, increased keratinocyte proliferation, psoriasis, encephalomyelitis, glomerulonephritis, lipodystrophies, as well as psychosomatic, depressive and neuropsychiatric diseases of all kinds. The compounds according to the invention may also be used in conjunction with other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI 262570) and antagonists, PPAR-gamma/alpha modulators (e.g. KRP 297), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), other DPPIV inhibitors, alpha2 antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. Also, SGLT2 inhibitors such as T-1095, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6 phosphatase, or fructose- 1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and its derivatives, PPAR-alpha agonists, PPAR-delta agonists, ACAT inhibitors (e.g. avasimibe) or cholesterol resorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, inhibitors of ileac bile acid transport, HDL-raising compounds such as for example inhibitors of CETP or regulators of ABC1 or C NRPorb\CCRBR\2542609 LDOC - 40 active substances for the treatment of obesity, such as e.g. sibutramine or tetrahydrolipostatin, dexfenfluramine, axokine, antagonists of the cannabinoid1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or B 3 -agonists such as SB-418790 or AD-9677 as well as agonists of the 5HT2c receptor. It is also possible to combine the compounds with drugs for treating high blood pressure such as e.g. All antagonists or ACE inhibitors, diuretics, B-blockers, Ca antagonists, etc., or combinations thereof. The dosage required to achieve such an effect is expediently, by intravenous route, 1 to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories. The Examples that follow are intended to illustrate the invention: C \NRPortbiDCCRBR\2842609 1.DOC -41 Preparation of the starting compounds: Example I 1, 3-d imethyl-7-(2.6-d icyano-benzvl)-8-bromo-xanth ine A mixture of 555 mg of 8-bromotheophyllin and 0.39 ml of Hunig base in 9 ml N,N dimethylformamide is combined with 600 mg of 2-bromomethyl-isophthalonitrile and stirred overnight at ambient temperature. For working up the reaction mixture is poured onto water. The precipitate formed is suction filtered, washed with water and dried. Yield: 686 mg (83 % of theory) Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 399, 401 [M+H]* The following compounds are obtained analogously to Example 1: (1) 3-methyl-7-(3-methyl-2-buten-1 -yl)-8-ch loro-xanthine Mass spectrum (ESIl): m/z = 269, 271 [M+H]* (2) 3-methyl-7-(2-cyano-benzyl)-8-chloro-xanth ine Mass spectrum (ESl*): m/z = 316, 318 [M+H]* (3) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn- 1 -yl)-8-bromo-xanthine Mass spectrum (ESIl): m/z = 415, 417 [M+H]* (4) 3-methyl-7-[(2-trimethylsilanyl-ethoxy)methyl]-8-bromo-xanth ine (Carried out in the presence of potassium carbonate) Mass spectrum (ESI*): m/z = 375, 377 [M+H]* (5) 3-methyl-7-(3-methyl-2-buten-1-yl)-8-bromo-xanthine Mass spectrum (ESl*): m/z = 313, 315 [M+H]* C '.IPo.bI3RBRU2S426)9_I.DC - 42 (6) 3-methyl-7-(2,3-d imethyl-2-buten- 1 -yl)-8-bromo-xanth ine Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 327, 329 [M+H]* (7) 3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.72 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 297/299 [M+H]* (8) 3-methyl-7-((E)-2-buten- 1 -yl)-8-bromo-xanthine (The product is contaminated with approx. 10-20 % of Z compound) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/methanol = 6:3:1) Mass spectrum (ESI*): m/z = 299, 301 [M+H]* (9) 3-methyl-7-[(1 -cyclopenten-1 -yl)methyl]-8-bromo-xanthine Mass spectrum (ESl*): m/z = 325, 327 [M+H]* (10) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-bromo xanthine Mass spectrum (ESl*): m/z = 443, 445 [M+H]* (11) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-bromo-xanthine (product contains approx. 25 % of Z isomer) Mass spectrum (ESl*): m/z = 417, 419 [M+H]* (12) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-aIlyl)-8-bromo-xanthine Rf value: 0.71 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 417, 419 [M+H]* (13) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyl)-8-bromo-xanthine Rf value: 0.68 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 481, 483, 485 [M+H]* C kNRPolb~klCCRBR2842(AN_ I.DC - 43 (14) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-bromo-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 443, 445 [M+H]* (15) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-bromo-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 437, 439, 441 [M+H]* (16) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-1-yl)-8-bromo xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 431, 433 [M+H]* (17) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-1-yl)-8-bromo xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 431, 433 [M+H]* (18) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(1-phenylsulphanyl-butyl)-8-bromo xanthine Rf value: 0.83 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 527, 529 [M+H]* (19) 3-methyl-7-(3-methyl- 1-phenylsulphanyl-butyl)-8-bromo-xanthine (The [(1-chloro-3-methyl-butyl)sulphanyl]-benzene used as starting material for the reaction is obtained by chlorination of [(3-methyl-butyl)sulphanyl]-benzene with N chloro-succinimide in carbon tetrachloride) Rf value: 0.38 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 423, 425 [M+H]* CANRPobrDCCRBR\2842&9 . DOC - 44 (20) 1,3-d imethyl-7-(2-bromo-benzyl)-8-chloro-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) (21) 1,3-d imethyl-7-(2-chloro-benzyl)-8-chloro-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) (22) 3-cyclopropyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 223/225 [M+H]* Example il 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yll-xanthine 63 mg of ethyl bromoacetate are added to a mixture of 200 mg of 1-[2-(2-hydroxy phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine and 63 mg of potassium carbonate in 3 ml N,N-dimethylformamide. The reaction mixture is stirred for five hours at ambient temperature. For working up it is combined with water and the precipitate formed is suction filtered, washed with water and dried for three hours at 80*C in the drying cupboard. Yield: 216 mg (94 % of theory) Mass spectrum (ESl*): m/z = 653 [M+H]* The following compounds are obtained analogously to Example II: (1) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 624 [M+H]* CNR~onbPOCCRBRVU2Uw DC - 45 (2) 1-(2-{3-[(methylsulphanyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESl*): m/z = 627 [M+H]* (3) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 3:7) (4) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 638 [M+H]* (5) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 652 [M+H]* (6) 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 639 [M+H]* (7) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 636 [M+H]* (8) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1 cyclopenten-1 -yl)methyll-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 650 [M+H]* (9) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C Pcnb4CC RBR 42(AW I DOC - 46 Mass spectrum (ESl*): m/z = 622 [M+H]* (10) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI*): m/z = 608 [M+H]* (11),1 -(2-{2-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 623 [M+H]* (12) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 667 [M+H]* (13) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 622 [M+H]* (14) 1 -(2-{2-[(methylam inocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains some Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 624 [M+H]* (15) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 636 [M+H]* (16) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI*): m/z = 622 [M+H]* C-PN'obCRBU42&Y-_I DOC - 47 (17) 1-(2-{2-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 639 [M+H]* (18) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 638 [M+H]* (19) 2-(2-acetyl-phenoxy)-N-ethyl-acetamide Mass spectrum (ESI*): m/z = 222 [M+H]* (20) 1-{2-[2-(1-methoxycarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Mass spectrum (ESI): m/z = 637 [M+H]* (21) 1-{2-[2-(1-aminocarbonyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 622 [M+H]* (22) 2-(2-acetyl-phenoxy)-N-methyl-acetamide Mass spectrum (ESI): m/z = 208 [M+H]* (23) 1-{2-[2-(2-oxo-propoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI*): m/z = 607 [M+H]* (24) 1-{2-[2-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7 (2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI*): m/z = 665 [M+H]* CIN RPonDCMBR'a2846(WI DC - 48 (25) 1-{2-{2-cyanomethoxy-phenyl]-2-oxo-ethyl}-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (ESl*): m/z = 590 [M+H]* (26) 1-(2-{2-[(methylsulphanyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 611 [M+H]* (27) 1-{[2-(tert.-butylcarbonyl)-benzofuran-3-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Formed as main product when 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7 (2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine is reacted with 1-chloro-3,3-dimethyl-butan-2-one) Mass spectrum (ESl*): m/z = 631 [M+H]* Example Ill 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yll-xanthine 1.30 g of 3-tert.-butyloxycarbonylamino-piperidine are added to a mixture of 2.51 g of 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 chloro-xanthine and 880 mg of sodium carbonate in 8 ml of dimethylsulphoxide. The reaction mixture is stirred for 18 hours at 60"C. For working up it is combined with water and the precipitate formed is suction filtered. The solid crude product is dissolved in ethyl acetate, the solution is dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with cyclohexane/ethyl acetate (10:1 to 1:1) as eluant. Yield: 2.56 g (91 % of theory) Mass spectrum (ESI*): m/z = 567 [M+H]* The following compounds are obtained analogously to Example Ill: C:\4RPortb\DCC\RBR\28426th 1.DOC -49 (1) 3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine Mass spectrum (ESI): m/z = 433 (M+H]* (2) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 565 [M+H]* (3) 3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylam ino)-piperid in- 1-yl] xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI-): m/z = 478 [M-H] (4) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 552 [M+H]* (5) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 519 [M+H]* (6) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 518 [M+H]* (7) 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate/methanol = 7:2:1) Mass spectrum (ESl*): m/z = 596 [M+H]* C kNRPonbMCRBR\282609-1 DC -50 (8) 1 -methyl-3-(2-propen- 1 -yl)-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 520 [M+H]* (9) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 535 [M+H]* (10) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.52 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESIl): m/z = 596 [M+H]* (11) 1 -methyl-3-phenyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 556 [M+H]* (12) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 596 [M+H]* (13) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine mixed with 1 -[(1,4-dihydro-cinnolin 4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Rf value: 0.62 (silica gel, ethyl acetate) (14) 1-({4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1-yl} methyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine (Carried out with potassium carbonate in the presence of Hunig base) C3NRPo,,bflCCRkBRU&426W I DC -51 Rf value: 0.27 (silica gel, cyclohexane/ethyl acetate 1:1) Mass spectrum (ESl*): m/z = 720 [M+H]* (15) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.31 (silica gel, ethyl acetate/petroleum ether = 7:3) Mass spectrum (ESl*): m/z = 574 [M+H]* (16) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5) Mass spectrum (ESl*): m/z = 605 [M+H]* (17) 3-methyl-7-(2,3-dimethyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.42 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 447 [M+H]* (18) 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl] xanthine (Carried out with potassium carbonate) Melting point: 235-237*C Mass spectrum (ESl*): m/z = 417 [M+H]* (19) 1-[(quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.36 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 558 [M+H]* C.\NRPortbI\DCC\RBR\282609 1. DOC -52 (20) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.71 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 558 [M+H]* (21) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine (Carried out with potassium carbonate; the product contains approx. 20 % of Z isomer) Rf value: 0.24 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESl*): m/z = 560 [M+H]* (22) 3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.64 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 417 [M+H]* (23) 3-methyl-7-(2-butyn-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin- 1 yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.64 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 417 [M+H]* (24) 3-methyl-7-((E)-2-buten-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperid in 1-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ ethyl acetate = 3:7) Mass spectrum (ESI*): m/z = 419 [M+H]* C \NR~oflbOfCC BRQM826)9- 1, DOC - 53 (25) 3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 419 [M+H]* (26) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (ESl*): m/z = 551 [M+H]* (27) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 578 [M+H]* (28) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 563 [M+H]* (29) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl] 8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 579 [M+H]* (30) 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Mass spectrum (ESI*): m/z = 522 [M+H]* (31) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 551 [M+H]* CxN1RPo, brnCC\,RBR2X2e39)I DOC - 54 (32) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 10 % of Z isomer) Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate =1:1) Mass spectrum (ESI*): m/z = 552 [M+H]* (33) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 25 % of Z isomer) Mass spectrum (ESI): m/z = 537 [M+H]* (34) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (35) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yI)-8-[3-(tert.
butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine (product contains some Z isomer) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESl*): m/z = 553 [M+H]* (36) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 551 [M+H]* (37) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 550 [M+H]* (38) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 [(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C:\NRPortb\DCCRBR\28426419 1.DOC - 55 Mass spectrum (ESI*): m/z = 567 [M+H]* (39) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 535 [M+H]* (40) 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 610 [M+H] (41) 3-methyl-7-(2-butyn-1-yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-i yl]-xanthine (Carried out with potassium carbonate) Rf value: 0.52 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 417 [M+H]* (42) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-allyl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.46 (silica gel, methylene chloride/methanol = 95:5) (43) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.22 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 601, 603 [M+HJ (44) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.41 (silica gel, methylene chloride/methanol = 95:5) (45) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C .NRPonbl'DCCBR2&& 2"- LDC - 56 Rf value: 0.49 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ES*): m/z = 557, 559 [M+H]* (46) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 535 [M+H]* (47) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESl*): m/z = 552 [M+H]* (48) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:2) (49) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 582 [M+H]* (50) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 626 [M+H]* (51) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-7 yl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 738 [M+H]* (52) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C \f~n b XM RU42 I- DOC - 57 Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 551 [M+H]* (53) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 551 [M+H]* (54) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-4 yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 722 [M+H]* (55) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 615 [M+H]* (56) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 615 [M+H]* (57) 1-[(1-methyl-1H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxy-carbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 560 [M+HJ (58) 1-[(quinolin-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 558 [M+H]* C kNRPonbIPDCCRBR\2426o9-I.DOC -58 (59) 1-{[1-(tert.-butyloxycarbonylamino)-1H-indol-2-yl]methyl}-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 646 [M+H]* (60) 1-[(2-methyl-1-((2-trimethylsilanyl-ethoxy)methyl]-1H-benzoimidazol-5 yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 yl]-xanthine (mixed with 1-[(2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine) Rf value: 0.15 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 691 [M+H]* (61) 1-[2-(quinolin-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 586 [M+Hj (62) 1 -[(1 -[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl)methyl]-3 methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (mixed with1-[(3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl)methyl] 3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl] xanthine) Rf value: 0.23 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 677 [M+H]* (63) 1-[(pyrazolo[1,5-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.46 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 547 [M+H]* C-kNRPorbDCC\RBR\2g426N9I .DOC - 59 (64) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-1-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 537 [M+H]* (65) 1-{2-[1-(tert.-butyloxycarbonyl)-1H-indol-7-yl]-2-oxo-ethyl}-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.38 (silica gel, petroleum ether/ethyl acetate = 1:1) (66) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8 [(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanth ine Rf value: 0.40 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 588 [M+H]* (67) 1,3-dimethyl-7-(2-bromo-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) (68) 1,3-dimethyl-7-(2-chloro-benzyl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine Rf value: 0.42 (silica gel, cyclohexane/ethyl acetate = 1:1) (69) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 635 [M+H]* Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) (70) 3-cyclopropyl-7-(2-butyn- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 yl]-xanthine Mass spectrum (ESl*): m/z = 443 [M+H]* Rf value: 0.70 (silica gel, ethyl acetate) C:N RPonbI\DCCORBR\2P426)9 LDOC - 60 (71) 3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 443 [M+H]* (72) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (ESI*): m/z = 644, 646 [M+H]* Rf value: 0.39 (silica gel, cyclohexane/ethyl acetate = 1:1) (73) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanth ine Mass spectrum (ESI): m/z = 644, 646 [M+H]* (74) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Prepared by reacting (4-methyl-q u inazolin-2-yl)-methylchloride and 3-methyl-7-(2 chlorobenzyl)-8-bromo-xanthine and subsequently reacting with (R)-3-(tert.
butyloxycarbonylamino)-piperidine Mass spectrum (ESl*): m/z = 645, 647 [M+H]* (75) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Prepared by reacting (4-phenyl-quinazolin-2-yl)-methylchloride and 3-methyl-7-(2 ch lorobenzyl)-8-bromo-xanthine and subsequently reacting with (R)-3-(tert.
butyloxycarbonylamino)-piperidine Mass spectrum (ESI): m/z = 707, 709 [M+H]* Example IV C kNRPobrUDCGBRUKl42N9 I DC -61 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-chloro xanthine Prepared by treating 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1-yl)-8-chloro-xanthine with boron tribromide in methylene chloride. The desired product is contaminated with approx. 20 % 1-[2-(2-hydroxy-phenyl)-2-oxo ethyl]-3-methyl-7-(3-bromo-3-methyl-butyl)-8-chloro-xanthine. Mass spectrum (ESI): m/z = 403, 405 [M+H]* The following compounds are obtained analogously to Example IV: (1) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine (product is contaminated with approx. 20 % 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl] 3-methyl-7-(3-bromo-2-buten-1 -yl)-8-bromo-xanthine) Mass spectrum (ESl*): m/z = 431, 433 [M+H]* (2) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8 bromo-xanthine Mass spectrum (ESl*): m/z = 459, 461 [M+H]* (3) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo xanthine (product contains some Z isomer) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESl*): m/z = 433, 435 [M+H]* (4) 1-[2-(2-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 bromo-xanthine Mass spectrum (ESl*): m/z = 447, 449 [M+H]* Example V C \NRPonbPDCC'BR\2K42&N- I DOC - 62 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-chloro xanthine 1.71 g of 2-bromo-1-(2-methoxy-phenyl)-ethanone are added to a mixture of 2.00 g of 3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro-xanthine and 1.38 mg of potassium carbonate in 15 ml of N,N-dimethylformamide. The reaction mixture is stirred for eight hours at ambient temperature. After aqueous working up the crude product is purified by chromatography through a silica gel column with cyclohexane/ethyl acetate (8:1 to 8:1) as eluant. Yield: 2.61 g (84 % of theory) Mass spectrum (ESIl): m/z = 417, 419 [M+H]* The following compounds are obtained analogously to Example V: (1) 1-[2-(3-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (The reaction is carried out with 2-bromo-1-[3-(tert.-butyldimethylsilanyloxy) phenyl]-ethanone) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 567 [M+H]* (2) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro xanthine Mass spectrum (ESI): m/z = 401, 403 [M+H]* (3) 1-(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-chloro-xanth ine Mass spectrum (ESl*): m/z = 391, 393 [M+Na]* (4) 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 600 [M+H]* C:V4RPonbCG'R BRV 4 2&)9- DOC - 63 (5) 1-(2-phenyl-2-oxo-ethyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI): m/z = 667 [M+H]* (6) 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 538 [M+H]* (7) 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-xanthine Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 412 [M+H]* (8) 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 7:2:1) Mass spectrum (ESl*): m/z = 432, 434 [M+H* (9) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(2-trimethylsilanyl-ethoxy)methyl]-8 bromo-xanthine Mass spectrum (ESl*): m/z = 493, 495 [M+H]* (10) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro xanthine Rf value: 0.64 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 432, 434 [M+H]* (11) 1 -[2-(2-n itro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-bromo xanthine Mass spectrum (ESl*): m/z = 476, 478 [M+H]* C:NRPnbr\DCC\RDR\28426"9 I DOC - 64 (12) 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.45 (silica gel, ethyl acetate/petroleum ether = 7:3) Mass spectrum (ESl*): m/z = 574 [M+H]* (13) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (The starting material 4-bromomethyl-chromen-2-one is prepared analogously to Kimura et al., Chem. Pharm. Bull. 1982, 30, 552-558.) Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 591 [M+H]* (14) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 604 [M+H]* (15) 1-[(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Melting point: 195-197 0 C Mass spectrum (ESl*): m/z = 575 [M+H]* (16) 1 -[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 604 [M+Hj (17) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.18 (silica gel, petroleum ether/ethyl acetate = 2:1) C:NRPonbI\DCC\RBR\2424 .I.DOC - 65 Mass spectrum (ESl*): m/z = 591 [M+H]* (18) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.53 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 600 [M+H]* (19) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.73 (silica gel, ethyl acetate) Mass spectrum (ESIl): m/z = 600 [M+H]* (20) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.43 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 597 [M+H]* (21) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60*C) Rf value: 0.27 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI): m/z = 609 [M+H]* (22) 1-[2-(2- ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60*C) Rf value: 0.35 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 623 [M+H]* (23) 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-[3-(tert.-butyloxycarbonylam ino)-piperidin-1 -yl]-xanthine C:'NRPonbIUDCCMBR\2842(AN-1 DOC - 66 (Carried out in N-methylpyrrolidin-2-one at 60 0 C) Rf value: 0.53 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 611 [M+H]* (24) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2,3-dimethyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in N-methylpyrrolidin-2-one at 60 0 C) Rf value: 0.38 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 565 [M+H]* (25) 1-((E)-3-phenyl-allyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 549 [M+H]* (26) 1 -[(1 -benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten- 1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 579 [M+H]* (27) 1-{[1-(tert.-butyloxycarbonyl)-indol-3-yl]methyl}-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.61 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 662 [M+H]* (28) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.68 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 599 [M+H]* C kR~oflbIVDCMBR%28426fNI LDOC - 67 (29) 1-[(1-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESl*): m/z = 557 [M+H]* (30) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl) 8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI*): m/z = 588 [M+H]* (31) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Melting point: 163-165*C Mass spectrum (ESl*): m/z = 557 [M+H]* (32) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.95 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESl*): m/z = 531 [M+H]* (33) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 559 [M+H]* (34) 1-[(2-methyl-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 571 [M+H]* C~,lC: WCRR2SJ2.w DOC - 68 (35) 1-[(5-nitro-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) (36) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.23 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 518 [M+H]* (37) 1 -[2-(piperidin- 1 -yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.44 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 558 [M+H]* (38) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 588 [M+H]* (39) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.30 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 604 [M+H]* (40) 1-[(2-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 587 [M+H]* (41) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C:'N~olbM~C0RBR%~262&WI DC - 69 Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 587 [M+H]* (42) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 572 [M+H]* (43) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-l-yl) 8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 611 [M+H]* (44) 1-[(5-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.78 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 602 [M+H]* (45) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.39 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 544 [M+H]* (46) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 572 [M+H]* (47) 1-[(2-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.78 (silica gel, ethyl acetate) CA.NRPoribrDCC\RB R\.2g4260') [ DC - 70 Mass spectrum (ESI*): m/z = 557 [M+H]* (48) 1-cyanomethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 456 [M+H]* (49) 1-[(quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonyl amino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 558 [M+H]* (50) 1-[(3-methoxy-naphthalen-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.83 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 587 [M+H]* (51) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.38 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESl*): m/z = 609 [M+H]* (52) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7 (3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with potassium-tert. butoxide in dimethylsulphoxide) Rf value: 0.48 (silica gel, ethyl acetate/petroleum ether = 2:1) Mass spectrum (ESl*): m/z = 622 [M+H]* (53) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 595 [M+H]* C:\NRPortbI\CC\RBR\842tN LDOC - 71 (54) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 559 [M+H]* (55) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxy carbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI*): m/z = 559 [M+H]* (56) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.30 (silica gel, ethyl acetate/cyclohexane = 8:2) Mass spectrum (ESI*): m/z = 561 [M+H]* (57) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine (product contains approx. 15 % of Z isomer) Rf value: 0.30 (silica gel, ethyl acetate/cyclohexane = 8:2) Mass spectrum (ESIl): m/z = 561 [M+H]* (58) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 17 % of Z isomer) Rf value: 0.58 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 574 [M+H]* (59) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 17 % of Z isomer) Rf value: 0.58 (silica gel, methylene chloride/methanol = 95:5) C kNRPa,,NODCMRR\2426N- DO - 72 Mass spectrum (ESl*): m/z = 574 [M+H]* (60) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine Mass spectrum (ESl*): m/z = 445, 447 [M+H]* (61) 1 -[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1 -cyclopenten- 1 -yl)methyl]-8 bromo-xanthine Mass spectrum (ESI*): m/z = 488, 490 [M+H]* (62) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl] 8-bromo-xanthine Mass spectrum (ESl*): m/z = 473, 475 [M+H]* (63) 1-[(isoquinolin-1-yl)methyll-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten 1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 95:5) (64) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yI)-8-bromo xanthine (product contains approx. 10 % of Z isomer) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI*): m/z = 462, 464 [M+H]* (65) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo xanthine (product contains some Z isomer) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 447, 449 [M+H]* (66) 1 -[2-(2-n itro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- 1 -yl)-8-bromo-xanthine CNRPorb\DCCRBR\24269 .DOC - 73 Rf value: 0.77 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 460, 462 [M+H]* (67) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 20 % of Z isomer) Mass spectrum (ESl*): m/z = 537 [M+H]* (68) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 bromo-xanthine Mass spectrum (ESl*): m/z = 461, 463 [M+H]* (69) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-bromo-xanthine Rf value: 0.61 (silica gel, cyclohexane/ethyl acetate = 4:6) (70) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 17 % of Z isomer) Mass spectrum (ESI): m/z = 638 [M+H]* (71) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 18 % of Z isomer) Rf value: 0.35 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESl*): m/z = 537 [M+Hj (72) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylam ino)-piperid in-1 -yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 580 [M+H]* C:NRPortbrl\CCRBR2842609 LDOC - 74 (73) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 572 [M+Hj (74) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 572 [M+H]* (75) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 572 [M+H]* (76) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 572 [M+H]* (77) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 574 [M+H]* (78) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 574 [M+H]* (79) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-[(R)-3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.18 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI): m/z = 593 [M+H]* C \NR obDCMBR\W&26N IDOC - 75 (80) 1-[2-(2,3-dihydro-benzo(1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESl*): m/z = 593 [M+H]* (81) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.56 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESl*): m/z = 587 [M+H]* (82) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 587 [M+H]* (83) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.86 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESl*): m/z = 579 [M+H]* (84) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.86 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESl*): m/z = 579 [M+H]* (85) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 573 [M+H]* (86) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C:XNRWonbIWCkBRU224N LDC - 76 Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 573 [M+H]* (87) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7 (3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.50 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESIl): m/z = 622 [M+H]* (88) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 638 [M+H]* (89) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 624 [M+H]* (90) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 624 [M+H]* (91) 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) (92) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-bromo-xanthine Mass spectrum (ESI'): m/z = 506, 508 [M+H]* (93) 1-[(4-dimethylamino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in the presence of caesium carbonate) C:wNRbICMBR'a42"OqI DC - 77 Rf value: 0.40 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 602 [M+H]* (94) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-7 yl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-bromo-xanthine Rf value: 0.75 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESl*): m/z = 618, 620 [M+H]* (95) 1-[(imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 547 [M+H]* (96) 1-[(quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonyl-amino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 559 [M+H]* (97) 1-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)-2-oxo-ethyl]-3 methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 619 [M+H]* (98) 1-[(quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.35 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 559 [M+H]* (99) 1-(2-{2-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-benzooxazol-4 yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-bromo-xanthine Rf value: 0.30 (silica gel, petroleum ether/ethyl acetate = 2:1) C RNombIKDCM~BRUK4 26OW- ]DOC - 78 Mass spectrum (ESI-): m/z = 600, 602 [M-H] (100) 1-[(3-methyl-quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI*): m/z = 573 [M+H]* (101) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.85 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 634 [M+H]* (102) 1-[(3,4-dimethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.60 (silica gel, ethyl acetate/methanol = 3:1) Mass spectrum (ESl*): m/z = 586 [M+H]* (103) 1-[(benzofuran-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-[(R)-3-(tert.-butyl oxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 547 [M+H]* (104) 1-{[4-(morpholin-4-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.28 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 644 [M+H]* (105) 1-{[4-(piperidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.35 (silica gel, ethyl acetate) C.VNRPo,1bIDCC\RBRU42(AI9-) I DC - 79 Mass spectrum (ESl*): m/z = 642 [M+H]* (106) 1-({4-[4-(tert.-butyloxycarbonyl)-piperazin-1-yl]-quinazolin-2-yl}methyl)-3 methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESIl): m/z = 743 [M+H]* (107) 1-{[4-(pyrrolidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanth ine (Carried out in the presence of caesium carbonate) Rf value: 0.59 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI'): m/z = 628 [M+H]* (108) 1-[2-(1-ethoxycarbonyl-3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazo-4-yl) 2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin 1-yl]-xanthine Rf value: 0.25 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESl*): m/z = 677 [M+H]* (109) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.77 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 582 [M+H]* (110) 1 -[(imidazo[1,2-a]pyridine-3-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 547 [M+H]* C:\NRPonbIOCC\RBR\2842609 .DOC -80 (111) 1-[(8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 561 [M+H]* (112) 1-[(8-methoxy-quinolin-5-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.60 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESl*): m/z = 588 [M+H]* (113) 1-[(5-methoxy-quinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 588 [M+H]* (114) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (ESl*): m/z = 635 [M+H]* (115) 1-[(7-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 561 [M+H]* (116) 1-(2-oxo-4-phenyl-butyl)-3-methyl-7-(2-butyn-1 -yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 563 [M+H]* (117) 1-(2-{2-oxo-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-2,3-dihydro-1 H benzoimidazol-4-yl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine CANRXoIbIODCCBW2&4 26D9 I 1DOC -81 Rf value: 0.50 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESI*): m/z = 851 [M+H]* (118) 1-[(3-difluoromethyl-isoquinolin-1 -yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (By-product of the reaction of 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine with 1 -chloromethyl-3-trifluoromethyl-3,4 dihydro-isoquinoline) Rf value: 0.75 (aluminium oxide, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI*): m/z = 608 [M+H]* (119) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-bromo-xanthine Mass spectrum (ESl*): m/z = 495, 497 [M+H]* (120) 1-[(3-methyl-imidazo[1,2-ajpyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI*): m/z = 561 [M+H]* (121) 1-[(5-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 561 [M+H]* (122) 1-[(6-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.10 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESl*): m/z = 561 [M+H}* C RP,*ICRBRU2S42"-NI DOC - 82 (123) 1-[(3-benzyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 637 [M+H]* (124) 1-[(4-isopropyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESl*): m/z = 601 [M+H]* (125) 1-[(2,3-dihydro-benzo[1,4]dioxin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)- 8 -[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.53 (silica gel, ethyl acetate/petroleum ether = 3:2) (126) 1-[(3-phenyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 623 [M+H]* (127) 1-[2-(naphthalen-1-yl]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.54 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 585 [M+H]* (128) 1-[(5-methoxy-isoquinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanth ine Rf value: 0.50 (silica gel, ethyl acetate/methanol = 24:1) Mass spectrum (ESl*): m/z = 588 [M+H]* (129) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C NRPonbICC\RBR\2X42609 I DOC - 83 (By-product of the reaction of 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine with 1 -chloromethyl-3-trifluoromethyl-3,4 dihydro-isoquinoline) Rf value: 0.75 (aluminium oxide, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESI*): m/z = 608 [M+H]* (130) 1-{[1-(1-cyano-1-methyl-ethyl)-isoquinolin-3-yl]methyl}-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 625 [M+H]* (132) 1-methoxycarbonylmethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonyl-amino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 489 [M+H]* (133) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 635 [M+H]* (134) 1-[(2,3-dimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in the presence of caesium carbonate) Rf value: 0.40 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 587 [M+H]* (135) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.55 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESl*): m/z = 635 [M+H]* (136) 1 -[2-(q u inolin-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn- 1 -yl)-8-bromo-xanthine CA RPonbIWDCCR 9 RU2g4Z6 1, DOC - 84 Rf value: 0.55 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 466, 468 [M+H]* (137) 1-[(3,4-dimethyl-6,7-dihydro-5H-[2]pyrindin-1-yl)methyl]-3-methyl-7-(2-butyn 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.65 (aluminium oxide, ethyl acetate/petroleum ether = 3:1) Mass spectrum (ESl*): m/z = 576 [M+H]* (138) 1-[(3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)methyl]-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 590 [M+H]* (139) 1-{2-[1-(tert.-butyloxycarbonyl)-1H-indol-4-yl]-2-oxo-ethyl}-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESl*): m/z = 674 [M+H]* (140) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (El): m/z = 587 [M]* (141) 1-({1-[(2-trimethylsilanyl-ethoxy)methyl]-2-oxo-1,2-dihydro-quinolin-6 yl}methyl)-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 yl]-xanthine Mass spectrum (ESI*): m/z = 704 [M+H]* (142) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 601 [M+H]* CNRPortbhCCRBR\2Jt42609- I DOC - 85 (143) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 573 [M+H]* (144) 1-[(4-methyl-phthalazin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 573 [M+H]* (145) 1-[(4-bromo-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 666, 668 [M+H]* (146) 1-[(4-difluoromethoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ES I): m/z = 623 [M+H]* (147) 1-{2-[1-(tert.-butyloxycarbonyl)-1H-indol-7-yl]-2-oxo-ethyl}-3-methyl-7-(2 butyn-1 -yl)-8-bromo-xanthine Rf value: 0.83 (silica gel, methylene chloride/methanol = 95:5) (148) 1 -[(E)-3-(2-nitro-phenyl)-2-propen-1 -yl]-3-methyl-7-(2-butyn- 1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 578 [M+H]* (149) 1-((E)-3-pentafluorophenyl-2-propen-1-yl)-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 623 [M+H]* C.N~onbM~CM\BR\2IW2(Aw- .OC - 86 (150) 1-[(4-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yi)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.41 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 602 [M+H]* (151) 1-[(benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbo-nylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 548 [M+H]* (152) 1-[(5-nitro-benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 593 [M+H]* (153) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8 bromo-xanthine Rf value: 0.65 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 468, 470 [M+H]* (154) 1-[(quinolin-7-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonyl-amino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 558 [M+H]* (155) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 559 [M+H]* (156) 1-[(8-methyl-quinoxalin-6-yl)methyll-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C WPonbI\CCRBR\2942609 I.DOC -87 Rf value: 0.45 (silica gel, methylene chloride/methanol = 19:1) Mass spectrum (ESl*): m/z = 573 [M+H]* (157) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.32 (silica gel, methylene chloride/methanol = 96:4) Mass spectrum (ESl*): m/z = 601 [M+H]* (158) 1-[([1,6]naphthyridin-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.20 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESl*): m/z = 559 [M+H]* (159) 1-[([1,8]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperid in-1 -yl]-xanth ine Rf value: 0.12 (silica gel, ethyl acetate/methanol = 98:2) Mass spectrum (ESl*): m/z = 559 [M+H]* (160) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.47 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 575 [M+H]* (161) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.39 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 559 [M+H]* (162) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7 (2-butyn-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.60 (silica gel, methylene chloride/methanol = 95:5) C.ANR~onb4DCMBR\24)9 I DC -88 Mass spectrum (ESI*): m/z = 606 [M+H]* (163) 1-[(8-phenyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI'): m/z = 356 [M+H]* (164) 1-[([1,5]naphthyridin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.25 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESI*): m/z = 559 [M+H]* (165) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 623 [M+Hj (166) 1-[(E)-3-(2-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 601 [M+H]* (167) 1-[(E)-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 601 [M+H]* (168) 1-[(E)-3-(4-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanth ine Mass spectrum (ESl*): m/z = 601 [M+H]* (169) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R) 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.68 (silica gel, cyclohexane/ethyl acetate = 3:7) CANRPonbIDCC\RBR\2R4269- LDOC - 89 Mass spectrum (ESI*): m/z = 626 [M+H]* (170) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-chloro xanthine (171) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R) 3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.38 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI): m/z = 608 [M+H]* (172) 1-[(4-chloro-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 622, 624 [M+H]* (173) 1-[(4-ethoxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.25 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 603 [M+H]* (174) 1-[(4-isopropyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.40 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 617 [M+H]* (175) 1-[(2-methyl-benzothiazol-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.56 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 578 [M+HJ CkN~onIOC RRQ42&9_1DOC - 90 (176) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 634 [M+H]* (177) 1-[(4-phenyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.35 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 651 [M+H]* (178) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.45 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 661 [M+H]* (179) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 598 [M+H]* (180) 1-[2-(3-difluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8 [(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.77 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 601 [M+H]* (181) 1-[(2-phenyl-quinazolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.65 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 635 [M+Hj C:W onbDCCRBR284(AN 1 DOC -91 (182) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.57 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 565 [M+H]* (183) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.63 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 565 [M+H]* (184) 1-[2-(3-trifluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8 [(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.64 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 619 [M+H]* (185) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.70 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 611 [M+H]* (186) 1-[2-(biphenyl-3-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 611 [M+H]* (187) 1-[2-(3-isopropyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanth ine Rf value: 0.66 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 593 [M+H]* C.NRPotbM~CCRBR\&L264)9-I DOC - 92 (188) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 598 [M+H]* (189) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 661 [M+H]* (190) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.75 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 608 [M+H]* (191) 1-[2-(2-phenyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.85 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 627 [M+H]* (192) 1-[2-(3-ethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.72 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 579 [M+H]* (193) 1 -[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- 1 -yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.67 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 565 [M+H]* C :NRPonbl\DCORBR\242609 I DC - 93 (194) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl)-xanthine Rf value: 0.57 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 565 [M+H]* (195) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-bromo xanthine (196) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-[(R)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (197) 1-[(1,2,3,4-tetrahyd ro-phenanthrid in-6-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8 [3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.55 (silica gel, ethyl acetate/ petroleum ether = 2:1) Mass spectrum (ESl*): m/z = 612 [M+H]* Example VI 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -vl)-8-[3-(tert.-butyloxvcarbonylamino)-piperidin-1 -vll-xanthine To a solution of 402 mg of 1-(2-{3-[(methylsulphanyl)methoxy]-phenyl}-2-oxo ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1-yl]-xanthine in 10 ml hexafluoroisopropanol are added 0.15 ml of a 35 % hydrogen peroxide solution. The reaction mixture is stirred for half an hour at ambient temperature.Then 5 ml of a 10 % sodium thiosulphate solution are added. The aqueous phase is extracted twice with 5 ml of methylene chloride. The combined extracts are dried over sodium sulphate and evaporated down. The yellow residue is purified by chromatography through a silica gel column with cyclohexane/ ethyl acetate/methanol (5:4:1) as eluant. Yield: 299 mg (73 % of theory) Rf value: 0.28 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) C NRPonbI\DCCORBR\28426tN I DOC - 94 Mass spectrum (ESl*): m/z = 643 [M+H]* The following compounds are obtained analogously to Example VI: (1) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.05 (silica gel, ethyl acetate/cyclohexane = 3:1) Mass spectrum (ESl*): m/z = 613 [M+H]* (2) 1-(2-{2-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Mass spectrum (ESI*): m/z = 627 [M+H]* Example VII 3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yll-xanthine 236 pl of 1,8-diazabicyclo[5.4.0]undec-7-ene are added dropwise to 630 mg of 7 (3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine in 11 ml of acetonitrile. The solution is stirred for two hours at ambient temperature, then the acetonitrile is distilled off in vacuo. The flask residue is taken up in 11 ml of N,N-dimethylformamide and combined with 258 mg of (2 trimethylsilanyl-ethoxy)methyl chloride. The reaction mixture is stirred for three hours at 120*C. For working up water is added, the precipitate formed is filtered off and taken up in ethyl acetate. The solution is dried over magnesium sulphate, evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/methanol (6:1:0 to 0:5:1) as eluant. Yield: 435 mg (53 % of theory) Mass spectrum (ESl*): m/z = 549 [M+H]* The following compounds are obtained analogously to Example VII: C WRPOnbI\DCCkBR%2826) I DC - 95 (1) 3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano-benzyl)-xanthine Mass spectrum (ESI-): m/z = 396 [M-H] (2) 3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 491 [M+H]* Example VIII 7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl] xanthine 510 mg of potassium-tert. butoxide are added to 2.32 g of 2-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-3-(3-methyl-2-buten-1-yl)-4-ethoxycarbonyl 5-{[(ethoxycarbonylamino)carbonyl]amino}-3H-imidazole in 35 ml of ethanol. The yellow solution is refluxed for five hours. After cooling to ambient temperature it is diluted with methylene chloride. The organic phase is washed with saturated ammonium chloride solution and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography through a silica gel column with methylene chloride/methanol/conc. methanolic ammonia (95:5:1 to 90:10:1) as eluant. Yield: 630 mg (35 % of theory) Rf value: 0.24 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 419 [M+H]* Example IX 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-3-(3-methyl-2-buten-1 -yl)-4 ethoxycarbonyl-5-{[(ethoxycarbonylamino)carbonyllaminol-3H-imidazole 2.97 ml of ethyl isocanatoformate are added to 4.00 g of 2-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-3-(3-methyl-2-buten-1 -yl)-4-ethoxycarbonyl- C\NRPortb\DCC\RBR\28426049v .DOC - 96 5-amino-3H-imidazole in 90 ml of 1,2-dimethoxyethane and the light brown solution is heated overnight at 120*C in an oil bath. Then a further 0.6 ml of ethyl isocyanatoformate is added and heating is continued for a further four hours. For working up the reaction mixture is combined with saturated potassium carbonate solution and extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, evaporated down and purified through a silica gel column with methylene chloride/methanol/conc. methanolic ammonia (98:2:1 to 90:10:1) as eluant. Yield: 2.27 g (45 % of theory) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 537 [M+H]* Example X 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-3-(3-methyl-2-buten-1-yl)-4 ethoxycarbonyl-5-amino-3H-imidazole Prepared by refluxing cyanimino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxy carbonylmethyl)-amino]-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-methane with sodium in ethanol. Rf value: 0.26 (aluminium oxide, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESl*): m/z = 422 [M+H]* Example XI Cyanimino-[N-(3-methyl-2-buten-1 -yl)-N-(ethoxycarbonylmethyl)-amino]-[3-(tert.
butyloxvcarbonylamino)-piperidin-1 -yll-methane Prepared by reacting cyanimino-[N-(3-methyl-2-buten-1-yl)-N-(ethoxy carbonylmethyl)-amino]-phenyloxy-methane with 3-(tert.-butyloxycarbonylamino) piperidine in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature. Rf value: 0.10 (silica gel, petroleum ether/ethyl acetate = 6:4) Mass spectrum (ESl*): m/z = 422 [M+H]* CANPobMDCMRIa42f6,J I DC - 97 Example XII cyanimino-[N-(3-methyl-2-buten-1 -yl)-N-(ethoxycarbonylmethyl)-amino]-phenvloxy methane Prepared by reacting cyanimino-[(ethoxycarbonylmethyl)amino]-phenyloxy methane with 1-bromo-3-methyl-2-butene in the presence of potassium carbonate in acetone at ambient temperature. Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 316 [M+H]* Example XIII cyanimino-[(ethoxycarbonylmethyl)aminol-phenyloxy-methan Prepared by reacting diphenylcyanocarbonimidate with ethyl aminoacetate hydrochloride in the presence of triethylamine in isopropanol at ambient temperature (analogously to R. Besse et al., Tetrahedron 1990, 46, 7803-7812). Rf value: 0.73 (silica gel, petroleum ether/ethyl acetate = 8:2) Mass spectrum (ESl*): m/z = 248 [M+H]* Example XIV 1 -methyl-3-[(methoxycarbonyl)methyll-7-(2-cyano-benzyl)-8-chloro-xanthine Prepared by reacting 1-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine with methyl bromoacetate in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature. Rf value: 0.80 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 388, 390 [M+H]* The following compounds are obtained analogously to Example XIV: (1) 1 -methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-ch loro-xanthine Mass spectrum (ESl*): m/z = 355, 357 [M+H]* C WRPorbI\DCRBR\25426)9 1.DOC - 98 (2) 1 -methyl-3-(2-propyn-1 -yl)-7-(2-cyano-benzyl)-8-chloro-xanthine Rf value: 0.80 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 354, 356 [M+H]* (3) 1 -methyl-3-(2-propen- 1 -yl)-7-(2-cyano-benzyl)-8-chloro-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 356, 358 [M+H]* (4) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.78 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 576 [M+H]* (5) 1 -methyl-3-isopropyl-7-(2-cyano-benzyl)-8-ch loro-xanthine Mass spectrum (ESI*): m/z = 358, 360 [M+H]* Example XV 1 -methyl-7-(2-cyano-benzvl)-8-chloro-xanthine Prepared by treating 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2-cyano benzyl)-8-chloro-xanthine with trifluoroacetic acid in methylene chloride at ambient temperature. Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 316, 318 [M+H]* The following compounds are obtained analogously to Example XV: (1) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-8-bromo-xanthine Rf value: 0.26 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI-): m/z = 361, 363 [M-H]- C %NRPortb\C\BR\284260 I DOC - 99 (2) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (As the compound still contains impurities which cannot be removed by chromatography, the material is again converted into the BOC-protected derivative and then purified by chromatography, cf. Ex. XXV(1).) Mass spectrum (ESIl): m/z = 491 [M+H]* Example XVI 1-methvl-3-[(2-trimethylsilanyl-ethoxy)methyll-7-(2-cyano-benzyl)-8-chloro xanthine Prepared by chlorination of 1-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-7-(2 cyano-benzyl)-xanthine with N-chlorosuccinimide in dichloroethane while refluxing. Mass spectrum (El): m/z = 445, 447 [M]* Example XVII 7-(2-cyano-benzvl)-xanthine Prepared by treating 16.68 g of 2-amino-7-(2-cyano-benzyl)-1,7-dihydro-purin-6 one with 17.00 g of sodium nitrite in a mixture of 375 ml of conc. acetic acid, 84 ml of water and 5.2 ml of conc. hydrochloric acid at 50*C. Yield: 8.46 g (50 % of theory) Mass spectrum (ESI*): m/z = 268 [M+H]* Example XVIII 2-amino-7-(2-cyano-benzvl)-1.7-dihydro-purin-6-one Prepared by reacting 20.00 g of guanosine-hyd rate with 22.54 g of 2-cyano benzylbromide in dimethylsulphoxide at 60 0 C and subsequent treatment with 57 ml of conc. hydrochloric acid. Yield: 18.00 g (97% of theory) Mass spectrum (ESI*): m/z = 267 [M+H]* C:NRPorl\CCRBR2842609 I.DOC - 100 Example XIX 1-{2-[3-(2-oxo-imidazolidin-1 -yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -vl)-8-[3-(tert.-butyloxvcarbonylamino)-piperidin-1 -vll-xanthine Prepared by treating 1-[2-(3-{[(2-chloro-ethylamino)carbonyl]amino}-phenyl)-2-oxo ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1-yl]-xanthine with potassium-tert. butoxide in N,N-dimethylformamide at ambient temperature. Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Example XX 1-[2-(3-{[(2-chloro-ethylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1 -yll-xanthine Prepared by reacting 221 mg of 1-[2-(3-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten- 1 -yl)-8-[3-(tert.-butyloxycarbonylam ino)-piperidin-1 -yl]-xanthine with 60 pl of 2-chloroethyl isocyanate in 3 ml methylene chloride at ambient temperature. Yield: 163 mg (64 % of theory) Rf value: 0.20 (silica gel, cyclohexane/ethyl acetate/methanol = 6:3:1) Mass spectrum (ES I): m/z = 671, 673 [M+H]* The following compounds are obtained analogously to Example XX: (1) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-methyl 7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl] xanthine (Carried out in N,N-dimethylformamide at 30*C) Rf value: 0.26 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESI*): m/z = 681 [M+H]* Example XXI C Po.1bhfCCARBRIJ9426O9_ I DOC - 101 1-[2-(3-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.
butyloxvcarbonylamino)-piperidin-1 -yll-xanthine Prepared by treating 1-[2-(3-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine with iron powder in a mixture of ethanol, water and glacial acetic acid (80:25:10) at 100*C. Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/methanol/conc. aqueous ammonia = 50:30:20:1) Mass spectrum (ESI*): m/z = 566 [M+H]* The following compounds are obtained analogously to Example XXI: (1) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Mass spectrum (ESIl): m/z = 566 [M+H]* (2) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 566 [M+H]* (3) 1-[(5-amino-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanth ine Rf value: 0.22 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 589 [M+H]* (4) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yI)methyl]-8 bromo-xanthine Mass spectrum (ESIl): m/z = 458, 460 [M+H]* (5) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-bromo xanthine (product contains approx. 10 % of Z isomer) C NR~onbWCCWRRUft426tWI LDC - 102 Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESl*): m/z = 432, 434 [M+H]* (6) 1 -[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- 1 -yl)-8-bromo-xanth ine Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 430, 432 [M+H]* (7) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 552 [M+H]* (8) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(S)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESI'): m/z = 552 [M+H]) (9) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.82 (silica gel, ethyl acetate/petroleum ether = 4:1) Mass spectrum (ESl*): m/z = 596 [M+H]* Example XXII 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten 1 -l)-8-[3-(tert.-butyloxvcarbonylamino)-piperid in-1 -vll-xanthine Prepared by reacting 248 mg of 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with 40 pl of propionic acid chloride in the presence of 60 pl of pyridine in N,N dimethylformamide at 800C. Yield: 168 mg (62 % of theory) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 622 [M+H]* C:NRPonbOlCCRBR\842609 I DOC - 103 The following compounds are obtained analogously to Example XXII: (1) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with methyl bromoacetate and potassium carbonate) Rf value: 0.42 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 661 [M+H]* (2) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESl*): m/z = 594 [M+H]* (3) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESl*): m/z = 622 [M+H]* (4) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 [(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 608 (M+H]* (5) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.34 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 592 [M+H]* (6) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylam ino)-piperid in-1 -yl]-xanthine Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate = 1:1) C \NRPonbICRR?2N-42. IDOC - 104 Mass spectrum (ESl*): m/z = 636 [M+H]* (7) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 620 [M+H]* (8) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.34 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 592 [M+H]* (9) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.44 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 620 [M+H]* (10) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in acetonitrile at 55 0 C) Rf value: 0.25 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 624 [M+H]* (11) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out in acetonitrile at 650C) Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESl*): m/z = 622 [M+H]* (12) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine C NRPnbI\lCCRBR\28426Iw-I DOC - 105 Mass spectrum (ESl*): m/z = 608 [M+H]* (13) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[(R) 3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 594 [M+H]* (14) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yI)-8-[(S) 3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.28 (silica gel, cyclohexane/ethyl acetate/isopropanol = 8:1:1) Mass spectrum (ESl*): m/z = 594 [M+H]* (15) 1 -(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.90 (silica gel, methylene chloride/methanol = 9:1) (16) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten- 1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin- 1 -yl])-xanthine (Carried out in 1,2-dichloroethane at 45 0 C) Rf value: 0.30 (silica gel, cyclohexane/ethyl acetate/isopropanol = 8:1:1) Mass spectrum (ESl*): m/z = 622 [M+H]* (17) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.48 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESl*): m/z = 608 [M+H]* (18) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl) 8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Mass spectrum (ESl*): m/z = 606 [M+H]* C VVRPonbI\DCCBR\I8426.F' DC - 106 (19) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl) 8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.22 (silica gel, methylene chloride/methanol = 95:5) (20) 1-(2-{2-[(phenylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate/isopropanol = 14:3:3) Mass spectrum (ESl*): m/z = 656 [M+H]* (21) 1-(2-{2-[(cyclopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1 cyclopenten-1 -yl)methyl]-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with Hunig base and 4-dimethylamino-pyridine in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol = 18:1) Example XXIII 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Prepared by treating 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3 methyl-7-(3-methyl-2-buten-1 -yl)-8-{3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl] xanthine with trifluoroacetic acid in methylene chloride at ambient temperature. Mass spectrum (ESl*): m/z = 539 [M+H]* The following compounds are obtained analogously to Example XXIII: (1) 1 -(2-{2-[(methoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 539 [M+H]* Example XXIV 1 -methyl-3-phenvl-7-(2-cyano-benzyl)-8-chloro-xanthine C \NRPotblDCCRBR\2842609 I DOC - 107 A mixture of 829 mg of 1-methyl-7-(2-cyano-benzyl)-8-chloro-xanthine, 640 mg of phenylboric acid, 509 mg of anhydrous copper acetate and 0.43 ml of pyridine in 20 ml methylene chloride is stirred for four days at ambient temperature in the presence of 100 mg of 4A molecular sieves.Then another 320 mg of phenylboric acid are added and the reaction mixture is stirred for another day at ambient temperature. For working up the mixture is filtered through talc and washed with ethyl acetate. The filtrate is evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate (7:3 to 1:1) as eluant. Yield: 142 mg (14 % of theory) Mass spectrum (ESl*): m/z = 392, 394 [M+H]* Example XXV 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxvcarbonyl amino)-piperidin-1 -vll-xanthine Prepared by reacting 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine with di-tert.butyl pyrocarbonate in the presence of Hunig base in methylene chloride at ambient temperature. Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) The following compounds are obtained analogously to Example XXV: (1) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-[3-(tert.-butyloxycarbonyl-amino)-piperidin-1 -yl]-xanthine Rf value: 0.27 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 591 [M+H]* (2) 7-acetyl-1-(tert.-butyloxycarbonyl)-1H-indole Rf value: 0.82 (silica gel, methylene chloride/petroleum ether/ethyl acetate= 5:4:1) Mass spectrum (ESl*): m/z = 260 [M+H]* C %NRPonbIODCOBR\2R42"-9 I DOC - 108 Example XXVI I -[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yl)-8-chloro-xanthine and 1-[(1,4-dihvdro-cinnolin-4-yl)methyll-3-methyl-7-(3-methyl-2-buten-1-vl)-8-chloro xanthine 510 mg of a mixture of (cinnolin-4-yl)-methanol and (1,4-dihydro-cinnolin-4-yl) methanol (see Ex. XXVII) are added to 830 mg of 3-methyl-7-(3-methyl-2-buten-1 yl)-8-chloro-xanthine and 1.25 g of triphenylphosphine in 25 ml of tetrahydrofuran. The reaction mixture is combined with 0.92 ml diethyl azodicarboxylate and stirred overnight at ambient temperature.Then it is evaporated down and chromatographed through a silica gel column with ethyl acetate/petroleum ether (7:3 to 0:1) as eluant. A mixture of cinnoline and 1,4-dihydro-cinnoline compound is obtained. Yield: 660 mg (52 % of theory) Rf value: 0.60 (silica gel, ethyl acetate/petroleum ether = 7:3) The following compounds are obtained analogously to Example XXVI: (1) 1-({4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1 yl}methyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-ch loro-xanth ine Rf value: 0.85 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 557, 559 [M+H]* (2) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-chloro xanthine Melting point: 194-195 0 C Mass spectrum (ESl*): m/z = 410, 412 [M+H]* (3) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-chloro-xanthine Rf value: 0.66 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 441, 443 [M+H]* C:\NRPorb\DCCRBR\28426(9 I DOC - 109 (4) 1 -[(quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine (Carried out with potassium carbonate) Rf value: 0.45 (silica gel, ethyl acetate) Mass spectrum (ESI*): m/z = 438, 440 [M+H]* (5) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine Rf value: 0.78 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 438, 440 [M+H]* (6) 1-[(4-dimethylamino-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.80 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 600 [M+H]* (7) 1 -[(isoq u inolin-1 -yl)methyl]-3-methyl-7-((E)-2-buten-1 -yl)-8-bromo-xanthine (The product contains approx. 20 % of Z isomer) Rf value: 0.71 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 440, 442 [M+H]* (8) 1 -[(1-methyl-1 H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-bromo-xanthine Rf value: 0.95 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 440, 442 [M+H]* (9) 1 -[(q uinolin-3-yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-bromo-xanthine Rf value: 0.55 (silica gel, ethyl acetate/petroleum ether = 8:2) Mass spectrum (ESl*): m/z = 438, 440 [M+H]* (10) 1-{[1-(tert.-butyloxycarbonylamino)-1H-indol-2-yl]methyl}-3-methyl-7-(2-butyn 1 -yl)-8-bromo-xanthine Rf value: 0.74 (silica gel, petroleum ether/ethyl acetate = 1:1) CANRPortbIDCORBR\2842609I .DOC -110 Mass spectrum (ESl*): m/z = 526, 528 [M+H]* (11) 1 -({2-methyl-1 -[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5 yl}methyl)-3-methyl-7-(2-butyn-1-yl)-8-bromo-xanthine (mixed with 1-({2-methyl-3 [(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl}methyl)-3-methyl-7-(2 butyn-1 -yl)-8-bromo-xanthine) Mass spectrum (ESl*): m/z = 571, 573 [M+H]* (12) 1-[(1-[(2-trimethylsilanyl-ethoxy)methyl]-1H-benzoimidazol-5-yl)methyl]-3 methyl-7-(2-butyn-1-yl)-8-bromo-xanthine (mixed with 1 -[(3-[(2-trimethylsilanyl ethoxy)methyl]-3H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-bromo xanthine) Rf value: 0.50 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 557, 559 [M+H]* (13) 1-[(pyrazolo[1,5-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine Rf value: 0.35 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESl*): m/z = 427, 429 [M+H]* Example XXVII (cinnolin-4-yl)-methanol and (1,4-dihydro-cinnolin-4-vl)-methanol A solution of 1.00 g of methyl cinnolin-4-carboxylate in 15 ml diethyl ether is added dropwise at 0*C to a suspension of 222 mg of lithium aluminium hydride in 5 ml of diethyl ether. After 1.5 hours water is carefully added dropwise to the reaction mixture, this is stirred with methylene chloride and suction filtered through a glass fibre filter. The aqueous phase is extracted with methylene chloride and the combined organic phases are dried over magnesium sulphate and evaporated down. According to 1 H-NMR a mixture of cinnoline and 1,4-dihydro-cinnoline compound is obtained as a yellow oil which is reacted further without any more purification.
CARPobIDCMR2X426rn DOC - 111 Yield: 530 mg (62 % of theory) Rf value: 0.63 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 161 [M1+H]* and 163 [M2+H]* The following compounds are obtained analogously to Example XXVIl: (1) {2-methyl-1 -[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl} methanol (mixed with {2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzoimidazol-5-yl} methanol) Mass spectrum (ESl*): m/z = 293 [M+H]* (2) (2,3,8-trimethyl-quinoxalin-6-yl)-methano Rf value: 0.45 (silica gel, petroleum ether/ethyl acetate = 1:2) Mass spectrum (ESl*): m/z = 203 [M+H]* (3) (8-methyl-quinoxalin-6-yl)-methanol Rf value: 0.18 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 175 [M+H]* (4) (E)-3-pentafluorophenyl-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Mass spectrum (El): m/z = 224 [M]* (5) (E)-3-(2-trifluoromethyl-phenyl)-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) (6) (E)-3-(3-trifluoromethyl-phenyl)-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Mass spectrum (El): m/z = 202 [M]* CV4PobICRBRI?426&)-_ DOC - 112 (7) (E)-3-(4-trifluoromethyl-phenyl)-2-propen-1-ol (Carried out with diisobutylaluminium hydride in toluene) Example XXVIII 4-hydroxymethyl-2-[(2-trimethylsilanyl-ethoxv)methyll-2H-phthalazin-1-one Prepared by treating methyl 4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4 dihydro-phthalazin-1-carboxylate with sodium borohydride in tetrahydrofuran at 40 0 C. Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate 1:1) Mass spectrum (ESl*): m/z = 307 [M+H]* The following compounds are obtained analogously to Example XXVIII: (1) (3,4-dimethyl-isoquinolin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.35 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 188 [M+H]* (2) (3-methyl-imidazo(1,2-a]pyridin-2-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESIl): m/z = 163 [M+H]* (3) (3,4-dimethyl-6,7-dihydro-5H-[2]pyrindin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) Rf value: 0.40 (aluminium oxide, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 178 [M+H]* (4) (3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)-methanol (Carried out with lithium borohydride in tetrahydrofuran) C \NRPonbI\DC\RBRU284 2U)9-1 DC -113 Rf value: 0.45 (aluminium oxide, petroleum ether/ethyl acetate = 3:1) Mass spectrum (ESl*): m/z = 192 [M+H]* (5) 6-hyd roxymethyl-1,2 ,3,4-tetrahydro-phenanth ridine (Carried out with lithium borohydride in tetrahydrofuran at ambient temperature) Rf value: 0.40 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 214 [M+H]* Example XXIX Methyl 4-oxo-3-[(2-trimethylsilanyl-ethoxy)methyl]-3,4-dihydro-phthalazin-1 carboxylate Prepared by reacting methyl 4-oxo-3,4-dihydro-phthalazin-1-carboxylate with (2 trimethylsilanyl-ethoxy)methylchloride in the presence of Honig base in methylene chloride at ambient temperature. Rf value: 0.75 (silica gel, cyclohexane/ethyl acetate 6:4) Mass spectrum (ESl*): m/z = 335 [M+H]* The following compounds are obtained analogously to Example XXIX: (1) 7-acetyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Mass spectrum (ESl*): m/z = 308 [M+H]* (2) 4-acetyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Rf value: 0.87 (silica gel, methylene chloride/methanol = 99:1) (3) 4-acetyl-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-1,3-dihydro-benzoimidazol 2-one (Carried out with potassium-tert. butoxide in N,N-dimethylformamide) Rf value: 0.90 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 437 [M+H]* CANRPoflbICC-IRRQ2S69- DC -114 (4) 6-methyl-1 -[(2-trimethylsilanyl-ethoxy)methyl]-1 H-quinolin-2-one Rf value: 0.78 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 290 [M+H]* (5) methyl {2-methyl-1 -[(2-trimethylsilanyl-ethoxy)methyl]-1 H-benzoimidazol-5-yl} carboxylate (mixed with methyl {2-methyl-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H benzoimidazol-5-yl}-carboxylate) Mass spectrum (ESl*): m/z = 321 [M+H]* Example XXX 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-_1.-vy) 8-[3-(tert.-butyloxvcarbonylamino)-piperidin-1 -vll-xanthine 0.22 ml of a 35 % hydrogen peroxide solution and 20 mg of sodium tungstate are added to 500 mg of 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 5 ml methylene chloride. The reaction mixture is stirred overnight at ambient temperature, then 1 ml of methanol is added. After another 48 hours a further 1.5 ml of 35 % hydrogen peroxide solution, a spatula tip of sodium tungstate and two drops of water are added. The next morning, the oxidation is complete according to thin layer chromatography and the reaction mixture is diluted with 50 ml methylene chloride and washed twice with 30 ml of 10 % sodium thiosulphate solution. The organic phase is dried over magnesium sulphate and evaporated down, leaving a viscous resin which is reacted further without any more purification. Yield: 530 mg (100 % of theory) Rf value: 0.72 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 629 [M+H]* Example XXXI 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.
butyloxvcarbonylamino)-piperidin-1 -yll-xanthine C :NRPonbl\DCCRBRU4269 ILDOC - 115 Prepared by treating 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine with 3 M sodium hydroxide solution in methanol at ambient temperature. Rf value: 0.34 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 595 [M+H]* The following compounds are obtained analogously to Example XXXI: (1) 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine Rf value: 0.49 (silica gel, methylene chloride/methanol = 9:1) (2) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine (Carried out with 4 M potassiuim hydroxide solution in tetrahydrofuran) Mass spectrum (ESl*): m/z = 609 [M+H]* (3) 1-[2-(2-carboxymethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl) 8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with 4 M potassium hydroxide solution in tetrahydrofuran) Rf value: 0.65 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESl*): m/z = 610 [M+H]* (4) 1-carboxymethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino) piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 475 [M+H]* Example XXXII 1 -{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2-buten 1 -vl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yll-xanthine C \NRPorb DCCBR\8426M DOC - 116 A mixture of 190 mg of 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl 2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine, 43 pl of a 40 % aqueous methylamine solution, 103 mg of O-(benzotriazol-1-y)-N,N,N',N' tetramethyluronium tetrafluoroborate, 43 mg of N-hydroxybenzotriazole and 45 pl of triethylamine in 3 ml of tetrahydrofuran is stirred for eight hours at ambient temperature. For working up the reaction mixture is diluted with ethyl acetate and washed with water, 10 % citric acid solution, 10 % potassium carbonate solution and saturated sodium chloride solution. The organic phase is evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (98:2 to 80:20) as eluant. Yield: 173 mg (89 % of theory) Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 608 [M+H]* The following compounds are obtained analogously to Example XXXII: (1) 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.28 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 622 [M+H]* (2) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 664 [M+H]* (3) 1-{2-[2-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 622 [M+H]* CANRPorbl\DCC\RBR\284269 I.DOC - 117 (4) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin- 1 -yl]-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI*): m/z = 664 [M+H]* (5) 1-(2-{2-[(isopropylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine (Carried out with HOnig base in N,N-dimethylformamide) Mass spectrum (ESl*): m/z = 650 [M+H]* (6) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with Hunig base in N,N-dimethylformamide) Mass spectrum (ESI*): m/z = 636 [M+H]* (7) 1-(2-{2-[2-oxo-2-(pyrrolidin-1-yl)-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine (Carried out with HOnig base in N,N-dimethylformamide) Mass spectrum (ESl*): m/z = 662 [M+H]* (8) 1-(2-{2-[2-(morpholin-4-yl)-2-oxo-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine (Carried out with HOnig base in N,N-dimethylformamide) Mass spectrum (ESl*): m/z = 678 [M+H]* (9) 1-(2-{2-[(methylaminocarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7 ((E)-2-buten-1 -yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 623 [M+H]* CANRPorbI\DCCRBR\284269 I DOC - 118 (10) 1-[(2-amino-phenylaminocarbonyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 565 [M+H]* Example XXXIII 1 -chloromethyl-4-methyl-isoquinoline-hydrochloride Prepared by treating (4-methyl-isoquinolin-1-yl)-methanol with thionyl chloride in methylene chloride. Rf value: 0.76 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 192, 194 [M+H]* The following compounds are obtained analogously to Example XXXIII: (1) 1-chloromethyl-3,4-dimethyl-isoquinoline-hydrochloride Rf value: 0.65 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 206, 208 [M+H]* (2) 5-chloromethyl-8-methoxy-quinoline-hydrochloride Mass spectrum (ESl*): m/z = 208, 210 [M+H]* (3) 8-chloromethyl-5-methoxy-quinoline-hydrochloride Mass spectrum (El): m/z = 207, 209 [M]* (4) 2-chloromethyl-3-methyl-imidazo[1,2-a]pyridine-hydrochloride Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 181, 183 [M+H]* (5) 8-chloromethyl-5-methoxy-isoquinoline-hydrochloride C TRPorblOCC\RBR\2842609 I DOC - 119 Mass spectrum (ESl*): m/z = 208, 210 [M+H]* (6) 1 -chloromethyl-3,4-d imethyl-6,7-d ihydro-5H-[2]pyrid ine-hyd rochloride Rf value: 0.50 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESl*): m/z = 196, 198 [M+H]* (7) 1-chloromethyl-3,4-dimethyl-5,6,7,8-tetrahydro-isoquinoline-hydrochloride Rf value: 0.50 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESl*): m/z = 210, 212 [M+H]* (8) 6-chloromethyl-2,3,8-trimethyl-quinoxaline-hydroch loride Mass spectrum (ESl*): m/z = 221, 223 [M+H]* (9) 6-chloromethyl-8-methyl-quinoxaline-hydrochloride Mass spectrum (ESl*): m/z = 193,195 [M+H]* (10) 6-chloromethyl-1,2 ,3,4-tetrahydro-phenanthridine-hyd roch loride Rf value: 0.50 (silica gel, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 232, 234 [M+H]* Example XXXIV 1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxvcarbonylamino)-piperidin-1 -yll-xanthine 0.5 ml of a 1 M sodium methoxide solution in methanol is added dropwise to a solution of 428 mg of 1-cyanomethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 3 ml of methanol at ambient temperature. After about 20 minutes the thick suspension formed is heated gently in a water bath and diluted with 2 ml of methanol. As soon as the reaction to form the iminoester is complete according to thin layer chromatography, the reaction mixture is neutralised with 0.5 ml 1 M glacial acetic acid solution in methanol and combined with a solution of 130 mg of anthranilic acid in 2 ml of methanol. Gentle C:NRPo1b4\CM RUM N W_)) LDC - 120 heating produces a clear solution, which is stirred for 2.5 hours at ambient temperature. Then the reaction mixture is gently refluxed for about 3.5 hours. After standing overnight at ambient temperature the methanol is distilled off and the residue is stirred with cold water, suction filtered and dried. The crude product is suspended in 5 ml of methanol, gently heated and after cooling suction filtered, washed with methanol and dried in the desiccator. Yield: 302 mg (56 % of theory) Rf value: 0.55 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 575 [M+H]* The following compounds are obtained analogously to Example XXXV: (1) (4-difluoromethoxy-naphthalen-1-yl)-methanol Rf value: 0.33 (silica gel, cyclohexane/ethyl acetate = 6:4) Mass spectrum (ESl~): m/z = 223 [M-H] Example XXXV (4-dimethylamino-naphthalen-1 -l)-methanol prepared by reduction of 4-dimethylamino-naphthalene-1-carbaldehyde with sodium borohydride in aqueous tetrahydrofuran. Rf value: 0.67 (silica gel, cyclohexane/ethyl acetate = 1:1) Example XXXVI 2-bromo-1-(2,3-dihvdro-benzo[1,4ldioxin-5-yl)-ethanone prepared by bromination of 1 -(2,3-d ihydro-benzo[1,4]dioxin-5-yl)-ethanone in methylene chloride while cooling gently with an ice bath. The dibromo compound formed as a by-product is separated off by column chromatography. Mass spectrum (ESI'): m/z = 257, 259 [M+H]* Rf value: 0.92 (silica gel, methylene chloride) The following compounds are obtained analogously to Example XXXVI: C:\NRPonbl\DCCRBR\25426_ DC - 121 (1) 7-(2-bromo-acetyl)-3-methyl-3H-benzooxazol-2-one (bromination is carried out in dioxane at 40*C; the product is contaminated with approx. 20 % dibromo compound) Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 270, 272 [M+H]* (2) 1 -benzo[1, 3]d ioxol-4-yl-2-bromo-ethanone Mass spectrum (ESI'): m/z = 243, 245 [M+H]* Rf value: 0.94 (silica gel, methylene chloride) (3) 2-[2-(2-bromo-acetyl)-phenoxy]-N-ethyl-acetamide (bromination is carried out with copper(II)bromide in dioxane) Mass spectrum (ESI*): m/z = 300, 302 [M+H]* (4) 4-(2-bromo-acetyl)-3-methyl-3H-benzooxazol-2-one Rf value: 0.67 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESl*): m/z = 270, 272 [M+H]* (5) 2-[2-(2-bromo-acetyl)-phenoxy]-N-methyl-acetamide Mass spectrum (ESl*): m/z = 386, 388 [M+H]* (6) 7-(2-bromo-acetyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one Rf value: 0.84 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESl*): m/z = 384, 386 [M+H]* (7) 4-(2-bromo-acetyl)-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one Rf value: 0.38 (silica gel, ethyl acetate/petroleum ether = 1:1) Mass spectrum (ESl'): m/z = 283, 285 [M+H]* (8) 4-(2-bromo-acetyl)-3-[(2-trimethylsilanyl-ethoxy)methyl]-3H-benzooxazol-2-one C:\N b\CORBR\28426 I.DOC - 122 Rf value: 0.82 (silica gel, methylene chloride/methanol = 99:1) (9) 4-(2-bromo-acetyl)-1-ethoxycarbonyl-3-methyl-1,3-dihydro-benzoimidazol-2 one Rf value: 0.39 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 341, 343 [M+H]* (10) 2-bromo- 1 -(2,2-d ifluoro-benzo[ 1, 3]dioxol-4-yl)-ethanone Mass spectrum (ESI-): m/z = 277, 279 [M-H] Example XXXVII (2,3-d ihydro-benzo[ 1,.4dioxin-5-yl)-ethanone Prepared by reacting 1-(2,3-dihydroxy-phenyl)-ethanone with 1,2-dibromoethane in the presence of potassium carbonate in N,N-dimethylformamide at 100 0 C. Rf value: 0.43 (silica gel, ethyl acetate/petroleum ether = 1:4) Mass spectrum (ESl*): m/z = 179 [M+H]* Example XXXVIII 1-[(3-methyl-4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl [3-(tert.-butyloxycarbonylamino)-piperidin-1 -yll-xanthine Prepared by reacting 1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2 butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine with methyl iodide in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature. Rf value: 0.50 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 589 [M+H]* The following compounds are obtained analogously to Example XXXVIII: (1) 7-acetyl-3-methyl-3H-benzooxazol-2-one (The methylation is carried out in the presence of sodium carbonate in methanol) C.VNRPorbIqDCORSR2%-Z4W9I DOC - 123 Rf value: 0.46 (silica gel, petroleum ether/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 192 [M+H]* (2) 4-acetyl-3-methyl-3H-benzooxazol-2-one (The methylation is carried out in the presence of sodium carbonate in methanol while refluxing) Rf value: 0.67 (silica gel, methylene chloride/methanol = 99:1) Mass spectrum (ESl*): m/z = 192 [M+H]* (3) 4-acetyl-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one (Carried out in the presence of potassium-tert. butoxide) Rf value: 0.40 (silica gel, ethyl acetate/petroleum ether = 2:1) Mass spectrum (ESl*): m/z = 205 [M+H]* (4) 4-acetyl-1-ethoxycarbonyl-3-methyl-1,3-dihydro-benzoimidazol-2-one Rf value: 0.23 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESI'): m/z = 263 [M+H]* (5) 1-[(1-methyl-1H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Mass spectrum (ESl*): m/z = 561 [M+H]* (6) 1-{[1-(2-cyano-ethyl)-1H-benzoimidazol-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl) 8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 600 [M+H]* (7) 1-({1-[(methylaminocarbonyl)methyl]-1H-benzoimidazol-2-yl}methyl)-3-methyl 7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.45 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 618 [M+H]* C 'NRPonbl\DCCRBR\284264N I.DOC -124 (8) 1-[(1-benzyl-1H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate/methanol = 5:4:1) Mass spectrum (ESl*): m/z = 637 [M+H]* Example XXXIX 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 vl)-8-13-(tert.-butyloxycarbonvlamino)-piperidin-1 -vll-xanthine Prepared by reacting 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten- 1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperid in-1 -yl]-xanthine with paraformaldehyde and potassium cyanide in the presence of zinc chloride in glacial acetic acid at 40 0 C. Rf value: 0.45 (silica gel, cyclohexane/ethyl acetate = 3:7) Mass spectrum (ESI*): m/z = 605 [M+H]* Example XL 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)- 3-(tert.
butyloxvcarbonylamino)-piperidin-1 -vll-xanthine prepared by reduction of 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-[(S)- 3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine with sodium dithionite in a mixture of methylglycol and water (2:1) at 100*C. Rf value: 0.34 (silica gel, methylene chloride/methanol = 95:5) The following compounds are obtained analogously to Example XL: (1) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl]-xanthine Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 4:6) Example XLI - 125 2-chloromethyl-4-methyl-quinazoline prepared by treatment of 2.95 g of 2-chloromethyl-4-methyl-quinazoline-3-oxide with 6 ml phosphorus trichloride in 150 ml chloroform while refluxing. Yield: 1.75 g (57 % of theory) Rf value: 0.81 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 193, 195 [M+H]* Example XLII 2-chloromethyl-4-dimethylamino-quinazoline A freshly prepared solution of 202 mg of dimethylamine in 3.2 ml of tetrahydrofuran is added dropwise to 500 mg of 4-chloro-2-chloromethyl quinazoline in 5 ml of tetrahydrofuran while cooling with an ice bath. Then the reaction mixture is stirred for another 3.5 hours while cooling with an ice bath and then for a further 30 minutes at ambient temperature. The solvent is then gently distilled off using a rotary evaporator and the residue is taken up in methylene chloride. The solution is washed with saturated sodium hydrogen carbonate solution and with water, dried over magnesium sulphate and evaporated down. The solid residue is stirred with a little tert.-butylmethylether, suction filtered, washed with petroleum ether and dried in vacuo. Yield: 323 mg (62 % of theory) Rf value: 0.60 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 222, 224 [M+H]* The following compounds are obtained analogously to Example XLII: (1) 2-chloromethyl-4-(morpholine-4-yl)-quinazoline Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 264, 266 [M+H]* (2) 2-chloromethyl-4-(piperidin-1-yl)-quinazoline Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 1:1) C:\NRPonb DCC\RBR\2R42W9-I DOC - 126 Mass spectrum (ESI*): m/z = 262, 264 [M+H]* (3) 4-[4-(tert.-butyloxycarbonyl)-piperazin-1-yl]-2-chloromethyl-quinazoline Rf value: 0.57 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 363, 365 [M+H]* (4) 2-chloromethyl-4-(pyrrolidin-1-yl)-quinazoline Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 248, 250 [M+H]* (5) 2-chloromethyl-4-ethoxy-quinazoline (The reaction is carried out with sodium ethoxide in ethanol at ambient temperature.) Rf value: 0.50 (silica gel, cyclohexane/ethyl acetate = 3:1) Mass spectrum (ESl*): m/z = 223, 225 [M+H]* (6) 2-chloromethyl-4-isopropyloxy-quinazoline (The reaction is carried out with sodium isopropoxide in isopropanol at ambient temperature.) Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 3:1) Mass spectrum (ESl*): m/z = 237, 239 [M+H]* (7) 2-chloromethyl-4-phenyloxy-quinazoline (The reaction is carried out with sodium hydride and phenol in tetrahydrofuran at ambient temperature.) Rf value: 0.65 (silica gel, cyclohexane/ethyl acetate = 3:1) Mass spectrum (ESl*): m/z = 271, 273 [M+H]* Example XLIII 1-(2-{2-[(ethoxycarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yll-xanthine C \NRPorbi\CC\tBR\2842609_ I.DOC - 127 A solution of 110 pL of ethyl diazoacetate in 0.5 ml of toluene is added dropwise to 531 mg of 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine and 10 mg of methyltrioxorhenium in 4.5 ml of toluene at ambient temperature under an argon atmosphere. The reaction mixture is stirred for 15 hours at ambient temperature.Then approx. another 5 mg of methyltrioxorhenium and 20 pL ethyl diazoacetate are added and the reaction mixture is heated to 50 0 C for two hours. After cooling to ambient temperature another 5 mg of methyltrioxorhenium and 20 pL ethyl diazoacetate are added. After another 16 hours at ambient temperature the reaction mixture is combined with 5 ml of conc. aqueous ammonia, shaken thoroughly and added to an Extrelut pack. After 15 min it is rinsed with 200 ml methylene chloride. The methylene chloride solution is evaporated down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/isopropanol (8:2:0 to 8:1:1) as eluant. Yield: 220 mg (36 % of theory) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 638 [M+H]* Example XLIV 1-[(2-cyano-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonvlamino)-piperidin-1 -yll-xanthine A mixture of 215 mg of 1-{2-[2-cyanomethoxy-phenyl]-2-oxo-ethyl}-3-methyl-7-(2 butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine and 244 mg of caesium carbonate in 4 ml of N,N-dimethylformamide is stirred for two hours at 50 0 C, then a further three hours at 70*C. For working up the reaction mixture is combined with water and the precipitate formed is suction filtered and dried. Yield: 130 mg (62 % of theory) Mass spectrum (ESl*): m/z = 572 [M+H]* Example XLV CARPObIUDX0RBR\2&42(NI DOC - 128 1-[2-(3-methyl-2-oxo-2,3-dihydro-1 H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7 (2-butyn-1 -vl)-8-f3-(tert.-butyloxvcarbonylamino)-piperidin-1 -yll-xanthine Prepared by treating 1-[2-(1-ethoxycarbonyl-3-methyl-2-oxo-2,3-dihydro-1 H benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1-yl]-xanthine with 1 N sodium hydroxide solution in methanol at ambient temperature. Rf value: 0.36 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 605 [M+H]* Example XLVI 4-acetyl-1-ethoxvcarbonyl-1,3-dihydro-benzoimidazol-2-one 5.29 g of diethyldicarbonat and 611 mg of dimethylaminopyridine are added to 1.50 g of 1-(2,3-diamino-phenyl)-ethanone in 75 ml methylene chloride. The reaction mixture is stirred for three hours at ambient temperature, then another 100 mg of dimethylaminopyridine and 1 ml of diethyldicarbonate are added and the mixture is stirred for a further 20 hours at ambient temperature. For working up the reaction mixture is diluted with methylene chloride, washed with 2 N citric acid solution as well as saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The residue is chromatographed through a silica gel column with petroleum ether/ethyl acetate (3:1 to 1:2) as eluant. The desired product is stirred with a little tert.-butylmethylether, suction filtered, nachwashed with a little ethyl acetate and tert.-butylmethylether and dried. Yield: 900 mg (36 % of theory) Rf value: 0.15 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 249 [M+H]* Example XLVII 1-[(4-amino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1 -yll-xanthine C \NRPorbl\DCCRBRi28426)I DOC - 129 501 mg of 1-cyanomethyl-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yl]-xanthine are added to a mixture of 17 mg of potassium-tert. butoxide in 10 ml of methanol. After brief heating with stirring a clear solution is formed and after about 20 minutes the nitrile has largely reacted to form the iminoester according to thin layer chromatography. 206 mg of 2-amino benzamidine-hydrochloride are then added and the reaction mixture is refluxed for four hours. After cooling to ambient temperature the precipitate formed is suction filtered, washed with methanol and dried. Yield: 143 mg (23 % of theory) Rf value: 0.15 (silica gel, ethyl acetate) Mass spectrum (ESl*): m/z = 574 [M+H]* Example XLVIII 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-buten-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1 -yl-xanthine 150 mg of 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butyloxy carbonylamino)-piperidin-1-yl]-xanthine are hydrogenated in a mixture of 5 ml of tetrahydrofuran and 5 ml of methanol in the presence of 30 mg of 5 %m palladium on activated charcoal (contaminated with quinoline) at ambient temperature, until the calculated amount of hydrogen has been taken up. Then a spatula tip of activated charcoal is added and the mixture is suction filtered. The filtrate is evaporated down and the crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (7:3 to 4:6). Yield: 120 mg (85 % of theory) Rf value: 0.40 (silica gel, cyclohexane/ethyl acetate = 4:6) Mass spectrum (ESl*): m/z = 537 [M+H]* Example XLIX 8-hydroxymethyl-5-methoxy-quinoline 148 mg of sodium hydride (approx. 60 % in mineral oil) are added batchwise to a solution of 640 mg of 8-hydroxymethyl-quinolin-5-ol in N,N-dimethylformamide C:XNRPotbI\DCC\RBR\28426'9 -. DOC - 130 while cooling with an ice bath and the reaction mixture is slowly heated to ambient temperature. After the development of gas has ended, 230 pl methyl iodide are added dropwise while cooling with an ice bath, then the reaction mixture is stirred for approx. another two hours at ambient temperature. For working up it is poured onto ice water, saturated with sodium chloride and extracted with a mixture of diethyl ether and ethyl acetate. The combined extracts are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The flask residue is triturated with petroleum ether and the supernatant is decanted. The crude product is purified through a silica gel column with ethyl acetate as eluant. Yield: 470 mg (68 % of theory) Rf value: 0.70 (silica gel, ethyl acetate) Mass spectrum (ESI): m/z = 190 [M+H]* The following compounds are obtained analogously to Example XLIX: (1) 8-hydroxymethyl-5-methoxy-isoquinoline Rf value: 0.40 (silica gel, methylene chloride/methanol = 10:1) Mass spectrum (ESl*): m/z = 190 [M+H]* Example L 8-hydroxymethyl-quinolin-5-ol 3.40 g of quinolin-5-ol is combined with 8 ml of conc. hydrochloric acid and 8 ml of 37 % formalin solution while cooling with an ice bath. Then hydrogen chloride gas is piped through the reaction mixture for about two hours, while the temperature slowly rises. The reaction mixture is stirred first overnight while cooling with an ice bath, then at ambient temperature and then evaporated down in vacuo. The flask residue is taken up in water, covered with a layer of diethyl ether and adjusted to pH 10 while cooling with an ice bath and vigorously stirring with dilute ammonia solution. After another two hours' vigorous stirring at ambient temperature the organic phase is separated off and the aqueous phase is extracted with diethyl C NRPonbI\DCC\RBR\2842(a I.DOC - 131 ether. The combined organic phases are washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (20:1) as eluant. Yield: 660 mg (16 % of theory) Mass spectrum (ESl*): m/z = 176 [M+H]* The following compounds are obtained analogously to Example L: (1) 8-hydroxymethyl-isoquinolin-5-ol Rf value: 0.50 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESl*): m/z = 176 [M+H]* Example LI 1-[(2-cyclopropyl-quinazolin-4-yl)methyl]-3-methyl-7-[(1-cyclopenten-1-vl)methyll 8-[3-(tert.-butyloxycarbonylam ino)-piperidin-1 -yll-xanth ine A mixture of 250 mg of 1 -(2-{2-[(cyclopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl) 3-methyl-7-[(1 -cyclopenten-1 -yl)methyl]-8-[3-(tert.-butyloxycarbonylamino) piperidin-1-yl]-xanthine and 7.5 ml of ethanolic ammonia solution (6 M) is heated to 150 *C for seven hours in a bomb. For working up the reaction mixture is evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant. The contaminated product fraction is evaporated down and again purified through a reversed phase HPLC column with water/ acetonitrile/trifluoroacetic acid (65:15:0.08 to 0:100:0.1) as eluant. The product fractions are evaporated down, made alkaline with dilute sodium hydroxide solution and extracted with methylene chloride. The combined extracts are dried over magnesium sulphate and evaporated down. Yield: 40 mg (14 % of theory) Rf value: 0.40 (silica gel, methylene chloride /ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 627 [M+H]* C. N1RPonbIDCCRBR\284264N_1 DOC - 132 Example LII 4-(2-bromo-acetyl)- 1, 3-bis-[(2-trimethylsilanyl-ethoxy)methyl]- 1, 3-dihydro benzoimidazol-2-one 520 mg of 2-pyrrolidinone-hydrotribromide and 89 mg of 2-pyrrolidinone are added to 420 mg of 4-acetyl-1,3-bis-[(2-trimethylsilanyl-ethoxy)methyl]-1,3-dihydro benzoimidazol-2-one in 5 ml of tetrahydrofuran under an argon atmosphere. The reaction mixture is refluxed for two hours and then suction filtered while still warm. The filter cake is washed with tetrahydrofuran and the filtrate is evaporated down, leaving 660 mg of a yelllowish-brown solid. This is stirred with a little methanol, suction filtered, washed with some methanol and dried. The crude product is reacted further without any more purification. Yield: 430 mg (87 % of theory) Rf value: 0.23 (silica gel, petroleum ether/ethyl acetate = 9:1) Mass spectrum (El): m/z = 514, 516 [M]* The following compounds are obtained analogously to Example LII: (1) 7-(2-bromo-acetyl)-1-(tert.-butyloxycarbonyl)-1H-indole Rf value: 0.33 (silica gel, petroleum ether/ethyl acetate = 9:1) Mass spectrum (ESl*): m/z = 338, 340 [M+H]* (2) 2-bromo-1 -(3-isopropyloxy-phenyl)-ethanone (Carried out with phenyltrimethylammonium tribromide in methylene chloride) Rf value: 0.39 (silica gel, cyclohexane/ethyl acetate = 9:1) (3) 2-bromo-1-(3-difluoromethoxy-phenyl)-ethanone (Carried out with phenyltrimethylammonium tribromide in methylene chloride) Rf value: 0.24 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Example LllI C RPorbIlDCCRBR\2842609 LDOC - 133 methyl 3-methyl-imidazo[1,2-alpyridine-2-carboxylate A mixture of 1.91 g of 2-aminopyridine and 4.40 g of methyl 3-bromo-2-oxo butyrate in 40 ml of ethanol is refluxed for 6 hours and then left to stand for 2 days at ambient temperature. The solvent is distilled off using the rotary evaporator and the crude product is purified by chromatography over a silica gel column with methylene chloride/methanol/methanolic ammonia solution (95:4:1 to 90:9:1) as eluant. 560 mg of the ethyl ester are isolated as the by-product. Yield: 2.09 g (54 % of theory) Rf value: 0.20 (silica gel, methylene chloride/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 191 [M+H]* Example LIV 2-chloromethyl-4-isopropyl-quinazoline Dry hydrogen chloride gas is piped through a solution of 2.86 g of 1-(2-amino phenyl)-2-methyl-propan-1-one and 1.33 ml of chloroacetonitrile in 14 ml dioxane with stirring at ambient temperature for approx. five hours. Then the dioxane is largely distilled off in a water jet vacuum. The honey-like residue is combined with ice water and the resulting suspension is made alkaline with saturated potassium carbonate solution while cooling with an ice bath. The precipitate is suction filtered, washed with water and dried. The crude product is purified by chromatography over a silica gel column with petroleum ether/methylene chloride (8:2 to 0:1) as eluant. Yield: 1.80 g (58 % of theory) Rf value: 0.30 (silica gel, methylene chloride/petroleum ether = 1:1) Mass spectrum (ESl*): m/z = 221, 223 [M+H]* Example LV 1-chloromethyl-3-trifluoromethyl-3,4-dihydro-isoquinoline 530 mg of N-(1-benzyl-2,2,2-trifluoro-ethyl)-2-chloro-acetamide (prepared by reacting 1 -benzyl-2,2,2-trifluoro-ethylamine with chloroacetyl chloride in the presence of triethylamine) and 0.74 ml of phosphorus oxychloride are added to CWNRPortbl\DCC\RBR\28L42609 1.DOC -134 4.00 g of polyphosphoric acid. The viscous mixture is stirred for 1.5 hours at 130*C. For working up the reaction mixture is cooled and combined with ice water, stirred vigorously for ten minutes and suction filtered. The filter cake is dissolved in ethyl acetate and the solution is dried over magnesium sulphate and evaporated down, leaving a white solid. Yield: 415 mg (84 % of theory) Rf value: 0.55 (aluminium oxide, petroleum ether/ethyl acetate = 10:1) Mass spectrum (ESl*): m/z = 248, 250 [M+H]* The following compound is obtained analogously to Example LV: (1) 1-methyl-3-trifluoromethyl-3,4-dihydro-isoquinoline (The starting material N-(1-benzyl-2,2,2-trifluoro-ethyl)-acetamide is obtained by reacting 1-benzyl-2,2,2-trifluoro-ethylamine with acetic anhydride.) Example LVI 3-bromomethyl-1-(1 -cyano-1 -methyl-ethyl)-isoquinoline A mixture of 375 mg of 1-(1-cyano-1-methyl-ethyl)-3-methyl-isoquinoline and 321 mg of N-bromosuccinimide in 5 ml carbon tetrachloride is combined with a spatula tip of 2,2-azoisobutyric acid dinitrile and refluxed for about six hours. The cooled reaction mixture is filtered and evaporated down. The flask residue is reacted further without any more purification. Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 3:1) The following compounds are obtained analogously to Example LVI: (1) 6-bromomethyl-1-[(2-trimethylsilanyl-ethoxy)methyl]-1H-quinolin-2-one (2) 1-bromomethyl-4-bromo-3-methoxy-isoquinoline (3) 2-bromomethyl-[1,5]naphthyridine C:\NRPo.bI\DCCRBR\2t426)9 1.DOC - 135 Mass spectrum (ESI+): m/z = 223, 225 [M+H]+ (4) 5-bromomethyl-[1,6]naphthyridine Rf value: 0.48 (silica gel, ethyl acetate/methanol = 98:2) (5) 7-bromomethyl-5-phenyl-quinoxaline Rf value: 0.85 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 299, 301 [M+H]* (6) 4-bromomethyl-[1,5]naphthyridine Rf value: 0.56 (silica gel, methylene chloride/ethyl acetate = 7:3) Mass spectrum (ESl*): m/z = 223, 225 [M+H]* (7) 1-bromomethyl-3-trifluoromethyl-isoquinoline Mass spectrum (ESl*): m/z = 290, 292 [M+H]* (8) 1-bromomethyl-3-difluoromethyl-isoquinoline Mass spectrum (ESl*): m/z = 272, 274 [M+H]* (9) 1-bromomethyl-4-chloro-3-methoxy-isoquinoline Example LVII 1-(1 -cyano-1 -methyl-ethyl)-3-methyl-isoquinoline 3.30 g of 2,2-azoisobutyric acid dinitrile are added to 1.60 g of 3-methyl isoquinoline-N-oxide in 30 ml of toluene. The reaction mixture is stirred for six hours at 85*C and then left to stand for two days at ambient temperature. For working up the reaction mixture is extracted with 20% hydrochloric acid. The combined aqueous phases are diluted with methylene chloride, made alkaline with saturated potassium carbonate solution while cooling with an ice bath and extracted with methylene chloride. The combined methylene chloride extracts are CANRPo-bIkDCCflR\292(AN-~I DOC - 136 dried over magnesium sulphate and evaporated down. The residue is chromatographed through a silica gel column with cyclohexane as eluant. Yield: 375 mg (18 % of theory) Mass spectrum (ESI'): m/z = 211 [M+H]* Rf value: 0.75 (silica gel, cyclohexane/ethyl acetate = 3:1) Example LVIII 1-(2-cyanoimino-2-phenyl-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-[3-(tert.
butyloxycarbonylamino)-piperidin-1-yll-xanthine (E/Z-mixture) 0.48 ml of a 1 M solution of titaniium tetrachloride in methylene chloride are added dropwise to 244 mg of 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-[3 (tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine in 7 ml of methylene chloride. Then 88 pl of 1,3-bis(trimethylsilyl)carbodiimide are added and the mixture is stirred for four hours at ambient temperature. For working up the reaction mixture is diluted with methylene chloride and poured onto ice water. The organic phase is washed with 0.5 N citric acid, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (98:2 to 95:5) as eluant. Yield: 206 mg (97 % of theory) Mass spectrum (ESI-): m/z = 557 [M-H] Rf value: 0.16 (silica gel, cyclohexane/ethyl acetate = 1:1) Example LIX 1-[(1H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert.-butvloxv carbonylamino)-piperidin-1 -yll-xanthine 350 mg of 1-[(2-amino-phenylaminocarbonyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 [3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine are refluxed in 3 ml glacial acetic acid for two hours. Then the reaction mixture is evaporated down, the flask residue is combined with 5 ml of 1 M sodium hydroxide solution and washed with methylene chloride. Then the aqueous phase is acidified with 1 M hydrochloric acid and extracted with methylene chloride. The combined extracts are evaporated C:\NRLPortb\DCC\RBR\2842(W LDOC - 137 down and chromatographed through a silica gel column with cyclohexane/ethyl acetate/methanol (6:4:0 to 5:4:1) as eluant. Yield: 250 mg of (74 % of theory) Mass spectrum (ESl*): m/z = 547 [M+H]* Example LX Ethyl 3,4-d imethyl-6,7-d ihyd ro-5H-21 pyrind in-1 -carboxylate Prepared by treating 1.16 g of ethyl 3,4-dimethyl-4a-(pyrrolidin-1-yl)-5,6,7,7a tetrahydro-4aH-[2]pyrindin-1-carboxylate with 1.08 g of 70 % 3-chloro-perbenzoic acid in 50 ml methylene chloride at ambient temperature. Yield: 850 mg (97 % of theory) Rf value: 0.30 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 220 [M+H]* The following compounds are obtained analogously to Example LX: (1) ethyl 3,4-dimethyl-5,6,7,8-tetrahydro-isoquinoline-1-carboxylate Rf value: 0.35 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 234 [M+H]* Example LXI Ethyl 3,4-dimethyl-4a-(pyrrolidin-1-yl)-5,6,7,7a-tetrahydro-4aH-[2]pyrindin-1 carboxylate Prepared by reacting 2.50 g of ethyl 5,6-dimethyl-[1,2,4]triazin-3-carboxylate with 2.74 g of 1-(cyclopenten-1-yl)-pyrrolidine in 25 ml chloroform at ambient temperature. Yield: 3.00 g (75 % of theory) Rf value: 0.60 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 291 [M+H]* The following compounds are obtained analogously to Example LXI: C \NR~obI\DC0RflR\18260 I DC - 138 (1) ethyl 3,4-dimethyl-4a-(pyrrolidin-1-yl)-4a,5,6,7,8,8a-hexahydro-isoquinoline-1 carboxylate Rf value: 0.60 (aluminium oxide, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 305 [M+H]* Example LXII Methyl 2.3,8-trimethyl-quinoxalin-6-carboxylate Prepared by reacting 1.60 g of methyl 3,4-diamino-5-methyl-benzoate with 0.86 ml diacetyl in a mixture of water and ethanol while refluxing. Yield: 1.53 g (80 % of theory) Rf value: 0.63 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI*): m/z = 231 [M+H]* The following compounds are obtained analogously to Example LXII: (1) methyl 8-methyl-quinoxalin-6-carboxylate (reaction is carried out with glyoxal in water.) Rf value: 0.55 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESl*): m/z = 203 [M+H]* (2) 5-bromo-7-methyl-quinoxaline (reaction is carried out with glyoxal in a water/ethanol mixture.) Rf value: 0.75 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 223, 225 [M+H]* Example LXIII Methyl 3,4-diamino-5-methyl-benzoate C N"-WO~b CC'JBR\2426 - _I DOC - 139 Prepared by reduction of methyl 3-nitro-4-amino-5-methyl-benzoate at a partial hydrogen pressure of 50 psi in the presence of Raney nickel in methanol at ambient temperature. Rf value: 0.40 (silica gel, tert.-butylmethylether) Example LXIV Methyl 3-nitro-4-amino-5-methyl-benzoate Prepared by treating 3-nitro-4-acetylamino-5-methyl-benzoic acid with hydrogen chloride gas in methanol at ambient temperature and subsequently heating while refluxing. Mass spectrum (ESl*): m/z = 211 [M+H]* Rf value: 0.75 (silica gel, tert.-butylmethylether/acetic acid = 99:1) Example LXV 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-1 -buten- 1 -yl)-8-bromo-xanthine 0.13 ml 35 % hydrogen peroxide solution are added to 290 mg of 1-(2-phenyl-2 oxo-ethyl)-3-methyl-7-(1 -phenylsulphanyl-butyl)-8-bromo-xanthine in 6 ml hexafluoroisopropanol. The reaction mixture is stirred for one hour at ambient temperature, diluted with methylene chloride and washed with sodium thiosulphate solution. The organic phase is dried over magnesium sulphate and evaporated down. The flask residue is taken up in 6 ml of toluene and refluxed for eight hours. Then the toluene is distilled off in vacuo and the crude product is purified through a silica gel column with methylene chloride/methanol (100:0 to 95:5) as eluant. Yield: 104 mg (45 % of theory) Rf value: 0.61 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl*): m/z = 417, 419 [M+H]* The following compounds are obtained analogously to Example LXV: (1) 3-methyl-7-(3-methyl-1-buten-1-yl)-8-bromo-xanthine Rf value: 0.24 (silica gel, methylene chloride/methanol = 95:5) C LNI"PODCOBRU&U26M_ DOC - 140 Mass spectrum (ESl*): m/z = 313, 315 [M+H]* Example LXVI 1 -methanesulphonyloxymethyl-4-difluoromethoxy-naphthalene Prepared by reacting (4-difluoromethoxy-naphthalen-1-yl)-methanol with methanesulphonic acid chloride in methylene chloride in the presence of triethylamine. The following compounds are obtained analogously to Example LXVI: (1) (E)- 1 -methanesulphonyloxy-3-(2-nitro-phenyl)-2-propene (2) (E)-1-methanesulphonyloxy-3-pentafluorophenyl-2-propene (3) (E)-1-methanesulphonyloxy-3-(2-trifluoromethyl-phenyl)-2-propene (4) (E)- 1 -methanesuphonyloxy-3-(3-trifluoromethyl-phenyl)-2-propene (5) (E)-1-methanesulphonyloxy-3-(4-trifluoromethyl-phenyl)-2-propene Example LXVII 7-methyl-5-phenyl-quinoxaline A mixture of 400 mg of 5-bromo-7-methyl-quinoxaline, 244 mg of phenylboric acid and 100 mg of tetrakis(triphenylphosphine)palladium in 12 ml dioxane, 4 ml of methanol and 3.6 ml 1 M aqueous sodium carbonate solution is refluxed for three hours under an argon atmosphere. Then the reaction mixture is evaporated down and the residue is distributed between ethyl acetate and water. The ethyl acetate phase is separated off, dried over magnesium sulphate and evaporated down. The C C4RNoWbKDCCRfRV824N_ I DOC - 141 crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (85:15 to 70:30) as eluant. Yield: 390 mg (66% of theory) Rf value: 0.36 (silica gel, petroleum ether/ethyl acetate = 5:1) Mass spectrum (ESl*): m/z = 221 [M+H]* Example LXVIII 1 -methyl-3-trifluoromethyl-isoquinoline Prepared by treating 905 mg of 1-chloromethyl-3-trifluoromethyl-3,4-dihydro isoquinoline with 420 mg of potassium-tert. butoxide in 10 ml of tetrahydrofuran at ambient temperature. Yield: 755 mg of (98% of theory) Mass spectrum (ESl*): m/z = 212 [M+H]* The following compounds are obtained analogously to Example LXVIII: (1) 1-methyl-3-difluoromethyl-isoquinoline (Prepared from 1-methyl-3-trifluoromethyl-3,4-dihydro-isoquinoline) Mass spectrum (ESl*): m/z = 194 [M+H]* Example LXIX 4-chloro-3-methoxy-1 -methyl-isoquinoline Prepared by treating 3-methoxy-1-methyl-isoquinoline with sulphuryl chloride in methylene chloride. Rf value: 0.30 (silica gel, cyclohexane) Mass spectrum (ESI*): m/z = 208, 210 [M+H]* Example LXX 3-cyclopropyl-8-bromo-xanthine - 142 Prepared by reacting 3-cyclopropyl-xanthine with bromine in the presence of potassium carbonate in acetonitrile at 60 0 C. Rf value: 0.65 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 271, 273 [M+H]* Example LXXI Ethyl 1,2,3,4-tetrahyd ro-phenanthridin-6-yl-carboxylate Analogously to the method described by Gonsalves et al. (Tetrahedron 1992, 48, 6821) a solution of 3.90 g of ethyl 5,6,7,8-tetrahydro-benzo[1,2,4]triazin-3 carboxylate (Sagi et al., Heterocycles 1989, 29, 2253) in 20 ml dioxane is refluxed. Then 8.22 g of anthranilic acid and 7.02 g of isoamylnitrite, in each case dissolved in 20 ml dioxane, are simultaneously added dropwise within 25 minutes by means of two dropping funnels. The reaction mixture is refluxed for a further 30 minutes. For working up the cooled deep-brown reaction solution is diluted with 150 ml diethyl ether, washed with 100 ml of 2 N sodium hydroxide solution and with water, dried over magnesium sulphate and evaporated down. The brown, oily flask residue is chromatographed through a silica gel column with ethyl acetate/petroleum ether (20:80 to 50:50) as eluant. The product obtained is still somewhat contaminated, but is reacted further without any more purification. Yield: 380 mg (8 % of theory) Rf value: 0.55 (silica gel, petroleum ether/ethyl acetate = 2:1) Mass spectrum (ESl*): m/z = 256 [M+H]* CANRPornbIDCMBR2NW26O I DC - 143 Preparation of the final compounds: Example 1 1, 3-dimethyl-7-(2,6-dicyano-benzyl)-8-(3-amino-piperidin- 1 -yl)-xanth ine 129 mg of 3-amino-piperidine-dihydrochloride are added to a mixture of 298 mg of 1, 3-d imethyl-7-(2,6-dicyano-benzyl)-8-bromo-xanthine and 420 mg of potassium carbonate in 9 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at 80*C. For working up the mixture is diluted with methylene chloride and washed with saturated sodium chloride solution. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography through a silica gel column with methylene chloride/methanol/conc. methanolic ammonia (95:5:1 to 80:20:1) as eluant. Yield: 43 mg (14 % of theory) Rf value: 0.67 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESl*): m/z = 419 [M+H]* The following compounds are obtained analogously to Example 1: (1) 1 -(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl) xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 433 [M+H]* Example 2 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten- 1 -yl)-8-(3-amino-piperid in-1 -yl)-xanthine A solution of 209 mg of 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3 methyl-7-(3-methyl-2-buten-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl] xanthine in 4 ml methylene chloride is combined with 1 ml of trifluoroacetic acid and stirred for half an hour at ambient temperature. For working up the reaction CAPfl CCRU 42tW9-I DOC - 144 mixture is diluted with methylene chloride and washed with saturated potassium carbonate solution. The organic phase is dried, evaporated down and chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 4:1) as eluant. Yield: 153 mg of (87 % of theory) Mass spectrum (ESl*): m/z = 553 [M+H]* The following compounds are obtained analogously to Example 2: (1) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESl*): m/z = 524 [M+H]* (2) 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.58 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESl*): m/z = 543 [M+H]* (3) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 465 [M+H]* (4) 1 -(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl) xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 500 [M+H]* (5) 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl) xanthine C RPflbiOC\RR\2UW I DOC - 145 Rf value: 0.58 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESI-): m/z = 435 [M-H] (6) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanth ine Mass spectrum (ESI*): m/z = 553 [M+H]* (7) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 538 [M+H]* (8) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 552 [M+H]* (9) 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl) xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 438 [M+H]* (10) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 452 [M+H]* (11) 1 -methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 419 [M+H]* C:XNRPortblDCC\BR2842609_.DOC - 146 (12) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl) xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 418 [M+H]* (13) 1-{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten- 1 -yl)-8-(3-amino-piperidin- 1 -yl)-xanthine Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESl*): m/z = 535 [M+H]* (14) 1 -methyl-3-(2-propen-1 -yl)-7-(2-cyano-benzyl)-8-(3-amino-piperid in- 1-yl) xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI*): m/z = 420 [M+H]* (15) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn- 1 -yl)-8-(3-amino-piperidin- 1-yl) xanthine Mass spectrum (ESI): m/z = 435 [M+H]* (16) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 100:100:0.1) Mass spectrum (ESl*): m/z = 522 [M+H]* (17) 1 -methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 456 [M+H]* C:\NRPortbI\DCCRBR\242&_9 I.OC - 147 (18) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-((S) 3-amino-piperidin-1 -yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 466 [M+H]* (19) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.07 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 476 [M+H]* (20) 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (21) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 491 [M+H]* Rf value: 0.16 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) (22) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1-yl)-xanthine (1:1 mixture with 1-[(1,4-dihydro-cinnolin-4-yl)methyl]-3 methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine) (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C N"ofbKM)CRBR2"260~9 IDOC - 148 Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 475 [M+H]* (23) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl-2 buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 178-181*C Mass spectrum (ESl*): m/z = 504 [M+H]* (24) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.06 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 491 [M+H]* (25) 1-{(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 475 [M+H]* (26) 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 504 [M+H]* C.kNRPotblDCCRBR\U4269 I.DOC - 149 (27) 1-[(isoquinoline-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (28) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:1) Mass spectrum (ESl*): m/z = 491 [M+H]* (29) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 500 [M+H]* (30) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.58 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 500 [M+H]* (31) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl 2-buten- 1 -yl)-8-(3-amino-piperidin- 1 -yl)-xanthine-hydrochloride C:\NRPnb\DCCRBR\2426W_1 DOC - 150 (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product precipitated as the hydrochloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 505 [M+H]* (32) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 497 [M+H]* (33) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 513 [M+H]* (34) 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.66 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 529 [M+H]* (35) 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product precipitated as the hydrochloride) Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 495 [M+H]* C :NRPonbI\DCRBRU42(O I.DC - 151 (36) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product precipitated as the hydrochloride) Rf value: 0.47 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 509 [M+H]* (37) 1-{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methy-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 508 [M+H]* (38) 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 522 [M+H]* (39) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperid in-1 -yl)-xanthine-hyd rochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) CAN".nOI RBRX29U2609-1 DOC - 152 Mass spectrum (ESI): m/z = 564 [M+H]* (40) 1 -[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3 amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 495 [M+H]* (41) 1-[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.41 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 523 [M+H]* (42) 1-{2-[2-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 522 [M+H]* (43) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) C:\RPorbICORBR\284269 I DOC - 153 Rf value: 0.53 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 564 [M+H]* (44) 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.44 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 511 [M+H]* (45) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2,3-dimethyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; product obtained as the hydrochloride) Rf value: 0.68 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 465 [M+H]* (46) 1 -((E)-3-phenyl-allyl)-3-methyl-7-(3-methyl-2-buten- 1 -yl)-8-(3-amino-piperid in 1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 449 [M+H]* (47) 1-[(benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C NRUobIrCCRBRU2S42609_1 DMC - 154 Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 479 [M+H]* (48) 1-[(1H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1-yl)-xanthine Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 462 [M+H]* (49) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.30 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI): m/z = 499 [M+H]* (50) 1 -[(1 -naphthyl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-(3-amino-piperid in- 1-yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.56 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 457 [M+H]* (51) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl) 8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 488 [M+H]* CANbIODCM'BRX2269 DOC - 155 (52) 1 -[(quinolin-4-yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-(3-amino-piperid in-1 -yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 458 [M+H]* (53) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass- spectrum (ESl*): m/z = 457 [M+H]* (54) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 431 [M+H]* (55) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 459 [M+H]* (56) 1-[(2-methyl-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) CW~RPonbIVDCCRBR\2K4260_ I DC - 156 Rf value: 0.25 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 471 [M+H]* (57) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.43 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 561 [M+H]* (58) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI'): m/z = 418 [M+H]* (59) 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 458 [M+H]* (60) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinoline-4-yl)methyl]-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.17 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 488 [M+H]* C.\NRPortbl\DCCRBR\84269I DOC - 157 (61) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinoline-4-yl)methyl]-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.13 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 504 [M+H]* (62) 1-[(2-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.17 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 487 [M+H]* (63) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.42 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 458 [M+H]* (64) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.14 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 487 [M+H]* (65) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine CRfo,,bICMBR2426O9_J DOC - 158 (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 155-158*C Mass spectrum (ESl*): m/z = 472 [M+H]* (66) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 511 [M+H]* (67) 1-[(5-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 502 [M+H]* (68) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.56 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 444 [M+H]* (69) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 472 [M+H]* CA.VRPobICRBRU9426Oq I DOC -159 (70) 1-[(2-naphthyl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESI*): m/z = 457 [M+H]* (71) 1-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 475 [M+H]* (72) 1-[(quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 458 [M+H]* (73) 1-[(4-dimethylamino-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.18 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 500 [M+H]* (74) 1-[(isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino-piperidin 1-yl)-xanthine C .NRPonbI\DCCRBRi24264)91.DOC - 160 (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; the product still contains approx. 20 % of Z isomer) Rf value: 0.66 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 460 [M+H]* (75) 1 -[(3-methoxy-naphthalen-2-yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.25 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 487 [M+H]* (76) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 509 [M+H]* (77) 1-[(3-methyl-4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 489 [M+H]* (78) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7 (3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) R, value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 522 [M+H]* C:NPobCCRBR28426i9 I DOC - 161 (79) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 495 [M+H]* (80) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin 1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 459 [M+H]* (81) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino-piperidin 1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI'): m/z = 459 [M+H]* (82) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; the product still contains approx. 20 % of Z isomer) Rf value: 0.12 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 461 [M+H]* (83) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; the product still contains approx. 15 % of Z isomer) Rf value: 0.12 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.1) Mass spectrum (ESl*): m/z = 461 [M+H]* C:\NRPortblDCCRBR\284269 1. DOC -162 (84) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; the product still contains approx. 17 % of Z isomer) Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (85) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride; the product still contains approx. 17 % of Z isomer) Rf value: 0.54 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (86) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 536 [M+H]* (87) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8 (3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 478 [M+H]* (88) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(1-cyclopenten-1-yl)methyl]-8-(3-amino piperidin-1 -yi)-xanthine Mass spectrum (ESl*): m/z = 463 [M+H]* (89) 1 -(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-[(1 cyclopenten-1 -yl)methyl]-8-(3-amino-piperidin-1 -yl)-xanthine C:NRPonbDCC\RBR\28426N 1.DOC - 163 Mass spectrum (ESI): m/z = 550 [M+H]* (90) 1 -methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin- 1 -yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 422 [M+H]* (91) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESl*): m/z = 522 [M+H]* (92) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 508 [M+H]* (93) 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 505 [M+H]* (94) 1 -(2-{2-[(isopropylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7 (2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 550 [M+H]* (95) 1-((isoquinolin-1-yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 532 [M+H]* C:\NRPortbl\DCC\RBR\2426ANL DC - 164 (96) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESl*): m/z = 494 [M+H]* (97) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-(3-amino-piperidin- 1 yl)-xanthine (product contains approx. 25 % of Z isomer) Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESIl): m/z = 437 [M+H]* (98) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESIl): m/z = 567 [M+H]* (99) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 522 [M+H]* (100) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (product contains approx. 10 % of Z isomer) Mass spectrum (ESI*): m/z = 522 [M+H]* (101) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7 ((E)-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (product contains approx. 8 % of Z isomer) Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*); m/z = 524 [M+H]* C XNRPonbIPDCORBR\28426"_ I DOC - 165 (102) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methy-7-(2 butyn-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI): m/z = 536 [M+H]* (103) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3 methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESl*): m/z = 581 [M+H]* (104) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.54 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 452 [M+H]* (105) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl) 8-((S)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.48 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 508 [M+H]* (106) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 450 [M+H]* (107) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 522 [M+H]* C:\NRPorbIlDCC\RBR\2842649I DOC - 166 (108) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine (product contains approx. 22 % of Z isomer) Mass spectrum (ESI*): m/z = 437 [M+H]* (109) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 536 [M+H]* (110) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3 amino-piperidin-1 -yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 492 [M+H]* (111) 1-(2-{2-[2-oxo-2-(pyrrolidin-1 -yl)-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESl*): m/z = 562 [M+H]* (112) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 538 [M+H]* (113) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-((R)-3-amino-piperidin 1-yl)-xanthine Mass spectrum (ESl*): m/z = 435 [M+H]* (114) 1 -(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine CNRPolnb\DCCRBR2S42609 1.DOC - 167 (product contains approx. 30 % of Z isomer) Mass spectrum (ESl*): m/z = 538 [M+H]* (115) 1 -methyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 380 [M+H]* (116) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 536 [M+H]* (117) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-((S)-3-amino piperidin-1 -yl)-xanthine (product contains approx. 23 % of Z isomer) Rf value: 0.42 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 437 [M+H]* (118) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 520 [M+H]* (119) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 -yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine Rf value: 0.15 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 492 [M+H]* C:\NRPortbI\DCCRBR\28426)9I DOC - 168 (120) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI): m/z = 520 [M+H]* (121) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-methyl-allyl)-8-(3-amino-piperidin-1 yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 437 [M+H]* (122) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-bromo-allyl)-8-(3-amino-piperidin- 1 yl)-xanthine Rf value: 0.14 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 501, 503 [M+H]* (123) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.42 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 524 [M+H]* (124) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-[(furan-2-yl)methyl]-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI'): m/z = 463 [M+H]* (125) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-chloro-allyl)-8-(3-amino-piperid in-1 yl)-xanthine C RPorbl\DCC\RBRX2K42(A_1 DOC - 169 Rf value: 0.18 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) (126) 1-{2-[2-(1-methoxycarbony-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 537 [M+H]* (127) 1 -{2-[2-(1 -aminocarbonyl-ethoxy)-pheny]-2-oxo-ethyl}-3-methyl-7-(2-butyn 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI): m/z = 522 [M+H]* (128) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 -yl)-8-((S)-3-amino-piperid in 1-yl)-xanthine Mass spectrum (ESI*): m/z = 435 [M+H]* (129) 1-[(3-methyl-isoq uinolin- 1 -yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 155-156.5*C Mass spectrum (ESl*): m/z = 472 [M+H]* (130) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 472 [M+H]* (131) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) CNR~nbIMCRBQX42)9- DOC - 170 Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 472 [M+H]* (132) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 472 [M+H]* (133) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (134) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 167.5-172 0 C Mass spectrum (ESl*): m/z = 474 [M+H]* (135) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-(3-(R)-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 493 [M+H]* CLR OflbJDCMB RUM42W)- 1. DOC - 171 (136) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-(3-(S)-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 493 [M+H]* (137) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3 amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 487 [M+H]* (138) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 487 [M+H]* (139) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.41 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 479 [M+H]* (140) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 479 [M+H]* C \RPotb\DCCRBRQ8426)9 LDOC - 172 (141) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(S) amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 473 [M+H]* (142) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R) amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 198-202 0 C Mass spectrum (ESIl): m/z = 473 [M+H]* (143) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7 (3-methyl-2-buten- 1 -yl)-8-(3-amino-piperid in-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.53 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 522 [M+H]* (144) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-((S)-3-amino-piperidin- 1 -yl)-xanth ine Mass spectrum (ESl*): m/z = 538 [M+H]* (145) 1 -(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 522 [M+H]* C WRPonibIW0CRBRQM~2(N I DC - 173 (146) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten 1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 508 [M+H]* (147) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)- 8 ((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 494 [M+H]* (148) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7 ((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESI): m/z = 524 [M+H]* (149) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-((E)-2-buten-1-yl)-8 ((S)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI): m/z = 494 [M+H]* (150) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7 ((E)-2-buten-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 524 [M+H]* (151) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 520 [M+H]* (152) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESIl): m/z = 522 [M+H]* C:NRPotnbI\DCCRBR\X28426 DOC - 174 (153) 1-(2-{2-[2-(morpholin-4-yl)-2-oxo-ethoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 578 [M+H]* (154) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten 1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 508 [M+H]* (155) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 506 [M+H]* (156) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-butyn-1 yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI): m/z = 506 [M+H]* (157) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 492 [M+H]* (158) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI): m/z = 526 [M+H]* C -. N~onbI0fCM~BR\2S42(AI9_I DOC - 175 (159) 1-(2-{2-[(phenylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 556 [M+H]* (160) 1-[(2-acetyl-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Obtained as main product when 1-{2-[2-(2-oxo-propoxy)-phenyl]-2-oxo-ethyl}-3 methyl-7-(2-butyn-1 -yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1 -yl]-xanthine is treated with trifluoroacetic acid in methylene chloride) Mass spectrum (ESI*): m/z = 489 [M+H]* (161) 1-{2-[2-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-oxo-ethyl}-3-methyl-7 (2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine Mass spectrum (ESl*): m/z = 565 [M+H]* (162) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 496 [M+H]* (163) 1-[(4-dimethylamino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine Rf value: 0.30 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 502 [M+H]* C \NRPonibI\DCCRBR\2842()_ . DC - 176 (164) 1 -[2-(2-oxo-2,3-dihydro-benzooxazo-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl 2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.42 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 508 [M+H]* (165) 1-(2-{2-[(ethoxycarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 538 [M+H]* (166) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 451 [M+H]* (167) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-methyl-2-buten-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.59 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 80:20:1) Mass spectrum (ESl*): m/z = 451 [M+H]* (168) 1-[(imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 447 [M+HJ C VNR~onbIDCM~BR%284 26& V DC - 177 (169) 1-[(quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 459 [M+H]* (170) 1-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)-2-oxo-ethyl]-3 methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 519 [M+H]* (171) 1-[(quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 459 [M+H]* (172) 1-[(2-cyano-benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 472 [M+H]* (173) 1-[2-(2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 492 [M+H]* Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) (174) 1-[(3-methyl-quinoxalin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine C:\NRPortbJ\DCCRBR\284269 I DOC - 178 Melting point: 188.5-191*C Mass spectrum (ESl*): m/z = 473 [M+H]* (175) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 534 [M+H]* (176) 1-(2-{2-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1-yl)-8-(3-amino-piperid in-1 -yl)-xanthine x trifluoroacetic acid Mass spectrum (ESl*): m/z = 527 (M+H]* (177) 1-[(benzofuran-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1 yl)-xanthine (Produced when 1-{[2-(tert.-butylcarbonyl)-benzofuran-3-yl]methyl}-3-methyl-7-(2 butyn-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine is treated with trifluoroacetic acid in methylene chloride) Mass spectrum (ESl*): m/z = 447 [M+H]* (178) 1-[(3,4-dimethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine-hyd rochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.75 (aluminium oxide, methylene chloride/methanol = 10:1) Mass spectrum (ESl*): m/z = 486 [M+H]* (179) 1-[(benzofuran-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine Mass spectrum (ESI'): m/z = 447 [M+H]* C.NRPonbl'DCC\RR2942609 1 DOC - 179 (180) 1-{[4-(morpholin-4-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESI*): m/z = 544 [M+H]* (181) 1-{[4-(piperidin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 542 [M+H]* (182) 1-{[4-(piperazin-1-yl)-quinazolin-2-yl]methyl}-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 543 [M+H]* (183) 1-{[4-(pyrrolidin-1-yl)-quinazolin-2-yllmethyl}-3-methyl-7-(2-butyn-l-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 528 [M+H]* (184) 1-[2-(3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)-2-oxo-ethyl]-3 methyl-7-(2-butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C NRPortbIDCCRBR\42W26t LDOC - 180 Rf value: 0.43 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 505 [M+H]* (185) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 482 [M+H]* (186) 1-[(imidazo[1,2-a]pyridine-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.37 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 447 [M+H]* (187) 1-[(8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 461 [M+H]* (188) 1-[(4-amino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 474 [M+H]* C-kNRPonbIkDCCRfBRII2026)9- DC - 181 (189) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((Z)-2-buten-1-yl)-8-(3-amino-piperidin 1-yl)-xanthine Mass spectrum (ESl*): m/z = 437 [M+H]* (190) 1-[(8-methoxy-quinolin-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine x 2 trifluoroacetic acid Rf value: 0.45 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESl*): m/z = 488 [M+H]* (191) 1-[(5-methoxy-quinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.20 (silica gel, ethyl acetate/methanol = 1:1) Mass spectrum (ESl*): m/z = 488 [M+H]* (192) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 535 [M+H]* (193) 1-[(7-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 461 [M+H]* (194) 1-[(2-cyclopropyl-quinazolin-4-yl)methyl]-3-methyl-7-[(1-cyclopenten-1 yl)methyl]-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C \NRPorblDCC\RBRZ2&269 I .DOC - 182 Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 527 [M+H]* (195) 1-(2-oxo-4-phenyl-butyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin 1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESl*): m/z = 463 [M+H]* (196) 1 -(2-{2-[(methylaminocarbonyl)methylamino]-phenyl}-2-oxo-ethyl)-3-methyl 7-((E)-2-buten-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.52 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 523 [M+H]* (197) 1-[2-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 491 [M+H]* (198) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.75 (silica gel, methylene chloride/methanol = 10:1) Mass spectrum (ESl*): m/z = 508 [M+H]* (199) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.80 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 96:4:0.5) Mass spectrum (ESl*): m/z = 515 [M+H]* C NRUonbIDCC'RflRQ&2&26-I DOC - 183 (200) 1-[(3-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine RrWet: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 461 [M+H]* (201) 1-[2-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1 yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 515 [M+H]* (202) 1-[(5-methyl-imidazo(1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.53 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 461 [M+H]* (203) 1-[(6-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 176.5-178*C Mass spectrum (ESl*): m/z = 461 [M+H]* (204) 1-[(3-benzyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 201-204 0 C Mass spectrum (ESl*): m/z = 537 [M+H]* C WNRPoahflDC(BRL'M4W9_ I DOC - 184 (205) 1-[(4-isopropyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 501 [M+H]* (206) 1-[(2,3-dihydro-benzo[1,4]dioxin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.65 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 465 [M+H]* (207) 1-[(1-methyl-1H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 460 [M+H]* (208) 1-[(quinolin-3-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 458 [M+H]* (209) 1-[(3-phenyl-imidazo[1,2-a]pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C:XNRPonbIODCOBRU2K4Y4NJ) DOC - 185 Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 523 [M+H]* (210) 1-[(1H-indol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl) xanthine-hydrochloride Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 446 [M+H]* (211) 1-[2-(naphthalen-1-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 485 [M+H]* (212) 1-[(5-methoxy-isoquinolin-8-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum (ESl*): m/z = 488 [M+H]* (213) 1-{[1-(1-cyano-1-methyl-ethyl)-isoquinolin-3-yl]methyl}-3-methyl-7-(2-butyn 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.25 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 525 [M+H]* (214) 1-(2-cyanoimino-2-phenyl-ethyl)-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine x trifluoroacetic acid (E/Z-mixture) C:NRPrbIlDCCRBR\29426'9 I DOC - 186 Mass spectrum (ESI*): m/z = 459 [M+H]* (215) 1-[(1H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESI*): m/z = 447 [M+H]* (216) 1-[(1-methyl-1H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 461 [M+H]* (217) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 535 [M+H]* (218) 1-[(2,3-dimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 487 [M+H]* (219) 1-[(2-methyl-1H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:0.1) Mass spectrum (ESl*): m/z = 461 [M+H]* (220) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C LNRPnflIflCRBR\I242(d9-IDO - 187 Mass spectrum (ESI*): m/z = 535 [M+H]* (221) 1-[2-(quinolin-8-yl-]-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.48 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESIl); m/z = 486 [M+H]* (222) 1-((3,4-dimethyl-6,7-dihydro-5H-[2]pyridin-1-yl)methyl]-3-methyl-7-(2-butyn 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.25 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 476 [M+H]* (223) 1-[(3,4-dimethyl-5,6,7,8-tetrahydro-isoquinolin-1-yl)methyl]-3-methyl-7-(2 butyn-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (aluminium oxide, methylene chloride/methanol = 20:1) Mass spectrum (ESl*): m/z = 490 [M+H]* (224) 1-[2-(1H-indol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (225) 1-[(1H-benzoimidazol-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESIl): m/z = 447 [M+H]* C\IIRP-bIIDCMB II*20- DOC - 188 (226) 1 -[(pyrazolo[ 1, 5-a]pyrid in-2-yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.47 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 447 [M+H]* (227) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 488 [M+H]* (228) 1-[(2-oxo-1,2-dihydro-quinolin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine Rf value: 0.23 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (229) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.37 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 501 [M+H]* (230) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C:\NRPotbI\DCC\RBR\242 t_ LDOC - 189 Rf value: 0.35 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 473 [M+H]* (231) 1-[(4-methyl-phthalazin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 473 [M+H]* (232) 1-[(4-bromo-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 566, 568 [M+H]* (233) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)- 1 -buten-1 -yl)-8-(3-am ino-piperid in 1-yl)-xanthine Rf value: 0.31 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 437 [M+H]* (234) 1-[(4-difluoromethoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 ((R)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.08 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:1) Mass spectrum (ESl*): m/z = 523 [M+H]* C:NRPorbIl\DCC\RBR\28426(N I DOC - 190 (235) 1-[2-(1H-indol-7-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 474 [M+H]* (236)1 -[(E)-3-(2-nitro-phenyl)-2-propen-1-yl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 478 [M+H]* (237) 1 -((E)-3-pentafluorophenyl-2-propen- 1 -yl)-3-methyl-7-(2-butyn- 1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 523 [M+H]* (238) 1-[(4-nitro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine Rf value: 0.38 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 502 [M+H]* (239) 1-{[1-(2-cyano-ethyl)-1H-benzoimidazol-2-yl]methyl}-3-methyl-7-(2-butyn-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine-hydrochloride (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESl*): m/z = 500 [M+H]* (240) 1-({1-[(methylaminocarbonyl)methyl]-1H-benzoimidazol-2-yl}methyl)-3 methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESl*): m/z = 518 [M+H]* C:\NRPonbflDCC\RBR\2542609 1. DC - 191 (241).1 -[(1 -benzyl-1 H-benzoimidazol-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3 amino-piperidin-1 -yl)-xanthine Rf value: 0.47 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 537 [M+H]* (242) 1 -[(benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1 -yI)-8-(3-amino-piperid in 1-yl)-xanthine x trifluoroacetic acid Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 448 [M+H]* (243) 1-{(5-nitro-benzooxazol-2-y)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine Rf value: 0.49 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI): m/z = 493 [M+H]* (244) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-8 ((R)-3-amino-piperidin-1 -yl)-xanthine Rf value: 0.21 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 488 [M+H]* (245) 1-[(quinolin-7-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl) xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 458 [M+H]* C\NRPonb\DCC\RBR\2426 DOC - 192 (246) 1-(([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 459 [M+H]* (247) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 473 [M+H]* (248) 1-[(2,3,8-trimethyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.46 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 501 [M+H]* (249) 1-[([1,6]naphthyridin-5-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 459 [M+H]* (250) 1-[([1,8]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) - 193 Rf value: 0.45 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 459 [M+H]* (251) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 475 [M+H]* (252) 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESl*): m/z = 459 [M+H]* (253) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7 (2-butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 187-189*C Mass spectrum (ESI): m/z = 506 [M+H]* (254) 1-[(8-phenyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 535 [M+H]* (255) 1-[([1,5]naphthyridine-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine C.NRP~nb\DCGRB RVZ4W) A-1 DXC - 194 (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.52 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 459 [M+H]* (256) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 523 [M+H]* (257) 1-[(E)-3-(2-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 501 [M+H]* (258) 1-[(E)-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Mass, spectrum (ESl*): m/z = 501 [M+H]* (259) 1-[(E)-3-(4-trifluoromethyl-phenyl)-allyl]-3-methyl-7-(2-butyn-l-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESI*): m/z = 501 [M+H]* (260) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Mass spectrum (ESl*): m/z = 526 [M+H]* (261) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-isopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (262) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-(4-fluorophenyl)-7-(2-butyn-1-yl)-8 ((R)-3-amino-piperidin-1-yl)-xanthine C:\NRPonbICCRBRI294261W IDOC - 195 (263) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.51 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 535 [M+H]* (264) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 508 [M+H]* (265) 1-[(4-chloro-3-methoxy-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8 (3-amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Mass spectrum (ESI): m/z = 522, 524 [M+H]* Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) (266) 1-[(4-ethoxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 1 M ethereal hydrochloric acid) Rf value: 0.60 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 503 [M+H]* (267) 1-[(4-isopropyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 517 [M+H]* C :NRPonbIDCC\RUBR\2e4_ DOC -196 (268) 1 -[(2-methyl-benzothiazol-6-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-amino piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 167*C Mass spectrum (ESl*): m/z = 478 [M+H]* (269) 1-[(3-phenyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI*): m/z = 534 [M+H]* (270) 1-[(4-phenyloxy-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.60 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 551 [M+H]* (271) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 561 [M+H]* (272) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-(3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) C:.NRPonbIDCC\RBR\28426O9I .DC - 197 Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 498 [M+H]* (273) 1-[(2-phenyl-quinazolin-4-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 535 [M+H]* (274) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 465 [M+H]* (275) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.27 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 465 [M+H]* (276) 1-[2-(3-trifluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8 ((R)-3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 519 [M+H]* C\NRPortbl\DCCRBR\2842 9 LDOC - 198 (277) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 511 [M+H]* (278) 1-[2-(biphenyl-3-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.35 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 511 [M+H]* (279) 1-[2-(3-isopropyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 493 [M+H]* (280) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.50 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 498 [M+H]* (281) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1-yl)-xanthine C~xRPnbKCOBRU2(WI DC - 199 (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.45 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 561 [M+H]* (282) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1-yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Melting point: 191*C Mass spectrum (ESl*): m/z = 508 [M+H]* (283) 1-[2-(2-phenyloxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.40 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESl*): m/z = 527 [M+H]* (284) 1-[2-(3-ethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.29 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 479 [M+H]* (285) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.28 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 465 [M+H]* C'NRPonbI\DCCRBRX2426) I DOC - 200 (286) 1-[2-(2-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI*): m/z = 465 [M+H]* (287) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3 amino-piperidin-1-yl)-xanthine Mass spectrum (ESI*): m/z = 544, 546 [M+H]* (288) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine Mass spectrum (ESl*): m/z = 588, 590 [M+Hj (289) 1 -[(1,2,3,4-tetrahyd ro-phenanthridin-6-yl)methyll-3-methyl-7-(2-butyn- 1-yl)-8 (3-amino-piperidin-1-yl)-xanthine x trifluoroacetic acid Rf value: 0.75 (aluminium oxide, methylene chloride/methanol = 10:1) Mass spectrum (ESl*): m/z = 512 [M+H]* (290) 1-[2-(3-difluoromethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8 ((R)-3-amino-piperidin-1 -yl)-xanthine (Carried out with 5-6 M isopropanolic hydrochloric acid in methylene chloride) Rf value: 0.28 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESl*): m/z = 501 [M+H]* (291) 1-[(3-methyl-isoquinolin-1-yl)methyll-3-methyl-7-(2-ethynyl-benzyl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine C.\NRFonbIOCRBRU2&42W)_I DOC - 201 (292) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-phenyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1-yl)-xanthine (293) 1 -[(phenanthren-9-yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-((R)-3-amino piperidin-1-yl)-xanthine (294) 1-((4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3 amino-piperidin-1-yl)-xanthine Rf value: 0.35 (silica gel, methylene chloride/methanol/triethylamine = 90:10:1) Mass spectrum (ESl*): m/z = 545, 547 [M+H]* (295) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3 amino-piperidin-1-yl)-xanthine Rf value: 0.40 (silica gel, methylene chloride/methanol/triethylamine = 90:10:1) Mass spectrum (ESl*): m/z = 607, 609 [M+H]* Example 3 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -y)-8 (3-amino-piperidin-1 -vl)-xanthine Prepared by saponifying 70 mg of 1-(2-{3-[(methoxycarbonyl)methoxy]-phenyl}-2 oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine with 0.10 ml of 4 M potassium hydroxide solution in a mixture of 1 ml of tetrahydrofuran and 0.5 ml of methanol at ambient temperature. Yield: 57 mg (84 % of theory) Rf value: 0.55 (ready-made reversed phase TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:0.1) Mass spectrum (ESI*): m/z = 525 [M+H]* The following compounds are obtained analogously to Example 3: C:\NRPorbIlDCCRBR\lS42(6t LDOC - 202 (1) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 yl)-8-(3-amino-piperidin-1 -yl)-xanthine (Carried out with sodium hydroxide solution) Mass spectrum (ES[~): m/z = 523 [M-H] Example 4 Coated tablets containing 75 mq of active substance 1 tablet core contains: active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg Preparation: The active substance is mixed with calcium phosphate, corn starch, polyvin ylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape. Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hyd roxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax. Weight of coated tablet: 245 mg.
C VNRPorbI\DCORBR\2426t49N .DOC - 203 Example 5 Tablets containing 100 mq of active substance Composition: 1 tablet contains: active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg Method of Preparation: The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50*C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets. Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side. Example 6 Tablets containing 150 mq of active substance Composition: 1 tablet contains: active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg C:\NRPonb\DCORBR\284269( .DOC - 204 magnesium stearate 1.0 mg 300.0 mg Preparation: The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45 0 C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture. Weight of tablet: 300 mg die: 10 mm, flat Example 7 Hard qelatine capsules containing 150 mq of active substance 1 capsule contains: active substance 150.0 mg corn starch (dried approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 mq approx. 420.0 mg Preparation: The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules. Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule. Example 8 Suppositories containing 150 mq of active substance C kNRPonbI\CC\RBR\242(AW L.DOC - 205 1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mq 2,000.0 mg Preparation: After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds. Example 9 Suspension containing 50 mg of active substance 100 ml of suspension contain: active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml Preparation: The distilled water is heated to 70 0 C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the CANRPonbl\DCOMRBR\2(269 I DOC - 206 sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air. 5 ml of suspension contain 50 mg of active substance. Example 10 Ampoules containing 10 mq active substance Composition: active substance 10.0 mg 0.01 N hydrochloric acid q.s. double-distilled water ad 2.0 ml Preparation: The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules. Example 11 Ampoules containing 50 mq of active substance Composition: active substance 50.0 mg 0.01 N hydrochloric acid q.s. double-distilled water ad 10.0 ml Preparation: The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication C:\NRPonbI\DCORBR\242(? I DOC - 207 (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
Claims (18)
1. Compounds of general formula 0 NH 2 RN N N~ 0Oi N 1/N R 2 wherein R 1 denotes a methyl group which is substituted by a dimethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, tert.-butylcarbonyl or a cyclohexylcarbonyl group, a methyl group which is substituted by a naphthyl, methylnaphthyl, methoxynaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, a methyl group which is substituted by a 2-phenylethenyl or a biphenylyl group, a methyl group which is substituted by a phenyl-oxadiazolyl, 5-methyl-3-phenyl isoxazolyl, phenyl-pyridinyl, indolyl, benzothiophenyl, quinolinyl, isoquinolinyl, methylisoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2 dihydro-2-methyl-1-oxo-isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro
3-methyl-4-oxo-phthalazinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl
4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a 2-methoxyethyl, 2-phenyloxyethyl or 2-cyanoethyl group, a phenylcarbonylmethyl or a 1-(phenylcarbonyl)-ethyl group, CA-NRPornbIIDCMRR\2&Y:6oI DC - 209 a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino) carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylaminocarbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1 -ylcarbonylmethoxy or morpholin-4 ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 (methoxycarbonyl)-ethyloxy or a 1-(aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups or -210 a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CH 2 -CH 2 -0 or a -N(CH 3 )-CO-O group, R 2 denotes a methyl, isopropyl or phenyl group and R 3 denotes a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen 1-yl group a 2-buten-1-yi or 2,3-dimethyl-2-buten-1-y group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group, as well as the compounds 1-(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, CMv4RPorb\DCC\RBR\242609_ 1.DOC -211 1 -(1 -methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl) xanthine, 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl) xanthine, 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin- 1-yl) xanthine, 1 -methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-am ino-piperid in-1 yl)-xanthine, 1 -methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-methyl-3-(2- propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, 1 -{2-[3-(2-oxo-imidazolidin-1 -yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yi)-8-(3-amino-piperidin-1 -yl)-xanthine, C:\NRPonbDCCRBR\264260 L DOC -212 1 -methyl-3-(2-propen-1 -yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1 -methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl)-xanthine, 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-((S)-3 amino-piperidin-1 -yl)-xanthine, 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 yl)-xanthine, 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 yl)-xanthine, 1 -[(1 -methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[(4-oxo-3,4-dihydro-phthalazin-1 -yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1 -yl)-xanthine, 1 -((quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, C.N"nbJCC\RBRUQ-42(r)I, DOC -213 1 -[(5-m ethyl -3-p he nyl-i soxazol1-4-yI) meth yll-3-methyl-7-(3-methyl-2 -b ute n- 1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, 1 -[(isoquinolin-3-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -[(3-phenyl-[1 ,2,4]oxadiazol-5-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3 amino-piperidin-1 -yI)-xanthine, 1 -[(4-phenyl-pyridin-2-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -[(5-phenyl-pyrid in-2-yI)methyl]-3-methyl-7-(3-methyl-2-buten- 1 -yI)-8-(3-amino piperidin-1 -yI)-xanthine, 1 -[(3-methyl-4-oxo-3,4-d ihyd ro-phthalazin- 1 -yI)methyl]-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(3-meth yls u Ip hanyl-p hen yl)-2-oxo-ethyl]- 3-methyl-7-(3-methyl-2-b ute n- 1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(3-meth anes ulIphi nyl-p hen yl)-2-oxo-ethyl]-3- meth yl-7-(3-methyl-2 -buten- 1 -yI)
8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(3-m eth anes uIph onyl-p hen yl)-2-oxo-ethyl]-3-methyl-7-(3-m ethyl-2-b ute n- 1l-yI) 8-(3-amino-piperidin-1 -yI)-xanthine, 1 -[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8-(3 amino-piperidin-1 -yI)-xanthine, -214 1 .[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI) 8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[3-(methylaminocarbonyI)-pheny]-2-oxo-ethyl}-3-methyI-7-(3-methyI-2-buten 1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten- 1 -yI)-8-(3-am ino-piperidin- 1 -yI)-xanthine, 1 -{2-[3-(morpholin-4-yI-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten- 1 -yI)-8-(3-am ino-piperidin- 1 -yI)-xanthine, 1 -[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- l-yI)-8-(3 amino-piperidin-1 -yI)-xanthine, 1 -[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yI)-8 (3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[2-(d imethylam inocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yI)-xanthine, 1 -{2-[2-(morpholin-4-yI-carbonyl)-phenylj-2-oxo-ethyl}-3-methyl-7-(3-methyl-2 buten-1 -yI)-8-(3-amino-piperidin-1 -yi)-xanthine, 1 -[2-(2 ,6-d imethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- I -yI)- 8 -(3 amino-piperidin-l -yI)-xanthine, 1 -((E)-3-ph enyl-a I ly)-3-m ethyl -7-(3-m ethyl-2-b uten- 1 -yI)-8-(3-am ino-piperid in-1 -yI) xanthine, C 1NRPonbl\CCRBR\254269_I DOC -215 1 -[(benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -[(1 H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin 1-yl)-xanthine, 1 -[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin 1-yl)-xanthine, 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1 -({5-[(methoxycarbonyl)methylamino]-isoquinolin-1 -yl}methyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-d imethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten- 1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(piperidin-1 -yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[(2-methyl-1 -oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-buten-1 -yl) 8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3 amino-piperidin-1 -yl)-xanthine, C:XNRPobIUCIRBRLP82(4I9- DC -216 1-[2-(pyrrolidin-1 -yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten 1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-y)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-(3 amino-piperidin-1 -yl)-xanthine, 1 -methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperid in-1 -yl)-xanthine, 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- 1 yl)-8-(3-amino-piperidin-1 -yi)-xanthine, 1 -[(isoquinolin-1 -yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-buten-1 -yl) 8-(3-amino-piperidin-1 -yi)-xanthine, 1 -(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]aminol-phenyl)-2-oxo-ethyl]-3-methyl-7 (3-methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8-((S) 3-amino-piperidin-1 -yl)-xanthine, 1 -(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-((S)-3-amino-piperidin-1 -yl)-xanthine, CkNPobKDCM B R426N- .DC -217 1 -methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methy-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3 methyl-2-buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl) 8-(3-amino-piperidin-1 -yl)-xanthine, 1-[2-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2 buten-1 -yl)-8-(3-amino-piperidin-1 -yl)-xanthine, 1-[(3-methyl-isoquinolin-1 -yl)methyl]-3-methyl-7-(3-methyl-1 -buten-1 -yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, 1-[(3-methyl-isoquinolin-1 -yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-amino piperidin-1 -yl)-xanthine, 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1-yl)-xanthine and C:\NRPobI\DCC\RBR\2842(A) LDOC -218 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1 -yl)-8 (3-amino-piperidin-1 -yl)-xanthine, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof. 2. Compounds of general formula I according to claim 1, wherein R 1 denotes a 4-methoxy-1-naphthylmethyl group, a 2-quinolinylmethyl, 4-quinolinylmethyl or a 6-quinolinylmethyl group, a 1-isoquinolinylmethyl, 3-methyl-1-isoquinolinylmethyl, 4-methyl-1-isoquinolinyl methyl or a 3-isoquinolinylmethyl group or a 2-quinazolinylmethyl, 4-methyl-2-quinazolinylmethyl or a 4-quinazolinylmethyl group, R 2 denotes a methyl group and R 3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. 3. Compounds of general formula I according to claim 1, wherein R' denotes a [2-(methylcarbonylamino)-phenyl]-carbonylmethyl group, a [2-(ethylcarbonylamino)-phenyl]-carbonylmethy group or C .NRPorbI\DCC\RBR\2L426)I DOC -219 a [2-(isopropylcarbonylamino)-phenyl]-carbonylmethyl group, R 2 denotes a methyl group and R 3 denotes a 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. 4. Compounds of general formula I according to claim 1, wherein R 1 denotes a [2-(aminocarbonylmethoxy)-phenyl]-carbonylmethyl group, [2-(methylaminocarbonylmethoxy)-phenyl]-carbonylmethy group, a [2-(ethylaminocarbonylmethoxy)-phenyl]-carbonylmethy group or a [2-(isopropylaminocarbonylmethoxy)-phenyl]-carbonylmethyl group, R 2 denotes a methyl group and R 3 denotes a 2-buten-1-yl group, a 2-butyn-1-yl group or a 1 -cyclopenten-1 -ylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. 5. Compounds of general formula I wherein C NJRPoIbW~CCtRBRU2(2WV! DXC -220 R 1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl, nitronaphthyl or (dimethylamino)-naphthyl group, a methyl group which is substituted by a phenanthrenyl group, a methyl group which is substituted by a 2-phenylethenyl, 2-[(trifluoromethyl) phenyl]-ethenyl, 2-(nitrophenyl)ethenyl, 2-(pentafluorophenyl)ethenyl or a biphenylyl group, a methyl group which is substituted by a phenyloxadiazolyl, phenylpyridinyl, indolyl, methylindolyl, dimethyl-6,7-dihydro-5H-[2]pyrindinyl, benzimidazolyl, methylbenzimidazolyl, (cyanoethyl)-benzimidazolyl, (methylaminocarbonylmethyl) benzimidazolyl, benzylbenzimidazolyl, benzofuranyl, acetylbenzofuranyl, cyanobenzofuranyl, benzoxazolyl, nitrobenzoxazolyl, benzothiophenyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methyl isoquinolinyl, (difluoromethyl)-isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethyl isoquinolinyl, (1-cyano-1-methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxy isoquinolinyl, methoxy-chloro-isoquinolinyl, methoxy-bromo-isoquinolinyl, (methoxycarbonylmethylamino)-isoquinolinyl, dimethyl-5,6,7,8 tetrahydroisoquinolinyl, 1,2,3,4-tetrahydrophenanthridinyl, cinnolinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino)-quinazolinyl, pyrrolidin-1 ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1-ylquinazolinyl, morpholin-4 ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, phenyloxyquinazolinyl, imidazo[1,2-a]pyridinyl, methylimidazo[1,2-a]pyridinyl, phenylimidazo[1,2 a]pyridinyl, benzylimidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, methylphthalazinyl, naphthyridinyl, 2,3-dihydro-benzo[1,4]dioxinyl, 1,2-dihydro-2 oxo-quinolinyl, 1,2-dihydro-1-methyl-2-oxo-quinolinyl, 1,2-dihydro-2-methyl-1-oxo- C .%RPonNhflCC)RHRUCS42(NN IDOC -221 isoquinolinyl, 3,4-dihydro-4-oxo-phthalazinyl, 3,4-dihydro-3-methyl-4-oxo-phthal azinyl, 3,4-dihydro-4-oxo-quinazolinyl, 3,4-dihydro-3-methyl-4-oxo-quinazolinyl or a 2-oxo-2H-chromenyl group, a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by an amino, cyanomethylamino, (ethyloxycarbonylmethyl)amino, (methylaminocarbonyl)methylamino, methylcarbonylamino, ethylcarbonylamino, isopropylcarbonylamino, phenylcarbonylamino, methoxycarbonylamino, (ethyloxycarbonylamino)-carbonylamino or a 2-oxo-imidazolidin-1-yl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a carboxy, methoxycarbonyl, ethyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl or morpholin-4-ylcarbonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphanyl, methylsulphinyl or methylsulphonyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methylsulphinylmethoxy, carboxymethoxy, ethyloxycarbonylmethoxy, isopropyloxycarbonylmethoxy, aminocarbonylmethoxy, methylaminocarbonylmethoxy, ethylaminocarbonylmethoxy, isopropylamino- C \NRPorbIlDCC\RBR\2S4269 1.DOC - 222 carbonylmethoxy, dimethylaminocarbonylmethoxy, pyrrolidin-1-ylcarbonylmethoxy or morpholin-4-ylcarbonylmethoxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a 1 (ethyloxycarbonyl)-1 -methyl-ethyloxy, 1 -(methoxycarbonyl)-ethyloxy or a 1 (aminocarbonyl)-ethyloxy group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by two methoxy groups, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and a nitro group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy group and an amino group, a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CF 2 -0, -O-CH 2 -CH 2 -0, -NH-CO NH, -N(CH 3 )-CO-NH, -N(CH 3 )-CO-N(CH 3 ), -NH-CO-0- or a -N(CH 3 )-CO-O group, a (2-phenylethyl)carbonylmethyl group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group, R 2 denotes a methyl, isopropyl, cyclopropyl, phenyl or fluorophenyl group and C:\NRPonbI\DCC\RBR\2g4264)9 .DOC -223 R 3 denotes a 2-methyl-2-propen-1-yl, 2-chloro-2-propen-1-yl or 3-bromo-2-propen 1-yi group a 1-buten-1-yl, 3-methyl-1-buten-1-yl, 2-buten-1-yl, 2-methyl-2-buten-1-yl or 2,3-dimethyl-2-buten-1-yl group, a 2-butyn-1-yl group, a 1-cyclopenten-1-ylmethyl group or a 2-furanylmethyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof. 6. Compounds of general formula I according to claim 5, wherein R 1 and R 2 are defined as in claim 5 and R 3 denotes a 1-buten-1-yl, 2-buten-1-yl or 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. 7. Compounds of general formula I according to claim 6, wherein R 1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, CINRP-nbI'CC\RBRI1fl2(AP0' DOC - 224 a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)- isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1 methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxyisoquinolinyl, 1,2,3,4 tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino) quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1 ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, [1,5]naphthyridinyl, [1,6]naphthyridinyl, [1,8]naphthyridinyl or a 1,2-dihydro-1 -methyl-2-oxo-quinolinyl group, a phenylcarbonylmethyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a phenyl group, a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by a methoxy, difluoromethoxy, trifluoromethoxy, ethyloxy, isopropyloxy or phenyloxy group, a phenylcarbonylmethyl group wherein in the phenyl moiety two adjacent hydrogen atoms are replaced by a -O-CH 2 -0, -O-CF 2 -0, -O-CH 2 -CH 2 -0, N(CH 3 )-CO-N(CH 3 ) or a -N(CH 3 )-CO-0 group, a naphthylcarbonylmethyl, indolylcarbonylmethyl or quinolinylcarbonylmethyl group or a 2-cyanimino-2-phenyl-ethyl group, C.\NRPonb\DCC\RBR\2&4260N .DOC -225 R 2 denotes a methyl, isopropyl, cyclopropyl, phenyl or 4-fluorophenyl group and R 3 denotes a 1-buten-1-yl, 2-buten-1-yl or a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. 8. Compounds of general formula I according to claim 5, wherein R 1 and R 2 are defined as in claim 7 and R 3 denotes a 1-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
9. Compounds of general formula I according to claim 5, wherein R' and R 2 are defined as in claim 7 and R 3 denotes a 2-buten-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
10. Compounds of general formula I according to claim 5, wherein R 1 and R 2 are defined as in claim 7 and R 3 denotes a 2-butyn-1-yl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
11. Compounds of general formula I wherein R 1 denotes a methyl group which is substituted by a naphthyl, fluoronaphthyl, methylnaphthyl, methoxynaphthyl, (difluoromethoxy)-naphthyl, cyanonaphthyl or nitronaphthyl- group, a methyl group which is substituted by a 2-(pentafluorophenyl)ethenyl group, or C:NRPonbl\DCC\RDR\2U269_I DOC - 226 a methyl group which is substituted by a benzofuranyl, methylbenzothiazolyl, quinolinyl, methoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, (difluoromethyl)- isoquinolinyl, (trifluoromethyl)-isoquinolinyl, dimethylisoquinolinyl, (1-cyano-1 methyl-ethyl)isoquinolinyl, phenylisoquinolinyl, methoxyisoquinolinyl, 1,2,3,4 tetrahydrophenanthridinyl, quinazolinyl, methylquinazolinyl, isopropylquinazolinyl, cyclopropylquinazolinyl, phenylquinazolinyl, aminoquinazolinyl, (dimethylamino) quinazolinyl, pyrrolidin-1-ylquinazolinyl, piperidin-1-ylquinazolinyl, piperazin-1 ylquinazolinyl, morpholin-4-ylquinazolinyl, ethoxyquinazolinyl, isopropyloxyquinazolinyl, quinoxalinyl, methylquinoxalinyl, dimethylquinoxalinyl, trimethylquinoxalinyl, phenylquinoxalinyl, [1,5]naphthyridinyl, [1,6]naphthyridinyl, [1,8]naphthyridinyl or a 1,2-dihydro-1-methyl-2-oxo-quinolinyl group, R 2 denotes a methyl, isopropyl, cyclopropyl or phenyl group and R 3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
12. Compounds of general formula I according to claim 11, wherein R' denotes a (3-methyl-isoquinolin-1-yl)methyl group, R 2 denotes a methyl group and R 3 denotes a 2-chlorobenzyl, 2-bromobenzyl, 2-ethynylbenzyl or 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof. C:\NRPonb\DCC\RBR\2426NI.DOC -227
13. Compounds of general formula I according to claim 11, wherein R 1 and R 2 are defined as in claim 11 and R 3 denotes a 2-chlorobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
14. Compounds of general formula I according to claim 11, wherein R 1 and R 2 are defined as in claim 11 and R 3 denotes a 2-bromobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
15. Compounds of general formula I according to claim 11, wherein R 1 and R 2 are defined as in claim 11 and R 3 denotes a 2-ethynylbenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
16. Compounds of general formula I according to claim 11, wherein R 1 and R 2 are defined as in claim 11 and R 3 denotes a 2-cyanobenzyl group, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
17. The following compounds of general formula I according to claims 1, 5 and 11: (1) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1 yl)-xanthine, (2) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn- 1 -yl)-8-((R)-3-amino-piperid in-1 -yl)-xanthine, (3) 1-(2-{2-[(methylaminocarbonyl)methoxyl-phenyl}-2-oxo-ethyl)-3-methyl-7-(2 butyn-1 -yl)-8-((R)-3-amino-piperidin-1 -yl)-xanthine, C VNRPb'lCBRQH42wN-' I DOC -228 (4) 1 -(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1 -yl)-8-((R)-3-amino-piperidin 1-yl)-xanthine, (5) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-((S)-3-amino piperidin-1 -yi)-xanthine, (6) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yi)-xanthine, (7) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-amino piperidin-1 -yl)-xanthine, (8) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-((R)-3-amino piperidin-1 -yl)-xanthine, (9) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl) 8-(3-(R)-amino-piperidin-1 -yl)-xanthine, (10) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yI)-8-((S)-3 amino-piperidin-1 -yl)-xanthine, (11) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (12) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino piperidin-1 -yl)-xanthine, CN:RPonbIOCC'.BRQ26IW-, .DOC - 229 (14) 1 -(2-{2-[(isopropylcarbonyl)amino]-phenyll-2-oxo-ethyl)-3-methyl-7-((E)-2 buten- 1 -yI)-8-((S)-3-a mino-piperid in- 1 -yI)-xa nth ine, (15) 1 -(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E) 2-buten- 1 -yI)-8-((R)-3-amino-piperidin- 1 -yI)-xanthine, (16) 1 -(2-{2-[(m ethyl am in ocarbonyI) methoxy]-p he nyl}-2-oxo-ethyI)-3-m ethy-7-((E) 2-buten- 1-yI)-8-((S)-3-amino-piperid in-i -yI)-xanthine, (17) 1 -(2-{2-[(isopropylcarbonyl)amino]-phenyl)-2-oxo-ethyl)-3-methyl-7-(2-butyn 1 -yI)-8-((R)-3-amino-piperidin-1 -yI)-xanthine, (18) 1 -(2-{2-[(isopropylcarbonyl)am ino]-phenyl)-2-oxo-ethyl)-3-methyl-7-((E)-2 buten- 1 -yI)-8-((R)-3-amino-piperidin- 1 -yI)-xanthine, (19) 1 -[(4-cyano-naphthalen-1 -yI)methyl]-3-methyl-7-(2-butyn-1 -yI)-8-((R)-3-amino piperidin-1 -yI)-xanthine, (20) 1 -[(4-phenyl-quinazolin-2-yI)methyl]-3-methyl-7-(2-butyn-1 -yI)-8-((R)-3-amino piperidin-1 -yI)-xanthine, (21) 1 -[(8-methyl-quinoxalin-6-yI)methyl]-3-methyl-7-(2-butyn-1 -yI)-8-((R)-3-amino piperidin-1 -yI)-xanthine, (22) 1 -[(4-fluoro-naphthalen- 1-yI)methyl]-3-methyl-7-(2-butyn-1 -yI)-8-((R)-3-amino piperidin-1-yI)-xanthine , (23) 1 -((E)-3-pentafluorophenyl-allyI)-3-methyl-7-(2-butyn- 1-yI)-8-((R)-3-amino piperidin-1-yI)-xanthine , C:\NRPorbIlDCCRBR W2942Ar .DOC -230 (24) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1 -yl)-xanthine, (25) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R) 3-amino-piperidin-1 -yl)-xanthine, (26) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino piperidin-1 -yl)-xanthine, (27) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (28) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine, (29) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)-3 amino-piperidin-1-yl)-xanthine and (30) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-3 amino-piperidin-1 -yl)-xanthine as well as the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.
18. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 17 with inorganic or organic acids or bases.
19. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 17 or a physiologically acceptable salt according to claim 18 optionally together with one or more inert carriers and/or diluents. C:\RPorbl\DCORBR2842609 1.DOC -231
20. Use of a compound according to at least one of claims 1 to 18 for preparing a pharmaceutical composition which is suitable for treating type I and type 11 diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis.
21. Process for preparing a pharmaceutical composition according to claim 19, characterised in that a compound according to at least one of claims 1 to 18 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
22. Process for preparing the compounds of general formula I according to claims 1 to 18, characterised in that a) a compound of general formula 0 R3 R NN N Zi (II), O N R 2 wherein R 1 to R 3 are defined as in claims 1 to 16 and Z' denotes a leaving group such as a halogen atom, a substituted hydroxy, mercapto, sulphinyl, sulphonyl or sulphonyloxy group, is reacted with 3-aminopiperidine, the enantiomers or the salts thereof, or C \NRPorb1\DCORBR\2X426)'1 DOC -232 b) a compound of general formula o R 3 \ NO O?/ N (iii), 0 N N R2 wherein R', R 2 and R 3 are defined as in claims 1 to 16, is deprotected, or c) to prepare a compound of general formula I wherein R 1 according to the definition mentioned in claim 1 contains a carboxy group: a compound of general formula o R 3 NH2 Ri N O~N I >NQ$(IV), 0 N wherein R 2 and R 3 are defined as in claims 1 to 16 and R contains a carboxy group protected by a C 1 4-alkyl group, is deprotected and/or subsequently, if desired, any protecting groups used during the reaction are cleaved and/or CANRPonbj\DCCRBR\2842W.I .DOC -233 the compounds of general formula I thus obtained are resolved into their enantiomers or diastereomers and/or the compounds of formula I thus obtained are converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof with inorganic or organic acids or bases.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010201384A AU2010201384C1 (en) | 2002-08-21 | 2010-04-07 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| AU2013202252A AU2013202252B2 (en) | 2002-08-21 | 2013-04-02 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10238243A DE10238243A1 (en) | 2002-08-21 | 2002-08-21 | New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity |
| DE10238243.3 | 2002-08-21 | ||
| DE10312353A DE10312353A1 (en) | 2003-03-20 | 2003-03-20 | New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity |
| DE10312353.9 | 2003-03-20 | ||
| PCT/EP2003/009127 WO2004018468A2 (en) | 2002-08-21 | 2003-08-18 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| AU2003253418A AU2003253418B2 (en) | 2002-08-21 | 2003-08-18 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| AU2010201384A AU2010201384C1 (en) | 2002-08-21 | 2010-04-07 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003253418A Division AU2003253418B2 (en) | 2002-08-21 | 2003-08-18 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013202252A Division AU2013202252B2 (en) | 2002-08-21 | 2013-04-02 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010201384A1 true AU2010201384A1 (en) | 2010-04-29 |
| AU2010201384B2 AU2010201384B2 (en) | 2013-05-02 |
| AU2010201384C1 AU2010201384C1 (en) | 2013-09-26 |
Family
ID=31947613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003253418A Active 2026-11-01 AU2003253418B2 (en) | 2002-08-21 | 2003-08-18 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| AU2010201384A Active 2028-05-21 AU2010201384C1 (en) | 2002-08-21 | 2010-04-07 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003253418A Active 2026-11-01 AU2003253418B2 (en) | 2002-08-21 | 2003-08-18 | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Country Status (38)
| Country | Link |
|---|---|
| EP (6) | EP3424926A1 (en) |
| JP (6) | JP4233524B2 (en) |
| KR (2) | KR101150449B1 (en) |
| CN (4) | CN102964347B (en) |
| AR (3) | AR041025A1 (en) |
| AT (1) | ATE453644T1 (en) |
| AU (2) | AU2003253418B2 (en) |
| BE (1) | BE2011C038I2 (en) |
| BR (2) | BR122012026540B8 (en) |
| CA (1) | CA2496249C (en) |
| CY (3) | CY1109928T1 (en) |
| DE (2) | DE50312295D1 (en) |
| DK (1) | DK1532149T3 (en) |
| EA (3) | EA010303B1 (en) |
| EC (2) | ECSP055617A (en) |
| EG (1) | EG25011A (en) |
| ES (1) | ES2339112T3 (en) |
| FR (1) | FR11C0052I2 (en) |
| HK (6) | HK1081552A1 (en) |
| HR (2) | HRP20050157B1 (en) |
| HU (1) | HUS1100028I1 (en) |
| IL (1) | IL166964A (en) |
| IN (2) | IN2015DN01133A (en) |
| LU (2) | LU91889I2 (en) |
| ME (1) | ME00396B (en) |
| MX (1) | MXPA05001684A (en) |
| MY (2) | MY137619A (en) |
| NO (4) | NO333970B1 (en) |
| PE (1) | PE20040897A1 (en) |
| PL (2) | PL216134B1 (en) |
| PT (1) | PT1532149E (en) |
| RS (2) | RS20120139A3 (en) |
| SA (1) | SA03240448B1 (en) |
| SI (1) | SI1532149T1 (en) |
| TW (3) | TWI469783B (en) |
| UA (1) | UA84275C2 (en) |
| UY (1) | UY27946A1 (en) |
| WO (1) | WO2004018468A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007247193B2 (en) * | 2006-05-04 | 2013-05-16 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
Families Citing this family (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2483923A1 (en) * | 2002-05-31 | 2003-12-11 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| KR101150449B1 (en) * | 2002-08-21 | 2012-06-01 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 8-3---1-- 8-[3-Amino-piperidin-1-yl]-xanthines the production thereof and the pharmaceutical composition containing the same |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10251927A1 (en) * | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity |
| DE10254304A1 (en) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New xanthine derivatives, their production and their use as medicines |
| DE602004026289D1 (en) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminyl INHIBITORS |
| US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10355304A1 (en) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals |
| ATE544765T1 (en) | 2003-12-22 | 2012-02-15 | Leuven K U Res & Dev | IMIDAZOÄ4,5-CUPYRIDINE COMPOUNDS AND METHOD FOR ANTIVIRAL TREATMENT |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| PT1758905E (en) * | 2004-02-18 | 2009-07-16 | Boehringer Ingelheim Int | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a ddp-iv inhibitor |
| AU2012202850B2 (en) * | 2004-02-18 | 2015-08-20 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor |
| DE102004009039A1 (en) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals |
| US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
| NZ549716A (en) | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
| US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
| DE102004030502A1 (en) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazoles and triazoles, their preparation and use as medicines |
| KR101238430B1 (en) | 2004-07-27 | 2013-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
| DE102004043944A1 (en) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals |
| DE102004044221A1 (en) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals |
| DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
| AU2012205240B2 (en) * | 2004-11-05 | 2015-03-26 | Boehringer Ingelheim International Gmbh | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
| CA2592388C (en) | 2004-12-21 | 2013-04-02 | Steven S. Bondy | Imidazo[4,5-c]pyridine compound and method of antiviral treatment |
| DOP2006000008A (en) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE102005035891A1 (en) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
| PE20070458A1 (en) † | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION INCLUDING 2 - [[6- (3R) -3-AMINO-1-PIPERIDINYL] -3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1 (2H) -PYRIMIDINYL] METHYL] -BENZONITRILE AS A DIPEPTIDYL PEPTIDASE INHIBITOR |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| CN101360723A (en) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | Process for the preparation of pyrimidinedione derivatives |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| CA2632021A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Gaba-b receptor modulators |
| TW200803855A (en) * | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
| PE20080251A1 (en) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| EA030606B1 (en) * | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Methods of preparing a medicament comprising polymorphs |
| ES2339298T3 (en) | 2006-07-07 | 2010-05-18 | Gilead Sciences, Inc. | PIRIDAZINE NOVEDOUS COMPOUND AND USE OF IT. |
| EP2057160A1 (en) * | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5667440B2 (en) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | Thiourea derivatives as glutaminyl cyclase inhibitors |
| UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
| UY31291A1 (en) * | 2007-08-16 | 2009-03-31 | PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO | |
| CL2008002427A1 (en) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
| KR101610005B1 (en) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Purin derivatives for use in the treatment of FAB-related diseases |
| PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| PE20100156A1 (en) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
| BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
| UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
| EA031225B1 (en) * | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Dpp-4 inhibitors for wound healing |
| EP2344195A2 (en) * | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
| UY32177A (en) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| BRPI0923121A2 (en) * | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Saline forms of organic compounds |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| AR075204A1 (en) * | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2 |
| JP5685550B2 (en) * | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition comprising SGLT2 inhibitor, DPP-IV inhibitor, and optionally antidiabetic agent, and use thereof |
| UY32427A (en) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME |
| JP2012517977A (en) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs |
| AR077642A1 (en) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME |
| MX2012002993A (en) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase. |
| NZ598318A (en) | 2009-09-30 | 2014-02-28 | Boehringer Ingelheim Int | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| JP5758900B2 (en) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for the preparation of glucopyranosyl-substituted benzylbenzene derivatives |
| PT2482812T (en) | 2009-10-02 | 2023-01-24 | Boehringer Ingelheim Int | Therapeutic uses of pharmaceutical compositions |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| ES2760917T3 (en) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin |
| JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
| MX2012010470A (en) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5). |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| BR112012025592A2 (en) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | gpr119 receptor modulators and the treatment of disorders related thereto |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| NZ602809A (en) | 2010-05-05 | 2015-02-27 | Boehringer Ingelheim Int | Pharmaceutical formulations comprising pioglitazone and linagliptin |
| JP6034781B2 (en) * | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy |
| EA201991014A1 (en) * | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | DIABETES TREATMENT |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| KR102117282B1 (en) * | 2010-11-15 | 2020-06-01 | 베링거 인겔하임 인터내셔날 게엠베하 | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| UY33937A (en) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| CA2835332C (en) | 2011-05-10 | 2019-03-26 | Sandoz Ag | Polymorph of linagliptin benzoate |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| MX366629B (en) * | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions. |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20130123282A1 (en) | 2011-11-16 | 2013-05-16 | Leonid Metsger | Solid state forms of linagliptin |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| CN103254192B (en) * | 2012-02-15 | 2015-12-02 | 上海医药工业研究院 | Xanthine derivative, its salt, intermediate, preparation method and application |
| CN103254193B (en) * | 2012-02-15 | 2015-04-22 | 上海医药工业研究院 | Xanthine compound intermediate and preparation method thereof |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9879011B2 (en) | 2012-03-12 | 2018-01-30 | Cadila Healthcare Limited | Amorphous form of linagliptin and process for preparation thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN103373999B (en) * | 2012-04-28 | 2016-01-13 | 上海医药工业研究院 | purine compound, intermediate, preparation method and application thereof |
| JP6218811B2 (en) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis |
| EP3685839A1 (en) * | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| JP6374862B2 (en) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Xanthine derivatives as DPP-4 inhibitors for use in the treatment of autoimmune diabetes, particularly LADA |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2013174769A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
| CN103509022B (en) * | 2012-06-20 | 2015-04-01 | 成都苑东药业有限公司 | Xanthine derivative |
| CN103509023B (en) * | 2012-06-20 | 2014-08-27 | 成都苑东药业有限公司 | Xanthine derivative |
| EA027274B1 (en) | 2012-08-13 | 2017-07-31 | Сандоз Аг | Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
| WO2014045266A1 (en) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
| CN103709163B (en) * | 2012-09-29 | 2016-12-21 | 齐鲁制药有限公司 | Xanthine derivative, Preparation Method And The Use |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| CN103319483B (en) * | 2012-10-19 | 2016-08-03 | 药源药物化学（上海）有限公司 | A kind of preparation method of important intermediate of linagliptin |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP2935266A1 (en) * | 2012-12-17 | 2015-10-28 | Mylan Laboratories Ltd. | An improved process for the preparation of linagliptin |
| ES2688367T3 (en) | 2012-12-21 | 2018-11-02 | Sanofi | Derivatives of exendin-4 as dual agonists of GLP1 / GIP or trigonal of GLP1 / GIP / glucagon |
| CN103936739B (en) * | 2013-01-23 | 2016-08-31 | 成都苑东生物制药股份有限公司 | Xanthine derivative |
| CN103936738B (en) * | 2013-01-23 | 2016-11-23 | 成都苑东生物制药股份有限公司 | Xanthine derivative |
| CN103936740B (en) * | 2013-01-23 | 2016-06-29 | 成都苑东生物制药股份有限公司 | Xanthine derivative |
| CN103936737B (en) * | 2013-01-23 | 2016-09-14 | 成都苑东生物制药股份有限公司 | Xanthine derivative |
| CN110075098A (en) | 2013-03-15 | 2019-08-02 | 勃林格殷格翰国际有限公司 | Purposes of the Li Gelieting in heart and protection renal antidiabetic treatment |
| HUE041709T2 (en) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Therapeutic uses of empagliflozin |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN113181161A (en) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | Pharmaceutical compositions, methods of treatment and uses thereof |
| KR102238860B1 (en) * | 2013-06-14 | 2021-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Dpp-4 inhibitors for treating diabetes and its complications |
| CN104292228B (en) * | 2013-07-16 | 2016-03-30 | 成都苑东生物制药股份有限公司 | Polymorphic of a kind of Xanthine compounds and preparation method thereof, purposes |
| WO2015011609A1 (en) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
| CN104418857A (en) * | 2013-08-22 | 2015-03-18 | 北京蓝丹医药科技有限公司 | Amorphous linagliptin and preparation method thereof |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
| CN104725379A (en) * | 2013-12-24 | 2015-06-24 | 杭州民生药物研究院有限公司 | Preparation method and application of purine ketone derivatives and composition thereof |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN104557935B (en) * | 2015-01-27 | 2016-08-17 | 江苏嘉逸医药有限公司 | Preparation (R)-8-(3-amino piperidine-1-base)-xanthic method of purification |
| EA201791982A1 (en) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| WO2016207364A1 (en) | 2015-06-25 | 2016-12-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of a xanthine-based compound |
| TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
| EP3359136A1 (en) | 2015-10-09 | 2018-08-15 | Hexal AG | Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
| EP3156048A1 (en) | 2015-10-13 | 2017-04-19 | Galenicum Health S.L. | Stable pharmaceutical composition of linagliptin in the form of immediate release tablets |
| CN105566271B (en) * | 2015-12-03 | 2019-09-13 | 福建医科大学 | The purposes of biflavone compound and its drug of preparation treating cancer |
| JP2019517542A (en) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of linagliptin and metformin |
| WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
| KR102469957B1 (en) | 2017-06-30 | 2022-11-24 | 한미약품 주식회사 | Pharmaceutical composition comprising linagliptin and metformin with improved stability |
| CN107325114B (en) * | 2017-07-04 | 2019-06-11 | 吉林省爱诺德生物工程有限公司 | A kind of preparation method of Ceftaroline Fosamil intermediate |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| KR102500835B1 (en) | 2017-10-24 | 2023-02-17 | 한미약품 주식회사 | Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof |
| CN108299436B (en) * | 2018-02-09 | 2020-01-17 | 上海慈瑞医药科技股份有限公司 | Xanthine compound and pharmaceutical composition and application thereof |
| KR102208009B1 (en) * | 2018-04-26 | 2021-01-28 | 주식회사 경보제약 | Preparation methode of 5-phenyl pentyl hexahydro cyclopentafuran compounds and cycloheptanoate compounds |
| KR102647472B1 (en) | 2018-07-31 | 2024-03-14 | 한미약품 주식회사 | Solid composite formulation for oral administration comprising dipeptidyl peptidase-4 inhibitor and metformine, and a process for the preparation thereof |
| HU231374B1 (en) | 2018-08-06 | 2023-04-28 | Richter Gedeon Nyrt. | Process for the preparation of boc-linagliptin |
| US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| CN110305131B (en) * | 2019-07-03 | 2021-12-31 | 山东百诺医药股份有限公司 | Novel crystal form of linagliptin and preparation method thereof |
| EP3811930A1 (en) | 2019-10-24 | 2021-04-28 | Authenda Pharmaceuticals AG | Oral gliptin compositions and method for preparation thereof |
| WO2021109970A1 (en) * | 2019-12-02 | 2021-06-10 | 成都苑东生物制药股份有限公司 | Xanthine derivative pharmaceutical composition and preparation method therefor |
| EP4103157A1 (en) | 2020-02-13 | 2022-12-21 | Zaklady Farmaceutyczne Polpharma S.A. | Pharmaceutical composition comprising linagliptin and metformin |
| CN112876409A (en) * | 2021-01-20 | 2021-06-01 | 都创(上海)医药科技股份有限公司 | Synthesis method of 2- (5-bromo-6-methoxypyridine-2-yl) acetonitrile and derivatives thereof |
| WO2023002036A1 (en) | 2021-07-22 | 2023-01-26 | Krka, D.D., Novo Mesto | Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride |
| KR20230055762A (en) | 2021-10-19 | 2023-04-26 | 한미약품 주식회사 | Pharmaceutical composite formulation comprising metformin, linagliptin and meglumine |
| WO2023156675A1 (en) | 2022-02-21 | 2023-08-24 | Krka, D.D., Novo Mesto | Process for purification of linagliptin |
| KR20230126664A (en) | 2022-02-23 | 2023-08-30 | 주식회사 제뉴원사이언스 | Pharmaceutical combination of controlled drug delivery comprising linagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof |
| EP4349837A1 (en) | 2022-10-05 | 2024-04-10 | Zaklady Farmaceutyczne "Polpharma" S.A. | A pharmaceutical intermediate |
| WO2024091863A1 (en) | 2022-10-25 | 2024-05-02 | Starrock Pharma Llc | Combinatorial, and rotational combinatorial therapies for obesity and other diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061753A (en) * | 1976-02-06 | 1977-12-06 | Interx Research Corporation | Treating psoriasis with transient pro-drug forms of xanthine derivatives |
| FR2558162B1 (en) * | 1984-01-17 | 1986-04-25 | Adir | NOVEL XANTHINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
| FR2654935B1 (en) * | 1989-11-28 | 1994-07-01 | Lvmh Rech | USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR. |
| US5965555A (en) * | 1996-06-07 | 1999-10-12 | Hoechst Aktiengesellschaft | Xanthine compounds having terminally animated alkynol side chains |
| EP0975608B1 (en) | 1997-04-15 | 2005-06-15 | Genentech, Inc. | Halo-alkoxycarbonyl prodrugs |
| DE19828114A1 (en) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs of unstable inhibitors of dipeptidyl peptidase IV |
| JP2003520226A (en) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
| NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| EP1404675B1 (en) * | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| EP1463727A2 (en) * | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| ATE409466T1 (en) * | 2002-01-11 | 2008-10-15 | Novo Nordisk As | METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION |
| KR101150449B1 (en) * | 2002-08-21 | 2012-06-01 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 8-3---1-- 8-[3-Amino-piperidin-1-yl]-xanthines the production thereof and the pharmaceutical composition containing the same |
| DE10251927A1 (en) * | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity |
-
2003
- 2003-08-18 KR KR1020057002834A patent/KR101150449B1/en active IP Right Review Request
- 2003-08-18 JP JP2004530186A patent/JP4233524B2/en not_active Expired - Lifetime
- 2003-08-18 AU AU2003253418A patent/AU2003253418B2/en active Active
- 2003-08-18 ME MEP-2008-597A patent/ME00396B/en unknown
- 2003-08-18 EP EP18185103.1A patent/EP3424926A1/en not_active Withdrawn
- 2003-08-18 PL PL375342A patent/PL216134B1/en unknown
- 2003-08-18 MX MXPA05001684A patent/MXPA05001684A/en active IP Right Grant
- 2003-08-18 UA UAA200502487A patent/UA84275C2/en unknown
- 2003-08-18 EP EP08161656A patent/EP2060573A3/en not_active Withdrawn
- 2003-08-18 BR BR122012026540A patent/BR122012026540B8/en active IP Right Grant
- 2003-08-18 AT AT03792359T patent/ATE453644T1/en active
- 2003-08-18 PL PL403104A patent/PL403104A1/en unknown
- 2003-08-18 EP EP03792359A patent/EP1532149B9/en not_active Expired - Lifetime
- 2003-08-18 PT PT03792359T patent/PT1532149E/en unknown
- 2003-08-18 EA EA200500302A patent/EA010303B1/en active Protection Beyond IP Right Term
- 2003-08-18 RS RS20120139 patent/RS20120139A3/en unknown
- 2003-08-18 EP EP08159141A patent/EP2070539A1/en not_active Withdrawn
- 2003-08-18 RS YU20050137A patent/RS52142B/en unknown
- 2003-08-18 CN CN201210423313.9A patent/CN102964347B/en not_active Expired - Lifetime
- 2003-08-18 CA CA2496249A patent/CA2496249C/en not_active Expired - Lifetime
- 2003-08-18 WO PCT/EP2003/009127 patent/WO2004018468A2/en active Application Filing
- 2003-08-18 EA EA200702022A patent/EA016166B1/en active Protection Beyond IP Right Term
- 2003-08-18 EP EP08159140A patent/EP2058311A3/en not_active Withdrawn
- 2003-08-18 ES ES03792359T patent/ES2339112T3/en not_active Expired - Lifetime
- 2003-08-18 CN CN201510299950.3A patent/CN105001222B/en not_active Expired - Lifetime
- 2003-08-18 BR BRPI0313648A patent/BRPI0313648B8/en active IP Right Grant
- 2003-08-18 SI SI200331782T patent/SI1532149T1/en unknown
- 2003-08-18 DK DK03792359.6T patent/DK1532149T3/en active
- 2003-08-18 CN CNB03819760XA patent/CN100522962C/en not_active Expired - Lifetime
- 2003-08-18 CN CN201710930674.5A patent/CN107674077A/en active Pending
- 2003-08-18 EA EA201001167A patent/EA024251B1/en not_active IP Right Cessation
- 2003-08-18 EP EP10185171A patent/EP2308878A3/en not_active Withdrawn
- 2003-08-18 KR KR1020097008185A patent/KR101111101B1/en active IP Right Review Request
- 2003-08-18 DE DE50312295T patent/DE50312295D1/en not_active Expired - Lifetime
- 2003-08-19 EG EG2003080818A patent/EG25011A/en active
- 2003-08-19 MY MYPI20033150A patent/MY137619A/en unknown
- 2003-08-19 PE PE2003000838A patent/PE20040897A1/en active IP Right Grant
- 2003-08-19 MY MYPI20083230A patent/MY165643A/en unknown
- 2003-08-20 TW TW101137343A patent/TWI469783B/en not_active IP Right Cessation
- 2003-08-20 TW TW098125780A patent/TWI388325B/en not_active IP Right Cessation
- 2003-08-20 TW TW092122890A patent/TWI319320B/en active
- 2003-08-20 AR ARP030103009A patent/AR041025A1/en active IP Right Grant
- 2003-08-21 UY UY27946A patent/UY27946A1/en not_active IP Right Cessation
- 2003-12-17 SA SA03240448A patent/SA03240448B1/en unknown
-
2005
- 2005-01-06 NO NO20050069A patent/NO333970B1/en not_active IP Right Cessation
- 2005-02-17 IL IL166964A patent/IL166964A/en active Protection Beyond IP Right Term
- 2005-02-18 HR HR20050157 patent/HRP20050157B1/en not_active IP Right Cessation
- 2005-02-18 EC EC2005005617A patent/ECSP055617A/en unknown
-
2006
- 2006-02-16 HK HK06101985.9A patent/HK1081552A1/en not_active IP Right Cessation
-
2008
- 2008-06-11 JP JP2008152875A patent/JP4971251B2/en not_active Expired - Lifetime
- 2008-10-16 JP JP2008267827A patent/JP5351486B2/en not_active Expired - Lifetime
-
2009
- 2009-12-14 HR HR20090665A patent/HRP20090665A2/en active Application Revival
-
2010
- 2010-01-28 HK HK10100903.4A patent/HK1134076A1/xx not_active IP Right Cessation
- 2010-01-28 HK HK10100904.3A patent/HK1134077A1/en not_active IP Right Cessation
- 2010-03-22 CY CY20101100275T patent/CY1109928T1/en unknown
- 2010-04-07 AU AU2010201384A patent/AU2010201384C1/en active Active
- 2010-08-13 AR ARP100102982A patent/AR077875A2/en active Pending
-
2011
- 2011-10-21 LU LU91889C patent/LU91889I2/en unknown
- 2011-10-27 BE BE2011C038C patent/BE2011C038I2/fr unknown
- 2011-11-03 DE DE201112100059 patent/DE122011100059I1/en active Pending
- 2011-11-29 FR FR11C0052C patent/FR11C0052I2/en active Active
- 2011-12-15 HU HUS1100028C patent/HUS1100028I1/en unknown
-
2012
- 2012-01-13 CY CY2012001C patent/CY2012001I2/en unknown
- 2012-03-06 EC ECSP12005617 patent/ECSP12005617A/en unknown
- 2012-04-11 JP JP2012090295A patent/JP5623459B2/en not_active Expired - Lifetime
- 2012-07-23 AR ARP120102668A patent/AR087287A2/en active Pending
-
2013
- 2013-01-08 CY CY2013002C patent/CY2013002I1/en unknown
- 2013-01-09 LU LU92128C patent/LU92128I2/en unknown
- 2013-07-12 NO NO20130968A patent/NO20130968L/en not_active Application Discontinuation
- 2013-08-18 IN IN1133DEN2015 patent/IN2015DN01133A/en unknown
- 2013-08-18 IN IN1132DEN2015 patent/IN2015DN01132A/en unknown
- 2013-09-09 HK HK13110418.8A patent/HK1183028A1/en not_active IP Right Cessation
-
2014
- 2014-02-24 NO NO20140234A patent/NO336641B1/en not_active IP Right Cessation
- 2014-04-08 NO NO2014008C patent/NO2014008I1/en unknown
- 2014-05-26 JP JP2014108575A patent/JP6114231B2/en not_active Expired - Lifetime
-
2016
- 2016-03-24 HK HK16103474.1A patent/HK1215439A1/en not_active IP Right Cessation
- 2016-07-04 JP JP2016132807A patent/JP6139004B2/en not_active Expired - Lifetime
-
2018
- 2018-08-02 HK HK18109982.1A patent/HK1250708A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007247193B2 (en) * | 2006-05-04 | 2013-05-16 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10202383B2 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | |
| AU2010201384C1 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments | |
| AU2013202252B2 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments | |
| AU2013251292B2 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments | |
| NZ564768A (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 APR 2013 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 APR |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: TRAJENTAMET LINAGLIPTIN METFORMIN HYDROCLORIDE Filing date: 20130521 |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 FEB 2014 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 FEB |
|
| NDA | Extension of term for standard patent accepted (sect.70) |
Free format text: PRODUCT NAME: TRAJENTAMET LINAGLIPTIN METFORMIN HYDROCHLORIDE Filing date: 20130521 |
|
| NDB | Extension of term for standard patent granted (sect.76) |
Free format text: PRODUCT NAME: TRAJENTAMET LINAGLIPTIN METFORMIN HYDROCHLORIDE Filing date: 20130521 Extension date: 20280521 |